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ABSTRACT
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Bipolar disorder or manic-depression is a severe and common psychiatric illness that is 
often treated with mood-stabilizing drugs. Several molecular targets and signalling 
pathways have been implicated in the pathophysiology o f  the illness and in the mechanism 
o f  action o f  these drugs. However, the precise targets that are responsible for the 
therapeutic action and side-effects o f  the drugs are not known.
In this PhD thesis we have analysed some o f  the potential drug targets, in particular 
extracellular signal-regulated kinase mitogen-activated protein kinase (ERK/M APK) and 
glycogen synthase kinase-3 (GSK.3). which mood stabilizers are believed to regulate. We 
showed, using cell and biochemical assays, that the effects o f  lithium, valproate or 
carbamazepine on ERIC M APK are not always observed in a given cell type. In addition, 
only lithium inhibits GSK3 directly and modulation o f  this kinase with potent and selective 
inhibitors does not mimic the effects o f  mood stabilizers on cortical and sensory neuron 
growth cone morphology.
A major part o f  my thesis focused on the enzyme prolyl oligopeptidase (PO), which is 
thought to modulate the phosphatidylinositol pathway, as shown from studies in 
Dictyostelium discoideum  and human astroglioma cells. PO inhibitors alone have no effect 
on sensory neuron growth cone morphology, but reverse the growth cone changes induced 
by mood stabilizers, mimicking addition o f /m  o-inositol to the culture media. We studied 
PO null-mutant mice and analysed the effects o f  mood stabilizers on the morphology o f  
growth cones from these mice. Unexpectedly, the PO null-mutant phenotype itself 
resembled wild-type neurons treated with a mood stabilizer and each drug had no further 
effect on growth cone morphology. These results show that PO is a critical component o f  
signalling pathways inv olv ed in mood-stabilizing drug action on growth cones. Using viral 
delivery o f  native or catalytically-dead PO, we showed that each restored the wild-type 
phenotype. In order to better understand PO function, a yeast-tvvo-hybrid screen (Y2H) 
was also performed at Gla.xoSmithK.line to determine protein interactors for PO, and we 
analysed one o f  these interactors, namely GAP43. We showed that both the native and the 
catalytically-dead PO co-precipitate with the neuronal protein GAP43. These results show 
that there are additional biological effects o f  PO independent o f  its catalytic domain.
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CHAPTER 1 
Introduction
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1.1 Bipolar disorder
In 1896 Emil Kraepelin differentiated the major psychoses into dementia praecox and 
manic-depressive illness. In particular, he referred to dementia praecox (named today as 
schizophrenia) as an illness with a deteriorating course, in contrast to manic-depressive 
illness, which was believed to be episodic, with full recovery between episodes and with 
good prognosis.
A more recent description o f  manic-depressiv e illness, also named bipolar disorder (BD), 
has revealed that this is a severe, chronic, and often life-threatening illness, and that the 
favourable long-term outcome may only represent the situation for a minority o f  
individuals (Goodwin & Jamison. 1990). Kraepelin 's classification still survives in the 
current classification o f  Diagnostic and Statistical Manual o f  Mental Disorders (DSM-IV) 
(DSM-IV. 2000). Current estimates suggest that BD affects about 1.5 %  o f  the world 
population (Goodwin & Jamison, 1990). it is equally distributed between men and women, 
and the median age o f  onset is in the early twenties (Weissman et al., 1996). It has been 
shown that BD individuals with a history o f  major traumatic events in childhood (about 
one-third) are more difficult to treat, have a more severe course o f  the illness and an 
increased incidence o f  suicide attempts (Leverich et al., 2002). There is an increased risk 
o f  onset in the post-partum period, therefore indicating that changes in hormonal levels 
may trigger the illness (Blehar et al ., 1998). In addition, for women with BD, the post­
partum period is a time o f  considerable risk o f  relapse.
Two almost diametrically opposite mood states characterise BD: mania and depression - 
and individuals cycle between these two opposite mood poles. Mania is characterised by a 
hyper-aroused state (either euphoric or dysphoric), decreased need for sleep, increased 
motor activity, racing thoughts and increased optimism that can become so extreme that 
the individual’s judgement is impaired. Individuals in the manic phase are prone to gamble 
and make inappropriate decisions, which may have a devastating impact on their lives. The 
depressive phases o f  the illness are characterised by a depressive mood, anhedonia and 
impaired sleep. These symptoms do not differ substantially from those observed in 
unipolar depression and are more recurrent than manic episodes. As highlighted in 
longitudinal studies, about two-thirds o f  BD individuals are greatly impacted by the illness
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and they spend about one-third o f  their life time in a depressive state (Post et al., 2003a; 
Post et al ., 2003b). BD is defined in DSM-IV as the occurrence o f  a major depressive 
episode in the context o f  having experienced at least one manic (BD type I) or hypo-manic 
(BD type II) episode. A longitudinal (20 years long) study has shown that BD-I and BD-II 
have similar demographic characteristics and ages o f  onset, with BD-II much more 
prevalent than type I and more difficult to diagnose (Judd et al ., 2003b; Judd et al., 2003a). 
BD-II has a higher prevalence o f  anxiety disorders and social phobia compared with BD-I. 
The occurrence o f  four or more episodes o f  depression or mania within a 12-month period 
is referred to as 'rapid cycling', and the depressive episodes predominate. BD individuals 
cycle between these different phases and experience intervals o f  euthymia when they are 
asymptomatic, but they still maintain vulnerability to mood episodes. These periods o f  
apparent clinical recovery are marked by subtle social, occupational, and cognitive 
impairments (Altshuler et a l ., 2004; El Badri et al., 2001). Recently, results from a meta­
analysis study have indicated that euthymic BD individuals present marked impairment in 
some aspects o f  executive function and verbal memory (Robinson et al., 2006). BD is 
diagnosed, on average, eight years after the first episode due to frequent misdiagnosis as 
unipolar depression (3 7 °o o f  BD individuals) (Ghaemi et al., 2000). The illness has 
afflicted many famous musicians, writers and political leaders and it has been linked to 
creativity and success (Jamison, 1995). However, there is evidence that only the early 
phase o f  mania contributes to creativity, whereas full-blown mania usually becomes 
destructive to many aspects o f  life. As a result, many BD individuals are concerned that the 
pharmacological treatment o f  their mood swings may reduce their creativity, and many o f  
them use or abuse alcohol or addictive drugs as self-medication (Jamison, 1996).
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1.2 Genetics
Family and twin studies have demonstrated a strong genetic basis for BD (-80% ) 
(Craddock & Forty, 2006; MacKinnon et al.. 1997; McGuffin et al.. 2003), yet classical 
genetic linkage analyses have not clearly identified the genes involved in the illness. A 
possible explanation for this lack o f  success so far is because BD is probably caused by the 
interaction o f  numerous genes, each o f  which exerts a modest increase in relative risk. 
Several genome regions o f  interest have been repeatedly implicated in individual studies, 
as indicated below;
4p16 6q 12q23-24 18q21
18q22
18 centromere
21q22
(Blackwood 
eta!., 1996)
(McQueen 
et al., 2005)
(Craddock 
et al., 1993)
(Stine et al., 1995) 
(Straub et al., 1994) 
(Berrettini et al., 1994)
(Straub 
et al., 1994)
Table 1.1 Chrom osom al regions implicated in BD.
Furthermore, a meta-analysis study has shown strong evidence for susceptibility loci on 
chromosome 13q and 22q (Badner & Gershon, 2002) and the study by Segurado et al. 
showed a modest level o f  support for regions on chromosomes 9p22.3-21.1, lOql 1.21-22.1 
and 14 q 2 4 .1-32.12 (Segurado et al.. 2003).
Candidate genes that have been implicated in BD are brain-derived neurotrophic factor 
(BDNF), melastatin-like transient receptor potential 2 channel (TRPM2), G72, glycogen 
synthase kinase-3 (GSK3) and the dopamine transporter (DAT), amongst others.
O f  these, the neurotrophin BDNF has drawn particular attention as it modulates synaptic 
activity, survival and differentiation, which may all be altered in BD subjects. Moreover, 
two drugs used to treat BD, lithium (Li ) and valproic acid (VPA), each increase BDNF 
levels in the rat cortex and hippocampus (Einat et al.. 2003). A single nucleotide 
polymorphism (SNP) has been identified in the BDNF gene (chromosome 11 p i 3), causing
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a Val6 6 Met change, with the Val allele considered as a risk allele for BD (Sklar et al., 
2002; Green & Craddock, 2003). An earlier age o f  onset o f  BD has been reported for 
Val Val genotype carriers compared with Val Met (Rybakowski et al ., 2003). The Val Met 
polymorphism seems also to affect the therapeutic response to lithium, with the Met 
polymorphism more frequent in lithium responders (Rybakowski et al., 2005). At the 
cellular level, the Val Met polymorphism has been shown to impact intracellular 
trafficking and activity-dependent secretion o f  BDNF (Rybakowski et al., 2005; 
Rybakowski et al., 2003; Egan et a l., 2003). A recent study in a population o f  -3 ,000  BD 
individuals has shown no association o f  Val Met BDNF polymorphism with BD, except 
for a subpopulation o f  rapid cycling subtypes (Green et al., 2006). These findings show 
that further functional and genetic studies are needed to understand the involvement o f  this 
gene in the illness, as it is possible that other, yet to be analysed. SNPs may be associated 
with BD.
Another gene with a very strong genetic association with BD is TRPM2 (located on 
chromosome 21) (Xu et al., 2006). Interestingly, alterations in TRPM2 levels associated 
with increased calcium concentration have been reported in BD blood cells (Yoon et al.,
2001). However, very limited studies have been performed in relation to BD and the 
relevance o f  these findings to the illness is not clear at present.
The most frequently replicated locus for BD to date is the higher primate-specific gene, 
G72 (on chromosome 13q33) (Schumacher et al., 2004; Chen et al., 2004; Hattori et al., 
2003). Recombinant G72 interacts with D-amino-acid oxidase (DAAO). DAAO oxidises 
D-serine, which is a potent activator o f  the N-methyl-D-aspartate glutamate receptor 
(NMDA). Interestingly, the G72 gene has also been associated with schizophrenia, 
therefore suggesting that the two illnesses may share some common susceptibility loci for 
some overlapping symptom domains (Schumacher et al., 2004). A caveat, however, is that 
G72 mRNA and protein have not yet been detected in human tissues.
Another genetically associated, although biologically controversial gene for BD is GSK3. 
The a  and p isoforms are mapped to human chromosome 1 Dq 13.1-13.2 and 3q 13.3-21.1, 
respectively (Shaw et al., 1998), regions that are weakly linked to BD (Badenhop et al.,
2002). One single nucleotide substitution in the promoter region o f  GSK3P at -50 T/C has
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been associated with therapeutic response to lithium in a group o f  BD-I subjects (Benedetti 
et al., 2005). In particular, carriers o f  the T T genotype were less responsive to lithium 
treatment and had an earlier age o f  onset o f  the illness (Benedetti et al., 2004a). In another 
study by the same group, 60 BD depressed individuals with the C/C genotype showed 
improved mood in response to total sleep deprivation (Benedetti et al., 2004b). These 
findings suggest that the C C genotype may be associated with a milder form o f  the 
disorder, and may have a protective role in respect to BD. Inhibition o f  GSK.3p has been 
linked with effects on neuronal survival and neuroprotection (Jope & Bijur, 2002). 
However, the functional consequences o f  the C C genotype on the above cellular effects 
have not been studied as yet. Overall, the biological and genetic data point to GSK.3 as an 
interesting candidate target for BD.
An imbalance in the dopaminergic system has been hypothesized to contribute to the 
pathogenesis o f  a number o f  psychiatric illnesses, including BD. In particular, the 
dopamine transporter, DAT, plays a crucial role in striatal dopaminergic 
neurotransmission, as it modulates synaptic levels o f  dopamine and thus controls the 
concentration o f  active neurotransmitter. Two missense substitutions were identified in the 
DAT gene (chromosome 5p 15.3) and were associated with BD: the Ala559Val mutant 
protein, which was shown to be functional, and the Glu602Gly mutant, which was not 
functional due to a failure in transport to the cell surface (Horschitz et al., 2005). More 
recently, other variants have been reported that seem to associate with BD (Greenwood et 
al., 2006). Interestingly, DAT knock-down mutant mice are hyper-active and VPA 
significantly attenuates the hyperactivity, therefore suggesting that the dopamine 
transporter is involved in manic behaviour.
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Other genes more weakly associated with BD are indicated in the table below:
Neuregulin-1
(NRG)
Disrupted
in schizophrenia ‘
(DISC1)
Catechol-O-
Methyltransferase
(COMT)
G-protein 
Receptor 
Kinase 3 
(GRK3)
Inositol
Monophosphatase
(IMPA2)
8p12 1q42 22q11 22q12.1 18p11.2
(Green 
et al., 2005)
(Thomson 
et al., 2005)
(Shifman 
et al., 2004)
(Barrett 
eta!., 2003)
(Sjoholt et al., 2004)
Table 1.2 Candidate genes associated with BD.
However, the role o f  these genes in the illness requires further investigation, such as 
replication o f  genetic association from well-controlled samples.
It is interesting to note that some susceptibility genes have been associated with both BD 
and schizophrenia or depression. In particular, o f  the above-mentioned genes, G72, DISCI 
and neuregulin-1 have been associated with BD and unipolar depression, therefore 
indicating that these illnesses may have shared susceptibility for some overlapping 
symptoms domains (Craddock et al., 2005). It is not unusual for a BD proband to have 
first-degree relatives diagnosed with schizophrenia and. to a lesser extent, unipolar 
depression. These findings show that there is a more complex relationship between the 
mood disorders than that reflected in the conventional Kraepelin dichotomy.
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1.3 Pharmacological treatment o f  BD
Several drugs are currently used in the clinic to treat BD and are efficacious in the different 
phases o f  mania or depression. These drugs are known as ‘mood stabilizers’, a term that 
was not clearly defined until recently. Charles Bowden and Gary Sachs each suggest 
different definitions o f  ‘mood stabilizer’. According to Bowden, a ‘mood stabilizer’ is a 
drug that alleviates the frequency and. or intensity o f  manic, hypomanic, depressive or 
mixed episodes in BD individuals and that does not increase the frequency or severity o f  
any o f  these types o f  BD episodes (Bowden, 1998). According to Sachs a ‘mood stabilizer’ 
is a drug that decreases the vulnerability to subsequent episodes o f  mania or depression and 
that does not exacerbate the current acute episode when administered during the acute, 
continuation or maintenance phase o f  treatment (Sachs. 1996). Both definitions seem to 
converge on a key feature that a ‘mood stabilizer' should not cause an affective switch. 
The summary o f  the two definitions is the ‘liberal definition’, which states that a ‘mood 
stabilizer’ is an agent with efficacy in at least one o f  the three phases o f  BD (acute mania, 
acute depression or maintenance) and it should neither cause an affective switch to the 
opposite mood state nor should it worsen the acute episode (Ghaemi, 2001). Joseph 
Calabrese, instead, proposed a ‘conservative definition’, which states that a ‘mood 
stabilizer' should be effective as monotherapy for the acute treatment o f  depression and 
mania and mixed states and for the prevention o f  relapse and recurrence (Calabrese & 
Rapport, 1999). Therefore, it becomes clear that different drugs are, or are not, considered 
as mood stabilizers depending on the definition used and this has caused great confusion in 
the field. Nassir Ghaemi, recently proposed an intermediate definition, which states that a 
‘mood stabilizer' is an agent with efficacy in two o f  the three phases o f  BD, namely acute 
mania, acute depression or prophylaxis o f  mania and depression (Ghaemi, 2001).
Following this definition the three most-commonly used mood stabilizers are L i’, VPA and 
carbamazepine (CBZ), which are all approved for mania and BD prophylaxis by the Food 
and Drug Administration (FDA), the European Agency for the Evaluation o f  Medicinal 
Products (EMEA) and the Medicines and Healthcare Products Regulatory Agency in the 
LK. (M HRA). More recently, olanzapine has been approved by the FDA and EMEA for 
the treatment o f  mania in 2000  and 2 0 0 2 , respectively, and for the maintenance therapy o f  
BD in 2004 and. therefore, can be considered a mood stabilizer. Additionally, lamotrigine 
(LTG) is a potential mood stabilizer (Calabrese et a l .  2006; Goodwin et al.. 2004; Muzina
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et al., 2005) and registration in the US is expected shortly. Mood stabilizer structures are 
very different and range from a cation (Li ) to a tricyclic molecule (CBZ) (Fig. 1.1).
L f
— \  0
y  '  O H
valproic acid
carbamazepine
H . N  N  N H .
lamotrigine
Fig. 1.1 Structure o f  the m ost-com m only  used mood-stabiliz ing drugs.
The recommended use o f  drugs in the treatment o f  BD is covered by UK or US guidelines 
(Goodwin & Young, 2003) and sometimes discrepancies exist between the two that point 
towards professional and cultural differences (Yestergaard, 2004).
The discov ery o f  lithium as an efficacious mood-stabilizing agent by Cade in 1949 and its 
introduction as a therapy by Mogens Schou revolutionised the treatment o f  BD. Lithium 
was approved for the treatment o f  acute mania in the US in 1970, and for the maintenance 
therapy in 1974. It shows some limited efficacy in the treatment o f  acute bipolar 
depression, and it has a strong anti-suicidal effect (Kessing et al., 2005; Muller- 
Oerlinghausen et al., 2005). It continues to be the “gold standard" for the treatment o f  BD, 
both for the acute manic phase and in preventing the frequency o f  episodes o f  mania and 
depression. There is, however, some evidence suggesting that certain groups o f  subjects do 
not respond adequately to lithium therapy, in particular those with rapid cycling, family 
history o f  affective illness in first-degree relatives, and co-morbid substance abuse 
(Calabrese & Woyshville, 1995). Lithium has a narrow therapeutic index (0.8 to 1.4 mEq/1) 
(Bowden, 1996) due to toxic effects on renal, neurological and cardiovascular systems. 
Other side-effects include gastric disturbances, diabetes insipidus, weight gain, flattened 
mood and loss o f  creativity. The intracellular concentrations o f  lithium, VPA and CBZ
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have not been clearly determined, nor is the mechanism by which they cross the cell 
membrane. Some literature on lithium reported efflux and influx studies using lithium 
sensitive microelectrodes. Lithium is believed to accumulate into cells via the voltage- 
dependent sodium channel and the sodium potassium exchange pump and possibly via 
calcium channels and extruded in an active manner using a sodium lithium exchanger. The 
influx o f  lithium appears to be rapid and linear with time, while the rate o f  lithium efflux is 
slower. Cellular accumulation o f  lithium was reported to be accompanied by an 
approximately equimolar loss o f  potassium (O'Day & Phillips, 1991). An intra to 
extracellular ratio o f  about 0.7 was obtained in motomeurons, and similarly in cultured 
neurons, and lithium did not seem to ever equilibrate (Gow & Ellis, 1996; Grafe et al., 
1982). Overall, it looks like there are different ways o f  influx and efflux for lithium, 
generally involving exchange with sodium ions.
A series o f  anticonvulsant compounds has emerged as the major anti-manic or maintenance 
alternative to lithium, namely VP A, CBZ and LTG.
Divalproex (commercialised as Depakote: 1:1 molar ratio o f  sodium valproate and valproic 
acid) is at least as effective as lithium in acute mania (Bowden et al., 1994) and more 
efficacious than lithium in mania accompanied by symptoms o f  depression (mixed states) 
(Swann et al., 1997). It was approved for the treatment o f  acute mania in the US in 1995 
and in the UK. in 2001. Side-effects o f  VPA include nausea, vomiting, hepatotoxicity and 
teratogenicity with an increased risk o f  spina bifida and cardiac malformations. V PA has 
the propensity to induce weight gain (Owens & Nemeroff, 2003). VPA is metabolised into 
at least 14 different species via conjugation with glucuronic acid and oxidation and some 
o f  these metabolites exhibit pharmacological activ ity (Kakee et al.. 2002).
CBZ displays at least comparable efficacy to lithium (Okuma et al ., 1990) and to VPA 
(Nasrallah et al., 2006) in acute mania and it was approved for this indication by the FDA 
in 2004. CBZ is less effective than lithium in preventing depressive breakthrough 
compared to manic relapse (Goodwin. 2003; Malhi et al., 2003). CBZ is metabolised by 
cytochrome P450 3A3/4 and the main metabolite, epoxide, is also biologically active. Drug 
side-effects include rash, white cell suppression, transient hepatic enzyme elevations and 
neurotoxicity. Like VPA. CBZ is also teratogenic.
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The sodium channel blocker LTG appears to be useful in monotherapy or combination 
therapy with another mood stabilizer for the treatment o f  BD depression without increasing 
cycling or provoking a switch into mania (Calabrese et a l ., 1996; Calabrese et al., 2002; 
Calabrese et al., 2003); moreover, it is also efficacious in prophylaxis o f  depressive 
episodes (Yatham, 2004). A meta-analysis o f  5 studies (performed by GlaxoSmithKline) (4 
o f  which did not find a statistically significant effect as underpowered) found evidence o f  a 
modest, but clinically worthwhile, benefit for LTG in BD depression (Geddes et al., 2006). 
LTG, instead, does not appear to have significant efficacy in treating acute mania 
(Calabrese et al., 2003). It is well tolerated and it has a good side-effect profile 
(Bhagwagar & Goodwin. 2005). In all BD clinical trials, the rate o f  serious rash was 0.1% 
(0.1% also for placebo). Rash seems to occur when the initial dose is too high and the risk 
can be reduced with proper dose titration (GlaxoSmithKline filed data). It received FDA 
approv al in 2003 for the maintenance treatment o f  BD, but it is not currently widely used 
in the UK (NICE guidelines).
Another anticonvulsant that has shown positive results in rapid-cycling BD subjects and in 
those refractory to conventional treatments is topiramate (Suppes, 2002). Further studies 
are required, however, to confirm its clinical efficacy. No evidence for efficacy in BD has 
been reported for the anticonvulsants gabapentin and phenytoin, at least as monotherapy 
(Yatham, 2004).
The atypical antipsychotic drugs, in particular olanzapine, aripiprazole, risperidone and 
ziprasidone, have all been approved by the FDA for the treatment o f  acute mania. 
Interestingly, the antipsychotic drug quetiapine has shown efficacy in depression as well as 
in manic episodes and it has just received approval from the FDA (Dando & Keating, 
2006; Post et al., 2003b).
Tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRI) are used for the 
treatment o f  depressive episodes in BD; however, there is still some controversy about 
whether they represent an appropriate treatment. In particular, the 2002 American 
Psychiatry Association Guidelines recommended a more conservative use o f  antidepressant 
drugs, which was criticised by the more ‘liberal’ Munich group (Moller & Grunze, 2000). 
According to Ghaemi et al., antidepressant drugs do not have a high risk o f  inducing mood
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cycling and switch to mania; they are not proven to prevent suicide (unlike lithium) or to 
be better than a mood stabilizer in the long-term treatment o f  BD depression (Ghaemi et 
al ., 2003). The American Psychiatry Association Guidelines recommend that
antidepressant drugs should be reserved for severe BD depression only and discontinued 
immediately after recovery. However, antidepressant drugs are generally prescribed earlier 
and more frequently than mood stabilizers due to misdiagnosis and - 20% o f  individuals 
experience a new or worsening rapid cycling (Ghaemi et al ., 2000). A previous study 
supporting the American Psychiatry Association recommendations has shown that 35% of 
individuals with BD had manic episodes rated as likely to have been antidepressant drug- 
induced. Furthermore, cycle acceleration has been reported in 26% o f  subjects after 
antidepressant drug treatments (Altshuler et a l .. 1995). Younger age at first treatment was a 
predictor o f  vulnerability to antidepressant drug-induced cycle acceleration and it was 
more likely to occur in women with BD-II (Altshuler et al ., 1995). A more recent study has 
shown that newer antidepressant drugs do not have lower rates o f  negative outcomes 
compared with tricyclic antidepressant drugs (Ghaemi et al.. 2004). Overall, the data 
suggest that antidepressant drugs are probably overused and mood stabilizers underused 
and that development o f  better treatments for bipolar depression presents a “niche” in BD 
treatment.
In the search for better treatments it is also important to consider drugs that have little 
efficacy on their own but may be effective in BD through ability to potentiate other 
primary therapies. For example, olanzapine and other atypical antipsychotic drugs may 
possess mild to moderate antidepressant properties as an add-on with an antidepressant 
drug (Ghaemi. 2000). Finally, electroconvulsive therapy (ECT) is efficacious both in 
mania and depression, but it is used only in severe cases o f  the illness (Fink. 2006).
Despite extensive clinical use o f  the drugs described above, the cellular mechanisms 
modulated by these compounds still remain to be elucidated. In particular, knowing the 
clinically-relevant targets for treating BD would indicate which signalling pathways are 
critical for mood control. Focusing on these pathways would then allow identification o f  
targets towards which more potent and selective drugs could be designed. Several 
molecules or pathways are known to be directly modulated by mood stabilizers and the 
literature points to GSK3 and to the phosphoinositide signalling pathway as a possible
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common target pathway affected by mood stabilizers. Additional secondary targets that 
may be invok ed in the mechanism o f  action o f  mood stabilizers are the extracellular 
signal-regulated kinase mitogen-activated protein kinase, the wvo-inositol transporters, 
wvo-inositol synthase, protein kinase C (PK.C) and prolyl oligopeptidase (PO). I have 
touched on all these targets in the course o f  this thesis, but have focussed my investigation 
primarily on the biological function o f  PO.
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1.4 Mood stabilizers and the phosphoinositide signalling pathway
Inositol phospholipids play a major role in receptor-mediated signal transduction pathways 
and are implicated in a diverse range o f  cellular processes in the central nervous system 
(CNS), such as enzyme activation, cytoskeletal changes, endocytosis, exocytosis, ion- 
channel activation, spine morphology and production o f  various second messengers (Fig. 
1.2) (McLaughlin & Murray, 2005).
Enzyme
activation PIP
Binding site for PH 
and other domains
Production of three 
second messengers
Exocytosis
Fig. 1.2 Schematic o f  different functions o f PIP2. Source: (McLaughlin & Murray, 2005).
Activation o f  a variety o f  G-protein-linked neurotransmitter receptor subtypes and 
electrical activity (Micheva et al., 2001) induce the hydrolysis o f  membrane phospholipids, 
in particular o f  phosphatidylinositol-4,5-bisphosphate (PIP2, also named PI(4 ,5)P2 or 
PtdIns(4 ,5)P2), by phospholipase C (PLC). The 11 mammalian PLC isozymes can be 
divided into three structural groups: p, y and 5 and they are differentially distributed 
(Phillis & O'Regan, 2004). Two PLC isoforms, PLC-P activated by G proteins, and, PLC-y 
activated by receptor tyrosine kinases, catalyse the PIP2 reaction. Protein surfaces that 
interact with phosphoinositides can consist either o f  clusters o f  basic residues within 
unstructured regions, such as those found in many actin regulatory proteins (e.g. profilin) 
or o f  folded molecules, such as the pleckstrin homology (PH) domain (Di Paolo & De 
Camilli, 2006). PLC has an absolute requirement for calcium and it has at least two 
potential lipid-binding domains: the PH and the C2 domains. PIP2 is a key regulator o f  the 
actin cytoskeleton and increased levels o f  presynaptic PEP2 have been linked to 
abnormalities in both the presynaptic actin cytoskeleton and the organisation o f  the
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synaptic vesicle pool (Osbom e et al., 2001). Moreover, a recent study has shown that PIP2 
is enriched in dendritic spines and the amount o f  PIP: affects spine morphology 
(Calabrese, B. and Halpain, S. 06). PIP2 is dephosphorylated by the phosphatase 
synaptojanin, a nerve terminal inositol 5-phosphatase that interacts with the endocytic 
machinery via its proline-rich domain (Slepnev & De Camilli, 2000). Another fate o f  PIP2 
is conversion to PIns(3 ,4 ,5 )P3 by class I phosphoinositide 3-kinase (PI3-kinases). This lipid 
is present in negligible amounts in resting cells, but can be dramatically increased in 
response to growth factor stimulation. PIns(3.4,5)P? is subsequently dephosphorylated by 
two types o f  enzymes: at the 3 position by the phosphatase PTEN to generate PI(4 ,5 )P2 and 
at the 5 position by 5 phosphatases, such as SHIP -1 and -2 to generate PIns(3 ,4 )P2. 
Hydrolysis o f  PIP2 by PLC generates two second messengers, inositol-1,4,5-trisphosphate 
(IP? or InsP?) and diacylglycerol (DAG).
DAG acts as a second messenger and activates PKC, which phosphorylates Munc-18 and, 
subsequently regulates the interaction o f  Munc-18 with syntaxin and the docking and/or 
the fusion o f  synaptic vesicles yvith the presynaptic plasma membrane (Fujita et al ., 1996). 
Munc-18 is specifically localised in nerve cells (and not in glia) and it is highly distributed 
in axons (Kalidas et al ., 2000). It therefore seems to be a key component in the regulation 
o f  synaptic function. More recently, other DAG targets have been identified, yvhich include 
protein kinase D (PKD). diacylglycerol kinases p and 7, ras guanine nucleotide releasing 
proteins (RasGRP), chimaerins and Munc-13. In particular, Munc-13 proteins are 
specifically localised to the presynaptic active zone and are essential for synaptic vesicle 
priming by activation o f  the SNARE protein syntaxin. It has recently been shoyvn that the 
increase in neurotransmitter release induced by phorbol esters in primary neurons is 
mediated exclusively by Munc-13 and not by PKC (Brose et al., 2004).
In the cytosol, IP;, stimulates the mobilisation o f  calcium from intracellular stores by 
binding to IP3 receptors in the endoplasmic reticulum. IP3 can be phosphorylated by 
kinases to high inositol phosphate molecules (ortho- and pyro-phosphate inositol), whose 
functions as intracellular messengers are still unclear as their levels do not seem to change 
in response to cell stimulation (Bennett et a l ., 2006). IP s and IP 6 are generally assumed to 
have “housekeeping” functions rather than being second messengers (Berridge & Irvine, 
1989). Moreover, IP3 can be phosphorylated by Ins(l,4 ,5 )P3 3-kinase to Ins( l ,3 .4 ,5 )P4,
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which is then dephosphorylated to In s ( l ,3 ,4 )P_3. IP4 is a second messenger in its own right 
as it can influence IP^-regulated calcium homeostasis (Irvine et al ., 2006). IP3 can be 
dephosphorylated to IP2, IP 1 and wvo-inositol by phosphatases. In particular, the inositol 
polyphosphate-l-phosphatase (IPPase) converts IP: to IP 1 and the inositol
monophosphatase (IMPase) dephosphorylates IP 1 (Ins(l)P , Ins(3)P or Ins(4)P) to myo­
inositol (Fig. 1.3).
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Fig. 1.3 Schematic o f  the Pins signalling pathway.
T = transporter; the other components o f the pathway are indicated in the text.
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Inositol is a cyclic hexitol, which can exist as nine isomeric forms. Myo-inositol is the most 
common form found in mammals and it has one axial and five equatorial hydroxyls (Fisher 
et al., 2002) (Fig. 1.4). It is a major brain osmolyte, mostly derived from diet. Scyllo- 
inositol, an isomer in which all six o f  the hydroxyl groups are equatorial (representing only 
8% o f  the total brain inositol) is the other most abundant inositol in the brain.
HO
HO
OH
OH
HO
OH
Fig. 1.4 A/yo-inositol structure. Source: (Irvine, 2005).
De-phosphorylated myo-inositol is incorporated into PI and PIP2 via a reaction involving 
activated phosphatidic acid (PA), named cytidine diphosphate-diacylglycerol (CDP-DAG) 
(Heacock & Agranoff, 1997). More precisely, DAG is phosphorylated at the plasma 
membrane to PA via the action o f  DAG kinase; subsequently, PA is converted to CDP- 
DAG. PI is converted to phosphatidylinositolphosphate (PIP) by the phosphatidylinositol 
kinase PI4-kinase and to PIP2 by the phosphatidylinositol 4-phosphate 5-kinase (PIP5- 
kinase) (Halstead et a l ., 2005). PI is formed in the endoplasmic reticulum and PI transfer 
proteins (PITP) then transport the newly synthesised PI to the plasma membrane 
(Cockcroft, 2001). How this works in synapses is unclear at present.
The ability o f  a cell to maintain sufficient levels o f  myo-inositol is crucial for the 
resynthesis o f  phosphoinositides and for the maintenance and efficiency o f  signal 
transduction. Differences in phosphatidylinositol (Pins) signalling exist amongst species 
and in different tissues and some confusion exists in the literature (Fig 1.5).
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Fig. 1.5 Two likely pathways for lnsP6 synthesis in mammalian cells.
Source: (Irvine et al., 2006). The upper pathway is found in yeasts and may exist in mammals.
Clinical studies have revealed modest and often contradictory abnormalities in the Pins 
signalling pathway in BD individuals. A magnetic resonance spectroscopy study showed 
that lithium induced myoinositol reductions in the frontal cortex o f  BD individuals after 
five days o f  drug administration, at a time when the clinical state o f  the subjects was 
completely unchanged (Moore et al., 1999). Furthermore, Silverstone et al. did not observe 
any differences in myoinositol levels in control and BD individuals; however, they showed 
that chronic treatment with both lithium and VPA may normalise the altered Pins cycle 
activity observed in BD (Silverstone et al., 2002). These studies point to the involvement 
o f  the Pins cycle in BD, however, it is still not clear at which level it occurs.
Moreover, some preliminary studies suggest that some genes encoding proteins belonging 
to the Pins pathway may be genetically associated with BD e.g. phosphoinositide 3-kinase 
class 3 (PIK3C3), phosphatidylinositol 4-kinase (PIK4CA) and phosphatidylinositol 4- 
phosphate 5-kinase II a  (PIP5K2A) (Halstead et al., 2005).
M echanisms of action of m ood-stabilizing drugs Chapter I Page 33
1.4.1 .Mood stabilizers and IM P ase/lP P ase
Allison & Stewart showed that lithium treatment resulted in a 30°o reduetion in mvo- 
mositol eoneentration in the rat cerebral cortex, which was accompanied by an increase in 
IP;, suggesting that the drug inhibited the enzyme IMPase, which converts /mw-inositol 1 
(or 4)-phosphate (D or L) to mvo-inositol (Allison & Stewart. 1 c>71). It was subsequently 
continued that lithium inhibits IMPase directly w ith a K., o f  0.S m \ l  (Hallcher & Shennan, 
19S0). which is w ithin the therapeutic plasma levels o f  lithium (0.6 - 1.2 m \ l )  (Bowden. 
14%). Lithium appears to inhibit the enzvme following substrate hydrolysis by occupying 
the second magnesium binding site before the phosphate group can dissociate from its 
interaction with the magnesium site (Ataek et al.. 1995). There are at least two IMPase 
genes in mammals. IMPA1 and IMPA2 (Shamir et al.. 2001) and it is still not clear 
whether functional differences between the two genes exist. IMPA1 mRNA seems to be 
expressed at levels several fold higher than IMPA2. both in mice and human frontal cortex 
(A gam et al.. 2002) (also see Allan Brain Gene Atlas at http: www.bramatlas.ore ).
Ohmshi et al. suggested that IMPA2 has a distinct function from IMPA1. as it has lower 
activity towards /mo-inositol monophosphate than IMPA1 and it shows different kinetics 
o f  lithium inhibition. No other substrates for IMPA2 hav e been identified so far (Ohnishi et 
al.. 2006). Very recently, an IMPA2 null-mutant mouse was generated and its behaviour 
analysed. The behaviour o f  the IMPA2 null-mutant mouse did not mimic the effects o f  
lithium treatment in the forced swim, tail suspension, elevated zero-maze and open field 
tests, therefore suggesting that IMPA2 is not the key target for mood control (Cryns et al.. 
2006).
IMPA1 therefore seems to be the predominant lithium-sensitive enzyme in the brain (Gee 
et al.. 1 OSS; Parthasarathv et id.. 1994; Ragan et al.. 19XS). The inhibition by lithium is 
uncompetitive. It also suggests that lithium does not bind to the enzyme directly, but rather 
to the enzyme-substrate complex. Interestingly, this finding also means that lithium is most 
effective when substrate levels are high. Yadnal & Parthasarathv reported that CBZ 
stimulates IMPase. while YPA does not have any direct effects (Yadnal & Parthasarathv, 
1995). More recently. Mudge & Thomas did not observe any inhibition o f  IMPase by CBZ 
(personal communication), suggesting that IMPase inhibition may be specific to lithium.
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Moreover, IMPAl mRNA expression was reported to be decreased (two-third reduction) in 
lymphoblastoid cell lines from drug-free BD compared with control subjects and increased 
(two-fold) by treatment with lithium (Nemanov et al.. 1999), therefore suggesting that 
chronic inhibition o f  the enz \m e  by lithium results in up-regulation o f  the gene at the 
transcriptional level.
Lithium also directly inhibits the phosphatase immediately upstream o f  IMPase. called 
IPPase in an uncompetitive manner with a K, o f  0.3 m \ l  (Ragan et al.. 1988). These 
findings suggest that the effects o f  lithium on Pins signalling are more pronounced in cells 
undergoing the highest rates o f  PIP: hydrolysis as opposed to quiescent cells (Nahorski et 
al.. 1991). Berridge et al. originally proposed the inositol depletion h\pothesis in order to 
explain the efficacy o f  lithium in the treatment o f  BD (Berridge et al.. 1989; Berridge & 
Irvine. 1989). This theory was refined in 1995 to state that lithium slows down the rate o f  
the Pins cycle rather than depleting intracellular concentrations o f  inositol (Batty & 
Downes. 1995). In fact, it seems that inositol concentrations in neurons can reach m.M 
levels, as it accumulates from the cerebrospinal tluid and the plasma, where inositol 
concentrations are -3 0 0  liM and -3 0  li\1 .  respectively, via the transporters SMIT1. SMIT2 
and possibly HMIT (Agranoff & Fisher. 2001; Shetty et al.. 1995).
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1.4.2 .Mood stabilizers and M IP-synthase
The mood stabilizer YPA also modulates the Pins cycle, although via a different 
mechanism than lithium, as it does not affect IMPase and IPPase (Murray & Greenberg, 
2000; Yadnal & Parthasarathv. 1005). In contrast to lithium, YPA decreases inositol 
phosphate levels (Yaden et al.. 2001) and it does so by decreasing the in vivo activity o f  
A?2V6>-inositol-1 -phosphate synthase in mammalian brain (MIP-synthase. known as ino-1 in 
yeast) (Shaltiel et al.. 2004; Again et al.. 2002). MIP-synthase catalyses the reaction that 
converts D-glueose-6-phosphate to D-/mo-inositol-3-phosphate (also named L-^no- 
inosito l-1-phosphate (Berridge & Irvine. 1080)). The reaction is NAD-dependent and the 
activity is decreased 30-fold when inositol is added (Ju et al.. 2004). Postmortem human 
brain MIP-synthase activity is inhibited indirectly in a non-competitive manner by YPA 
with a K., o f  0.21 m \ I  (Shaltiel et al.. 2004). The purified recombinant human enzyme is, 
however, not inhibited directly by YPA (Ju et al.. 2004). suggesting that either a metabolite 
o f  YPA is the true inhibitor or that YPA targets an additional protein required for MIP- 
synthase activity. MIP-synthase protein has been reported to be expressed in the periphery 
in testes and within the brain, to be associated mainly with the endothelium and the 
vasculature (W ong et al.. 1987) (see Allan Brain Gene Atlas at http: www.brainatlas.oru ); 
its involvement in the mechanism of action o f  mood stabilizers is therefore not clear.
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1.4.3 \ l o o d  stabilizers and inositol transporters
Brain inositol levels are regulated via three main pathways: synthesis from glucose-6- 
phosphate to inositol-1-phosphate by the enzyme VHP synthase (see section 1.4.2). 
recycling from PIP: breakdown, and transport from the blood and cerebrospinal fluid. Key 
components o f  this third route are the inositol transporters, o f  w hich three are known. The 
sodium-dependent myoinositol transporter 1 (SM IT l. SLC5A3) has been reported to be 
inhibited by lithium. YPA or CBZ after long-term treatment o f  astrocytes (at least 8 days 
treatment) (van Calker & Belmaker. 2000). Moreover, all three mood stabilizers decreased 
SM ITl mRXA levels in astrocytes dissected from different brain areas or in human 
astrocytoma cell lines, but only after very prolonged treatment (8 to 14 days), indicating 
that SM ITl may not be the primary target for the action o f  mood stabilizers (Lubrich & 
van Calker. 1090). A more recent study by the same group showed increased SMITl 
m RN A  levels in neutrophils from BD-I individuals when compared with healthy subjects 
and decreased SM ITl expression in neutrophils from BD individuals treated with lithium 
(Willmroth et al.. 2006). The relevance and correlation o f  these findings to the brain are 
not clear. SMITl m RN A  expression is increased in neural tissue following brain injury 
(Guo et al.. 1007); moreover, in the mature brain the highest levels o f  SMITl expression 
are in the choroid plexus (Guo et al.. 1007). SM ITl is regulated by osmolarity and it is 
expressed also in the periphery, especially in the kidney (Yamauchi et al.. 1005). SM ITl 
null-mutant mice die soon after birth due to central apnoea (Berry et al.. 2003). The fetuses 
have a 02° o reduction in brain inositol levels with no change in phosphatidylinositol levels. 
Maternal treatment with inositol prevents lethality (Chau et al.. 2005). Heterozygote mice 
were also analysed and they showed no effect on lithium-sensitive behaviour (e.g. forced 
swim test). These results led the authors to rule out the inositol depletion hypothesis 
(Shaldubina et al.. 2006b). In addition, a second sodium-dependent myoinositol 
transporter has been described. SMIT2 (SLC5A13), which is widely distributed in 
peripheral tissues and also in the brain (Coady et al.. 2002). Little is known, however, 
about this isoform, except that it is regulated by osmolarity (Bissonnette et al.. 2004).
Cldry et al. recently described a H dependent m yoinosito l transporter (HMIT), which has 
a more restricted tissue distribution than SMIT. and is expressed in several brain regions, 
including neurons in the frontal cortex and in the hippocampus (Uldry et al.. 2001) (see 
Allan Brain Gene Atlas at http: www.bramatlas.oru ). Interestingly. HMIT is inserted into
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the neuronal plasma membrane from a vesieular compartment in an activity-dependent 
manner, suggesting that HMIT may be involved in regulating neuronal Pins synthesis 
during periods o f  high activity (L’ldry et al., 2001).
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1.4.4 M ood stabilizers and PKC
The PKC family is subdivided into three subfamilies: the eonventional. novel, and atvpieal 
PK C s(cPK C . nPKC, and aPKC. respeetively). ePK.Cs are activated by calcium and DAG, 
nPKCs are activated by DAG. but not by calcium, and aPK.Cs are not activated by either o f  
these molecules. PK.Cs are heterogeneously distributed in the brain with particularly high 
levels in presynaptic terminals. Sev eral PKC isoforms play a major role in the regulation o f  
neuronal excitability and long-term alterations in gene expression and plasticity 
(Nishizuka. 1995). Chronic lithium treatment has been shown to significantly decrease 
membrane-associated PKC levels in the rat hippocampus and frontal cortex (Chen et al.. 
2000a). Exposure o f  immortalised hippocampal cells to lithium induced a isozyme- 
selective decrease in PKC a  and or g levels, iso forms involved in facilitating 
neurotransmitter release, and a decrease in the levels o f  the PKC substrate myristoylated 
alanine-rich C-kinase substrate (MARCKS) (Lenox et al.. 1992; Watson & Lenox. 1996). 
Addition o f  /?mo-inositol completely reversed the lithium-induced dovvn-regulation o f  
MARCKS. indicating a link with the Pins pathway (Watson & Lenox. 1996). The mood 
stabilizer. YPA. produced strikingly similar effects to lithium on PKC a  and c isozymes, 
and on M ARCKS (Chen et al.. 1994). but neither lithium nor YPA affect PKC activity 
directly. Another PKC downstream target is the growth-associated protein 43 (GAP43, also 
called B-50. p57. neuromodulin. pp46 or L I ) (Benovvitz & Routtenberg. 1997). GAP43 is a 
cytoplasmic protein inv olv ed in neuronal plasticity and it is a major constituent o f  growth 
cones. It has been suggested that attenuation o f  PKC activity may play a role in the anti- 
manic effects o f  lithium and YPA. A pilot study found that tamoxifen (a non-steroidal anti­
oestrogen known to be a PKC inhibitor at higher concentrations) may indeed possess anti- 
manic efficacy (Bebchuk et al.. 2000); however, the study was very small and there have 
been no further data to support these findings. Overall, it seems that alterations in PKC 
signalling may be relev ant to BD - it may not be PKC itself, but other components o f  the 
pathway that are affected by mood stabilizers.
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1.4.5 Mood stabilizers and PO
Prolyl oligopeptidase (PO or PREP) is an enzyme (EC 3.4.21.26. 710 amino acids. -80  
kDa) that belongs to a class o f  serine peptidases, family S9A. The human PO gene is 
located on chromosome 6q22 (Goossens et al.. 1006). PO was first identified in human 
uterus as an oxytocin-cleaving enxvme (Koida & Walter. 1076). Subsequently, it was 
shown to cleave a number o f  neuropeptides, including substance P. thyrotropin-releasing 
hormone (TRH). and arginine-vasopressin at the carboxyl o f  the proline residue in vitro. 
For this reason it was originally termed post-proline cleaving enzyme. PO cannot 
hydrolyse peptides containing more than about 30 amino acids, the reason for which is 
evident from its crystal structure (see Chapter 4). Other members o f  this senne peptidase 
family include dipeptidyl peptidase IV. oligopeptidase B and aeylaminoacyl peptidase, 
some o f  which are o f  pharmaceutical interest (Polgar. 2002). More recently Szeltner et al. 
identified a new member o f  the PO family, the prolyl endopeptidase-like protein, PREPL. 
which lacks enzymatic activity and shares only - 2 0 ° o similarity with PO (Szeltner et al.,
2005). PREPL exists as a homodimer and possesses negligible hydrolytic activity. PREPL 
has high homolog>' with oligopeptidase B. Interestingly, lower PREPL mRNA expression 
levels have recently been reported in the orbitofrontal cortex o f  BD individuals when 
compared with controls, whereas PO levels did not change significantl)' (Ryan et al.,
2006).
PO is highly conserved through evolution from bacteria, eukaryocytes and plants 
(Harwood et al., 1007). Human and porcine PO share - 0 7 ° o amino acid identity. PO 
cellular localisation (intracellular versus secreted) has changed through evolution 
(Yenalainen et al.. 2004). Specifically, mammalian PO does not contain any predicted 
transmembrane domain sequences or signal peptides and is mainly a cytosolic enzyme. 
How ev er, a membrane-bound form o f PO has been identified in synaptosomal and myelin 
membranes (O'Leary & O'Connor. 1095; O'Leary et al., 1996). This particulate form has 
an apparent molecular weight o f -87  kDa, is 10-fold less active than cytosolic PO and 
differs in terms o f  sensitivity to inhibitors and affinity for peptide substrates (Irazusta et al.,
2002). PO is synthesised as an active peptidase and it is not found as a zymogen or 
proenzyme. Moreover, two proteins with PO activity have been detected in bovine and 
human plasma, whose origins are not clear: PO and an enzyme that is activity-resistant to 
the specific PO inhibitor Z-Gly-Pro-Prolinal (Breen et al., 2004; Cunningham & O'Connor,
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1997); this second enzyme has been called ZIP. as Z-Gly-Pro-Prolinal Insensitive Protease. 
PO and ZIP cleave substrates differentially. They both cleave TRH, but ZIP fails to 
hydrolyse substance P and vasopressin for reasons which are not clear. ZIP forms a 
homodimer with molecular weight more than twice that o f  monomeric PO (Bimey & 
O'Connor, 2001).
PO is widely distributed in the rat. mouse and human periphery and CNS, as indicated by 
PO activity and mRNA expression studies. Rossner et al. studied PO activity in mouse and 
found the highest levels o f  activity in the cerebellum, and an increase in hippocampal PO 
activity in aged mice (Rossner et al.. 2005). In contrast, in the rat brain, a reduction in PO 
activity was reported during development (Agirregoitia et al.. 2003). Analysis o f  human 
PO brain activity revealed the highest levels in the cortex, and the lowest in cerebellum. 
The temporal profile o f  these alterations was. however, area specific and differences in the 
activity between the soluble and particulate forms o f  PO were observed (Agirregoitia et al..
2003). PO activity in the CNS is higher than in peripheral tissues, such as skin (Rusuhara 
et al.. 1003). muscle and testes (Rato et al.. 1080; Irazusta et al., 2002).
PO mRNA expression in the rat has been analysed in detail by Bellemere et al. who 
reported high expression levels in cerebellar Purkinje and granule cells, in hypothalamic 
nuclei, in pyramidal neurons o f  Ammon's horn, in granule cells o f  the dentate gyrus, and 
within the amygdala. Moderate levels were observed in the cerebral cortex, the anterior 
thalamic group, the septal region and substantia nigra (Bellemere et al.. 2004).
PC) has been implicated in memory and cognition and in several illnesses. Naturally 
occurring PC) inhibitors have been obtained from several sources (e.g. wine, plant extracts, 
green tea and fungi). Several PO inhibitors have also been chemically synthesised and 
some o f  these showed memory enhancement in pre-clinical and human studies. For 
example, the potent and selective PO inhibitor, S - 17092, improved memory impairment in 
1 -methyl-4-phenyl-1,2.3.6-tetrahydropyridine (MPTP)-treated monkeys (Schneider et al., 
2002) and increased memory performance in humans (Morain et al.. 2000). Another 
inhibitor. JTP-4819. reversed scopolamine-induced amnesia in the passive avoidance test 
in rats, ameliorated memory deficits in rats with middle cerebral artery occlusion in the 
Morris water maze, and increased cortical and hippocampal levels o f  substance P and TRH
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immunoreactivity in aged rats (Shinoda et a!.. 1995: Shinoda et al., 1999: Toide et al., 
1995: Toide et al.. 1997). Five PO inhibitors have entered elinieal trials at phase 11. 
although none have progressed to the market.
Interestingly, abnormal PO plasma and aetivity levels have been measured in individuals 
with affeetive disorders. In particular. PO serum aetivity was increased (—14° o) in manic 
and schizophrenic individuals (Maes et al.. 1995). In contrast, decreased serum PO activity 
has been observed in individuals suffering from depression (Maes et al.. 1994). 
Interestingly, in depressed subjects, plasma PO aetivity was significantly increased during 
treatment with antidepressant drugs, such as fluoxetine, whereas, in manic subjects, short­
term treatment with YPA decreased PO aetivity (Maes et al.. 1995). An important control 
that is missing from these studies is the assessment o f  the drug effect in control conditions, 
which could be easily performed in vitro by treating blood cells from healthy controls with 
drugs. A more recent study by Breen et al. showed a -25° o decrease in PO aetivity in BD 
euthymic subjects under lithium treatment compared with controls (Breen et al.. 2004). 
How ever, this study lacks the untreated-BD sample control making interpretation o f  these 
data difficult. In addition, two sets o f  data are presented in an unconventional way. with or 
without a "quenching correction", which resembles the standard sample blank, which is 
conventionally subtracted in enzymatic assays. Moreover, no controls for the effect o f  
lithium on PO levels in cells were performed.
Since its identification, the mechanism o f  action o f  PO has been related to the cleavage o f  
neuropeptides. To support this mechanism, it has been demonstrated that orally 
administered PO inhibitors increase substance P. vasopressin and TRH levels in the rat 
brain (Nakajima et al.. 1992; Toide et al.. 1995). However, only very recently it has been 
emphasised that mammalian PO is a cytosolic enzyme and, therefore, it is located in a 
different cellular compartment to neuropeptides, which are generated in vesicles and then 
secreted (Schulz et al.. 2005). There are only very limited data on the intracellular 
signalling pathways modulated by PO at present and the precise intracellular targets remain 
unknown. A study in Dictyostelium discoideam  showed that ablation o f  the PO gene 
(DpoA) resulted in a 3-fold increase in IP? levels and induced resistance to the 
morphological effects o f  lithium. Similar effects were observed with a selective PO 
inhibitor (Williams et al.. 1999). These data suggest that the PO mechanism o f  action is
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somehow related to the Pins signalling pathway. The increase in IP;, levels via PO 
inhibition may derive from regulation o f  the activity o f  the enzyme multiple inositol 
polyphosphate phosphatase (MlnsPP) (Harwood. 2005). However, there is no evidence that 
PO inhibits MlnsPP directly. MlnsPP generates IP; from IP<,. a very abundant inositol 
phosphate present in cells, which may act as a cellular store o f  inositol and phosphates in 
Dictyostelium discoideum  (Harwood. 2003; Harwood & Again, 2003). However, MlnsPP 
is localised in the endoplasmic reticulum in mammals, whereas PO is a cytosolic protein; 
moreover, there is no evidence that MlnsPP is involved in signalling events in particular in 
the regulation o f  IP; levels. Furthermore, the intracellular signalling in Dictyostelium  
discoideum  differs substantially from mammalian systems; therefore, it is critical to 
confirm these findings in neurons. For example. Mudge & Saiardi did not find any 
evidence that IP> and IPf1 levels change when neurons are treated with the muscarinic agent 
earbaehol used to stimulate the Pins signalling pathway (personal communication).
O f  the mood stabilizers, only' YPA inhibits recombinant PO directly, whereas lithium and 
CBZ are without direct effect on the enzyme (Cheng et al., 2005). The fact that VP A 
inhibits PO directly (Cheng et al.. 2005). but its effects on growth cone size are reversed by 
PO inhibitors (Williams et al.. 2002). seems at first contradictory. However, the authors 
hypothesised that YPA may act as an inhibitor or an activator o f  PO depending on the 
intracellular signalling conditions and this would, therefore, explain the dual action o f  VTA 
in stabilizing mood from 'above' or from 'below ' baseline levels (Cheng et al.. 2005). 
Their model suggests that euthymic mood may be dependent on stable Pins signalling and 
YPA mav limit mood swings to mania by decreasing Pins signalling, and it may limit 
mood swings to depression by inhibiting PO and thus increasing Pins signalling.
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1.5 Mood stabilizers and GSK3
The serine-threonine kinase GSK.3 is a central component in many intracellular signalling 
pathways, in particular in the Wnt and in the PI3K/Akt pathways (Fig. 1.6).
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Fig. 1.6 GSK3 and intracellular signalling pathway. Source: (Gould & Manji, 2005).
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Wnt signalling is often subdivided into canonical and non-canonical pathways. In humans, 
the Wnt protein family is composed o f  at least 15 secreted glycoproteins. The non- 
eanonical pathway is activated by Wnt5a and W n t l l .  This pathway branches into two 
cascades: the Wnt JXK pathway, which involves c-Jun N-tenninal kinase (JNK) and the 
Wnt ( V  pathway, which involves PKC. In the canonical Wnt pathway. Wnt 
glycoproteins, such as Wntl and Wnt3. bind to the seven-transmembrane Wnt receptor. 
Friz/led. resulting in a signal that is transduced via the intracellular protein Dishevelled, 
which plays pivotal roles in both the canonical and non-canonical Wnt pathways. 
Signalling through Dishevelled results in inhibition o f  GSK3. through formation o f  a 
multicomponent complex, comprising Axin. Adenomatous Polyposis Coli (APC), 
Frequently Rearranged in T-cell Lymphoma (FRAT1). Casein Kinase I epsilon, and 
Protein Phosphatase-2A. One o f the main GSK3 substrates is p-catenin, which is found 
both in the cytoplasm and at the plasma membrane. The cytoplasmic pool is involved in 
transmitting the Wnt signal to the nucleus, whereas the membrane-associated pool interacts 
with cadherin to prov ide structural support in cell adhesions. Phosphorylation o f  p-catenin 
by GSK3 results in its degradation in an ubiquitin-dependent manner, thereby 
terminating inhibiting the actions o f  this important mediator (Peifer & Polakis, 2000). 
I 'nphosphorylated p-catenin binds to the T-eell factor Lymphoid enhancer factor (Tcf Let) 
that translocates to the nucleus and acts as a transcription factor at Tcf Lef promoter sites 
in a number o f  genes (Novak & Dedhar. 1099).
GSK3 is also a component o f  the PI3K Akt (also known as PKB) pathway, which is 
activated by growth factors, such as insulin. Insulin binds to a tyrosine kinase receptor, 
inducing receptor autophosphorylation at several intracellular tyrosine residues. This leads 
to the recruitment o f  the lipid PI3K to the plasma membrane and in close proximity to its 
physiological substrate PUN, which is then phosphorylated to PIP;. A key effector o f  PIP; 
in insulin signalling is PKB. PKB has a PH domain located in the N-tenninal domain, 
which binds to PIP;. This results in recruitment o f  PKB from the cytosol to the plasma 
membrane, where PIP; is located. Once activated. PKB dissociates from the plasma 
membrane and phosphorylates numerous substrates both in the cytoplasm and in the 
nucleus, including GSK3.
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Two isoforms o f  GSK3 arc known, namely a  and (3, which share nearly identical 
sequences in their kinase domains. GSK3 is constitutively active within cells, and 
phosphorylation at Serf) or Ser21 (GSK3(J or a. respectively) by PKB. decreases GSK3 
activity (Cross et a /., 1095). Other kinases are capable o f  phosphorylating GSK3[3 SerO, 
such as p7() S6 kinase. p90Rsk. PKC and PKA (Fang et al., 2000; Sutherland et al., 1993). 
Phosphorylation o f  GSK3(3 on Tvt216. in contrast, increases its activity (Hughes et al., 
1993; Wang et al.. 1994). GSK3 has a preference for phosphorylating substrates that have 
been pre-phosphorylated or “primed" by other kinases e.g. p-catenin pre-phosphorylated 
by casein kinase. GSK3 is known to regulate the activation states o f  several transcription 
factors, including heat shock factor-1. cyclic AMP-response element binding protein 
(CREB). c-jun. NF-KB. Mye and AP-1. among others (Grimes & Jope. 2001). O f  these 
transcription factors particularly noteworthy is CREB. a nuclear phosphoprotein that 
controls the expression o f  genes containing promoters with the cyclic AMP-response 
element. CREB plays a critical role in long-term memory, synaptic plasticity and cell 
survival (Shayvvitz & Greenberg. 1999). Another interesting downstream GSK3 target is 
glycogen synthase, which is phosphorylated and. therefore, inactivated by GSK3. resulting 
in inhibition o f  glycogen formation (Plyte et al.. 1992). This effect has stimulated the 
dev elopment o f  GSK3 inhibitors for the treatment o f  diabetes and several compounds are 
presently undergoing clinical trials.
GSK3 inhibitors are currently in development also for the treatment o f  Alzheimer's 
disease, as GSK3 directly modulates the phosphorylation state and. therefore, the function 
o f  sev eral microtubule-associated proteins, including tau and MAP-1 B. This results in loss 
and or unbundling o f  stable axonal microtubules (Lee et al., 2003; Lucas et al.. 199S; Sang 
et al.. 2001).
GSK3 is highly expressed in the adult brain (Ali et al., 2001), in the cytoplasm, nucleus 
and mitochondria o f  both neurons and glia (Jope & Johnson, 2004). Cytosolic GSK3 
inhibits protein synthesis and destabilises microtubules, while the nuclear enzyme inhibits 
expression o f  anti-apoptotic proteins and promotes p53-dependent apoptosis. In 
mitochondria. GSK3 can regulate energy production, but its precise mechanism is still 
unknown.
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GSK3 is involved in several neuronal processes, such as apoptosis, neurite outgrowth and 
growth cone morphology. Inhibition o f  GSK3 with synthetic inhibitors has been shown to 
protect from cell death induced by several apoptotie stimuli in different cell systems, 
whereas transient over-expression o f  GSK3(J induces spontaneous apoptosis in cell lines, 
such as PC 12 (Hetman et al.. 2000; Pap & Cooper. 1008). Similar neuroprotective results 
were obtained in rat sympathetic neurons (Crowder & Freeman. 2000) and in rat cerebellar 
granule neurons (Maggirwar et al ., 1000).
O f the mood stabilizers, lithium directly inhibits GSK3. with an ICS0 o f  approximately
2 m \ l  (above therapeutic plasma concentrations) (Klein & Melton. 1006; Phiel & Klein, 
2001) and inhibition occurs via competition for a low-affmity magnesium binding site 
(Ryves & Harwood. 2001). Importantly, however, lithium inhibits GSK3 also indirectly by 
increasing the phosphorylation of Akt. which phosphorylates SerO and inhibits GSK3. The 
direct and indirect effects o f  lithium on GSK3 act in concert to influence crucial GSK3- 
regulated functions (Chaleeka-Franaszek & Chuang. 1000; Jope. 2003). As a result o f  
GSK3 inhibition, lithium reduces MAP-1 B and tau phosphorylation levels (Lovestone et 
al.. 1000; Lucas & Salinas, 1007). decreases glycogen synthase phosphorylation and 
increases p-eatenin levels. Interestingly. O'Brien et al. and Gould et al. have shown that the 
antidepressant effect o f  lithium in the forced swim test is mimicked by the GSK3 inhibitor 
AR-A01441S and in mice lacking one copy o f  the GSK3P gene (Gould et al.. 2004; 
O'Brien et al.. 2004).
It is interesting to note that other group II cations, such as beryllium and zinc can also 
inhibit GSK3. but are not efficacious in the treatment o f  BD (Ilouz et al.. 2002; Ryves et 
al.. 2002).
Conflicting reports indicate that YPA directly or indirectly (via Akt and SerO 
phosphorylation) inhibits GSK3 (Chen et al.. 1009a; Hall et al.. 2002; Kim et al.. 2005a; 
Werstuck et al.. 2004), or does not have any effects at all (De Samo et al.. 2002; Eickholt 
et al.. 2005; Jin et al.. 2005; Phiel et al.. 2001; Williams et al.. 2002).
O f the mood stabilizers. CBZ has been shown very recently not to affect GSK3 either 
directly or indirectly (Ryves et al.. 2005). LTG. instead, attenuated staurosporine- and heat
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shock-induced caspase 3 activity in a cell line over-expressing GSK.3 (Bijur et al., 2000). 
although there is no evidence for a direet effect o f  LTG on GSK.3. ECT treatment, used for 
severe depression and mania, has been reported to alter phosphorylation o f  GSK.3, amongst 
other intracellular effects (Roh et al., 2003).
Moreover, acute treatment with several antipsychotic drugs e.g. risperidone, olanzapine, 
elozapine. quetiapine. and ziprasidone. has been shown to inhibit indirectly GSK.3 by 
increasing SerO phosphorylation in the mouse cortex, hippocampus, striatum, and 
cerebellum in a concentration-dependent manner, therefore showing that antipsychotic 
drugs, as well as mood stabilizers, modulate GSK3 activity (Li et al., 2006).
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1.6 Mood stabilizers and ERK/MAPK
Mitogen-activated protein kinases (MAPKs) transmit extracellular signals to the nucleus, 
where the transcription of  specific genes is induced by the synthesis, phosphorylation and 
activation o f  transcription factors. Three MAPK signal transduction pathways have been 
identified in mammalian cells: extracellular-signal regulated kinase 1 2 (ERK1 2), JNK 
and p3S (Gutkind. 1998) (Fig. 1.7). In particular, the ERK MAPK pathway is sometimes 
activated by neurotrophic factors to regulate neurogenesis, neurite outgrowth, and neuronal 
survival (Skaper & Walsh. 1998). Activation o f  the JNK. pathway has also been linked to 
neurite outgrowth and branching (Xiao et al ., 2006; Xiao & Liu. 2003; Xiao et al.. 2006).
MAP kinases are abundant in the brain, and a broad role for the MAPK. cascade in 
regulating gene expression in long-term forms o f  synaptic plasticity has been amply 
demonstrated (Roberson et al.. 1999).
The mood stabili/er YPA has been shown to strongly activate ERK MAPK in SEI-SY5Y 
cells (Yuan et al.. 2001). The effect was blocked by the MEK inhibitor PD098059. as well 
as by dominant negative-Ras and dominant negative-Raf. suggesting the involvement o f  
the R a s R a fM A P K  kinase pathway in the mechanism o f  action o f  VPA. VPA also 
increased ERK M APK phosphorylation in neurons o f  the rat anterior cingulate and in 
cultured cortical cells (Hao et al.. 2004). More recently, lithium was also shown to activate 
ERK MAPK in rat cerebellar granule neurons, but to exert the opposite effect in astrocytes 
(Kopnisky et al.. 2003; Pardo et ah. 2003). Chronic lithium or VPA treatment also 
increased levels o f  activated ERK MAPK in the rat hippocampus and frontal cortex, and 
this resulted in behavioural changes that mimic anti-manic effects. In fact, lithium was 
shown to reverse the effects o f  the ERK MAPK inhibitor SL327 in the open field test by 
decreasing locomotor activity (Einat et al.. 2003). Only one report suggests that CBZ 
modulates the ERK MAPK pathway and the study was performed in SH-SY5Y cells, 
therefore making the relevance to the brain unclear (Mai et al.. 2002).
Activation o f  the ERK MAPK pathway inhibits cell death and promotes survival by 
inducing the phosphorylation (and inactivation) o f  Bad, and increasing the expression o f  
the B-cell lymphoma leukemia-2 gene (bcl-2), most likely through CREB activation
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(Riccio et al.. 1999). Bcl-2 is expressed in the rodent and mammalian nervous system and 
is localised to the outer mitochondrial membrane, endoplasmic reticulum and nuclear 
membrane. Although the precise mechanisms o f  action o f  bcl-2 are unknown, it is now 
clear that bcl-2 is a protein that inhibits both apoptotic and necrotic cell death induced by 
diverse stimuli (Adams & Cory, 1998). Lithium exerts neuroprotective effects in a variety 
o f  preclinical in vitro assays e.g. N M DA receptor activation, ageing, serum/nerve growth 
factor deprivation, ouabain, thapsigargin, p-amyloid and these effects may be related to its 
effects on bcl-2 (Manji et al., 2000). Lithium was shown to increase levels o f  bcl-2 in the 
rat dentate gyrus and striatum (Manji et a l ., 2000), in rat cerebellar granule neurons (Chen 
& Chuang. 1999) and in SH-SY5Y cells (Lai et al., 2006). Moreover, lithium reduced 
levels o f  the pro-apoptotic protein p53 both in cerebellar granule neurons (Chen & Chuang, 
1999) and in SH-SY5Y cells (Lu et al.. 1999). Importantly, cytoprotective effects were 
observed in vivo as well. Treatment with lithium attenuated the biochemical deficits 
produced by kainic acid and ibotenic acid infusion and forebrain cholinergic system 
lesions, exerted dramatic protective effects against middle cerebral artery occlusion 
(Nonaka & Chuang, 1998) and enhanced hippocampal neurogenesis in the adult rodent 
(Chen et al.. 2000b).
VPA is also neuroprotective in in vitro systems, such as serum deprivation and oxidative 
stress (Lai et al.. 2006; Manji & Chen, 2002: Wang et al.. 2003; Yuan et al.. 2001) and the 
effects may be related to bcl-2. In fact, chronic treatment o f  rodents with therapeutic doses 
o f  lithium and VPA has been reported to produce a doubling o f  bcl-2 levels in the frontal 
cortex, as reflected in a marked increase in the number o f  bcl-2 immunoreactive cells in 
layers II and IV' o f  the cortex (Chen et al.. 1999b). VPA protected cerebellar granule 
neurons against excitotoxic agents (Bruno et al.. 1995), apoptosis induced by low 
potassium (Mora et al.. 2002), as well as injury to rat hippocampal neurons caused by p- 
amyloid and glutamate (Mark et al.. 1995).
Neuroplasticity underlies diverse processes o f  vital importance by which the brain 
perceives, adapts to and responds to a variety o f  internal and external stimuli. The 
manifestation o f  neuroplasticity in the adult CNS has been characterised as including 
alterations o f  dendritic function, synaptic remodelling, long-term potentiation, axonal 
sprouting, neurite extension, synaptogenesis and even neurogenesis. Recent brain
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morphometric studies are beginning to lead to a fuller appreciation o f  the magnitude o f  the 
neuroplastic events involved in the pathophysiology o f  BD (Duman et al. , 2000). Some 
reports suggest regional reduction in CNS volume, as well as reduction in the number 
and/or sizes o f  glia and neurons in discrete brain areas o f  BD individuals; however, results 
have been inconsistent. The most robust finding from a meta-analysis o f  26 studies in BD 
brains is enlargement o f  the right lateral ventricle; no other regional volumetric deviations 
were measured (McDonald et al ., 2004). Strong heterogeneity existed, however, for several 
regions, including the third ventricle, left subgenual preffontal cortex, bilateral amygdala 
and thalamus.
A clinical study using proton magnetic resonance spectroscopy to quantitate N-acetyl- 
aspartate levels (putative neuronal marker, localised to mature neurons and not found in 
mature glial cells, cerebrospinal fluid or blood (Tsai & Coyle, 1995)) reported that chronic 
lithium administration at therapeutic doses increased N-acetyl-aspartate concentrations in 
the human brain (M oore et al., 2000). It is therefore intriguing to speculate that chronic 
lithium treatment may not only exert robust neuroprotective effects, but also neurotrophic 
effects in humans.
The development o f  novel treatments for BD, which more directly target molecules 
involved in critical CNS cell survival and cell death pathways, has the potential to enhance 
neuroplasticity and cellular resilience, thereby modulating the long-term course o f  the 
illness.
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Fig. 1.7 Schematic o f  the MAPK pathways. Source: Cell Signalling web site (adapted).
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1.7 Mood stabilizers and growth cone morphology
Neuronal growth cones navigate over long distances along specific pathways to find their 
correct targets. Growth cones appear to be guided by at least four different mechanisms: 
contact attraction, chemoattraction, contact repulsion and chemorepulsion, and there is 
evidence that these mechanisms act simultaneously and in a coordinated manner to direct 
pathfinding (Tessier-Lavigne & Goodman, 1996). Growth cones have, therefore, been 
extensively studied to understand the processes o f  neuronal development. Alternatively, 
growth cones from sensory' neurons have also been exploited to analyse the action o f  drugs 
on signalling pathways (Lucas & Salinas, 1997: Lucas et al ., 1998; Owen & Gordon- 
Weeks, 2003). The axonal growth cone can be seen as a precursor o f  the presynaptic 
terminal. Therefore, it can be speculated that changes at the growth cone level can be 
reproduced in the CNS nerve terminals and may be relevant to the study o f  psychiatric 
illnesses. In fact, several signalling pathways have been implicated in BD and in the 
mechanism o f  action o f  mood stabilizers and, in particular, the Pins pathway. This pathway 
has a key role in synaptic connectivity and is involved in endo- and exocytosis, all 
processes that occur at the growth cone.
Growth cones were first described by Ramon y Cajal in 1890 as conical expansions at the 
tips o f  developing axons and dendrites. They are dynamic structures, as they extend and 
retract by sensing the environment during processes o f  neurite outgrowth and axonal 
pathfinding. Growth cones use receptors to sense extracellular cues and to transduce 
information to the cellular machinery that mediates growth cone turning responses. One o f  
the key players to regulate the growth cone motility is calcium. Calcium signals localised 
to one side o f  the growth cone can cause asymmetric activation o f  enzymes to direct the 
growth cone and high calcium levels can inhibit growth cone motility and arrest growth. 
Gradients o f  NGF, BDNF, netrin-1 and myelin associated glycoprotein (MAG) all induce 
growth cone turning responses that depend on their concentration (Tessier-Lavigne, 2002; 
Tessier-Lavigne & Goodman, 1996). Growth cones migrate by assembly and disassembly 
o f  filamentous actin (F-actin) and microtubules, and cycle between fast moving, elongated 
forms with a contracted appearance and slow moving, spread forms. Steering depends on 
intact filopodia and F-actin, whereas extension requires intact microtubules. Briefly, 
microtubules are eukaryotic cytoskeletal organelles involved in several cellular processes.
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such as cell division and transport o f  vesicles. Microtubules are formed by tubulin, which 
is a heterodimer o f  two polypeptide chains, called a  and p. Different genes encode for six 
a  and seven p isoforms, which differ in localisation (Bianchi et al., 2005). Microtubules 
are functionally modified by post-translational modifications, including tyrosination, 
detyrosination, acetylation, phosphorylation and glutamylation. These modifications 
usually affect the carboxyl-terminal domain. In contrast, acetylation occurs at Lys 40 o f  a -  
tubulin. Acetylated-tubulin is currently considered a marker o f  stable microtubules, in 
contrast to tyrosinated-tubulin representing dynamic microtubules (Table 1.3) (Bianchi et 
al.. 2005).
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T able 1.3 O verview  o f  the m iorotubular system  in m am m alian brain.
The growth cone peripheral domain is devoid o f  cytoplasmic organelles, but includes 
tilopodia and lamellipodia, which are flattened veils between filopodia. The thicker, central 
domain is rich in vesicles and organelles. F-actin and microtubules are arranged as parallel 
bundles in the neurite shaft but splay apart and turn as they enter the growth cone central 
domain. Microtubules dominate the central domain o f  the growth cone, but they can also 
penetrate the growth cone peripheral domain and interact with F-actin (Fig. 1.8A).
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Growth cones can be observed in processes o f  cultured neurons, including sensory 
ganglionic neuron explants, a few hours after plating. This occurs even in the absence o f  
signals involved in dynamic behaviour, as a result o f  spontaneous electrical activity in the 
culture. Cheng & Mudge have observed that tetrodotoxin (TTX) affects growth cone 
dynamics by decreasing the percentage o f  growth cone collapse in sensory explants 
(personal communication). TTX blocks action potentials in nerves by binding to the pores 
o f  the voltage-gated sodium channels in nerve cell membranes. Growth cone behaviour can 
also be altered by pharmacological agents. For example, cytochalasin B causes 
depolymerisation o f  F-actin and retraction o f  filopodia, whereas colchicine induces 
disruption o f  microtubules (without affecting filopodia), which results in neurite retraction 
and induction o f  protrusions o f  new lamellipodia and filopodia along the axon. O f  the 
mood stabilizers, high doses o f  lithium have been reported to increase the number o f  stable 
(detyrosinated) microtubules in sensory neuron growth cones and increase growth cone 
spread area (Goold et al., 1999; Hall et al., 2000; Lucas et al., 1998; Owen & Gordon- 
Weeks, 2003); these effects were mimicked by potent GSK3 inhibitors (Fig. 1.8B). 
Lithium (20 mM) and GSK.3 inhibitors (SB-216763 -  10 pM - and SB-415286 -  30 pM) 
were also shown to prevent the collapse induced by the repulsive guidance cue Sema3A 
(Luo et al., 1993), which activates GSK.3 at the leading edge o f  growth cones (Eickholt et 
al., 2002). Sema3A is known to bind \e u ro p i l in - l  receptor and to interact with the 
signalling co-receptor Plexin to subsequently activate GSK3. Another study has shown that 
Sema3A suppresses PI3K signalling concomitant with the activation o f  GSK3, which 
depends on the phosphatase activity o f  PTEN. Interestingly, application o f  the PI3K 
inhibitor LY294002 (10 pM) induced a very fast collapse (within minutes) in DRG 
neurons (Chadbom et al., 2006). Another study showed that addition o f  LY294002 to DRG 
neurons induced apoptosis and prevented neurite outgrowth and when added to newly 
formed neurites it caused neurite retraction (Virdee et al., 1999).
These data suggested that GSK3, via PI3K, may be a key signalling player in regulating 
growth cone morphology and other cellular processes, such as cell survival.
Another study using sensory neuron explants showed a common effect o f  lithium, VPA 
and CBZ on the growth cone dynamics (Williams et al., 2002). Each o f  the drugs increased 
the growth cone spread area and decreased the percentage o f  collapsed growth cones.
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Interestingly, this common effect was reversed by addition o f  exogenous myo- inositol, 
thereby implicating the Pins pathway as the common pathway regulated by the drugs.
The key signalling players in regulating growth cone dynamics and vesicle trafficking in 
both neuronal and non-neuronal cell types are the Rho family o f  GTPases. This family 
includes RhoA, Racl and Cdc42 that are regulated by guanine nucleotide exchange factors 
(GEFs), which promote their activation, and by GTPase-activating proteins (GAPs), which 
attenuate the function and retain the inactive GDP-bound state. Small GTPases shuttle 
between a GDP- (inactive) and a GTP- (active) bound state. When bound to GTP they 
interact with a variety o f  effectors. Am ong these, PI(4,5)P: is a key signalling molecule, 
which in cooperation with Cdc42, binds N-W ASP and triggers a conformational change 
that allows activation o f  the ARP2 3 complex, a potent actin assembly nucleator (Pollard & 
Borisy. 2003; Rohatgi et al., 2000). PI(4,5)P: facilitates actin filament elongation by 
promoting the dissociation o f  capping proteins, such as gelsolin. In addition, PI(4,5)P2, 
through its binding to profilin, promotes the association o f  actin-monomer-profilin 
complexes, thus making G-actin available.
Interestingly, Rho and Rac associate with PIP5-kinase, which catalyses the formation o f  
PI(4,5)P: (Ren & Schwartz, 1998; Tolias et al., 1998; Chong et al ., 1994) Rho proteins 
affect actin polymerisation by regulating cofilin, an actin filament-severing and actin- 
depolymerising factor. The Rho target ROCK in turn phosphorylates and activates LIM 
kinases, which directly phosphorylate cofilin and, therefore, inactivate it, leading to an 
increase in polymerised actin (Ridley, 2006).
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B
Fig. 1.8 Examples o f  growth cone morphology.
A Example o f  a large paused cortical growth cone imaged in differential interference 
contrast microscopy. The central, transition and peripheral regions of the growth cone are 
indicated in green, yellow and pink, respectively. Source: (Dent & Kalil, 2001)
B Low-power, phase-contrast images o f chicken embryonic DRG explant cultures grown for 
24 h in vitro in control conditions (Control) or in the presence o f either 10 mM LiCl or 10 
pM SB-216763. In control cultures, there is a profuse, radial outgrowth o f axons tipped with 
growth cones (arrows). In drug-treated cultures, outgrowth is also profuse, but axons are 
shorter in length than controls and have larger growth cones (arrows). Ganglia are marked 
with G. Source: (Owen & Gordon-Weeks, 2003).
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AIMS OF THE THESIS
The aims o f  this thesis are to investigate candidate signalling pathways involved in the 
m echanism  o f action o f  mood stabilizers in neurons, to determ ine if  any o f  these are 
com m only regulated by lithium, VPA or CBZ, and to identify new drug targets.
In the first part o f my thesis I have focussed on the signalling component GSK3 and used 
biochem ical assays as well as the growth cone assay to investigate the role o f this kinase in 
the action o f m ood-stabilizing drugs.
Subsequently, I have focussed on the Pins pathway, a key pathw ay im plicated in synaptic 
activity and cellular morphology. I have analysed the neuronal expression o f  key 
com ponents o f  this pathway, including the inositol transporters HMIT, SMIT1 and SMIT2 
and the enzym e M IP-synthase and showed that HMIT only is expressed in neurons and it 
can, therefore, contribute to the action o f  the mood stabilizers. M oreover, the effects o f 
each o f  the mood stabilizers examined in the growth cone assay seem to be dependent on 
inositol.
Furthermore, I have extensively analysed the enzym e PO, which has been reported to 
m odulate the Pins pathw ay and has been im plicated in the mechanism  o f action o f  the 
drugs. I have used a PO null-mutant mouse, viral delivery technology and the results o f 
Y2H assay to shed light on the role o f this enzym e in the action o f  mood stabilizers.
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CHAPTER 2 
Materials and Methods
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2.1 Reagents
VPA, LiCl, CBZ, trychostatin A (TSA), /m o-inositol, gabapentin (GPT) and dimethyl 
sulfoxide (DM SO) were purchased from Sigma Aldrich; SB-415286, SB-216763 and the 
PO inhibitor S -17092 were synthesised at G laxoSm ithKline; phenytoin (PTN) was from 
Calbiochem ; Z-Pro-Pro-aldehyde-dim ethyl acetal was from Bachem. All chem icals used 
for buffer preparation were purchased from Sigma Aldrich, unless otherwise stated.
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2.2 Cell culture
2.2.1 Cell lines
H um an embryonic kidney cells, HEK-M RSII, HEK293 and HEK293T (obtained from 
GlaxoSm ithKline) were cultured in M EM (Invitrogen), 10% (v/v) fetal bovine serum 
(FBS), 1% (v/v) MEM non-essential am ino acids (Invitrogen) and 2 mM L-glutamine. The 
Chinese ham ster ovary cells, CH O JK 1, (obtained from GlaxoSm ithKline) were cultured in 
H am ’s F I 2 m edium  (Invitrogen) with 10% (v/v) FBS.
2.2.2 Rat prim ary cortical, h ippocam pal and striatal neurons
Cortical, striatal and hippocampal neurons were prepared from em bryonic day 18 ( E l8) 
Sprague Dawley rat brains (Charles River). Anim als were euthanased in accordance with 
the 1986 A nim als (Scientific Procedures) Act. The cortex (or striatum or hippocam pus) 
was carefully dissected, placed into ice-cold H ank’s Balanced Salt Solution (HBSS)
(Invitrogen) with 1 mM  sodium pyruvate (no Ca or Mg ) (Invitrogen), 100 U 
penicillin 50 pg streptom ycin/m l (Invitrogen), 10 mM N -2-hydroxyethylpiperazine-N '-2- 
ethanesulfonic acid (H EPES) pH 7.4 (Invitrogen), 0.035%  (v/v) N aH CO, (Invitrogen), and
dissociated with 0.5%  (v/v) trypsin ethylenediam inetetraacetic acid (EDTA) (Invitrogen) 
for 5 min at 37°C (or for hippocampal neurons with 0.1% (v/v) trypsin/EDTA for 30 min 
at 37°C). Trypsin was neutralised by adding an equal volum e o f Neurobasal M edium 
(Invitrogen) with 10% (v/v) FBS, and cells were dissociated using fire-polished Pasteur 
pipettes o f  decreasing size. Cells were centrifuged for 5 min at lOOxg and resuspended in 
Neurobasal M edium (wvo-inositol concentration o f  7.2 mg/1) (Brewer et a l., 1993) 
containing 1 mM sodium pyruvate, 100 U penicillin/50 pg streptom ycin/m l, 2%  B27 
supplem ent with antioxidants (Invitrogen), 0.025 mM L-glutamate (Sigma) and 1 mM L- 
glutamine. For W estern blotting analysis, neurons were seeded at 500,000 cells/well in 
poly-D -lysine (m olecular weight (MW ) >300,000, Sigma) coated 6-well plates. For m RN A  
analysis, neurons were seeded at 500,000 cells/well in poly-D -lysine coated 6-well plates 
and lvsed after 5, 7, or 9 days in culture (die). For growth cone m orphological studies,
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neurons were plated at 12,500 cells/well on poly-D-lysine coated coverslips in 24-well 
plates and treated with drugs 20 h after plating for 4 days.
2.2.3 M ouse prim ary neurons
Cortical neurons were dissociated from em bryonic day 15 ( E l5) m ouse brains in 
accordance with the 1986 A nim als (Scientific Procedures) Act. The papain dissociation kit 
from Lom e Laboratories was used following the m anufacturer’s instructions. Briefly, 
cortices were carefully dissected, placed into ice-cold HBSS with 1 mM sodium pyruvate
(no Ca or M g ), 100 U penicillin. 50 pg streptom ycin/m l, lO m M  HEPES pH 7.4, and
0.035%  (v/v) N aH CO ,. Cortices were subsequently incubated with 5 ml o f  a solution made 
with 0.005%  DNAse. 20 units ml papain. 1 mM  L-cysteine and 0.5 mM EDTA for 10 min 
at 37°C. After trituration, the cell suspension was filtered through a 70 pm strainer 
(Falcon) and centrifuged for 5 min at 150xg. The pellet was then re-suspended in a solution 
made by 2.7 ml EBSS and 300 pi o f  10 m g ml ovom ucoid protease inhibitor in EBSS, 
10 m g ml bovine serum  albumin and 150 pi o f DNAse solution (2,000 units/ml). The cell 
suspension was applied gently on the top o f  5 ml EBSS solution with 10 mg/ml albumin 
and 10 m g ml ovom ucoid inhibitor solution and centrifuged for 5 min at 70xg. The pellet 
was then resuspended in Neurobasal m edium containing 1 mM sodium pyruvate, 100 U 
penicillin.'50 pg streptom ycin ml, 2% (v/v) B27 supplem ent with antioxidants, 0.025 mM 
L-glutamate, 1 mM L-glutamine and neurons were plated at 100,000 cells/well in a 24-well 
plate for im munocytochem istry.
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2.2.4 Rat and m ouse dorsal root ganglia explants
Dorsal root ganglia (DRG) from P0-P2 rats (Charles River) or P0-P1 mice (Deltagen and 
G laxoSm ithKline) were dissected in L15 medium with 100 U penicillin/50 pg 
streptom ycinm l (Invitrogen) and cultured as explants on coverslips. Coverslips were 
coated with 500 pi o f  10 pg  pi poly-D -lysine (M W  >300,000, Sigma) overnight at 37°C, 
washed three times with distilled water, air-dried for -3 0  min and subsequently coated with 
laminin (50 p g m l, Sigma - note that this is 5x concentration when com pared with that 
used for culture o f  other cell types) for 4h at 37°C. The following plating m edium  was 
used: DMEM  F12 with Glutamax (Invitrogen; it contains 12.60 mg/1 o f  wvo-inositol), 
nerve growth factor (50 ng ml, Invitrogen, stored at -20°C), insulin (5 p g  ml. Sigma, stored 
at -80°C), and SATO medium, as previously described (Cheng & Mudge, 1996; W illiams 
et a l., 2002; Cheng et al., 2005). A X I0 solution o f  the following com ponents (SATO) was 
m ade and stored at -20°C (Bottenstein & Sato, 1979): 500 ml DMEM F I2 with Glutamax, 
transferrin (1 m g ml. Sigma), BSA (1 m g ml. Sigma), putrescine (160 mg/ml, Sigma), 
sodium selenite (390 n g m l, Sigma), L-thyroxine (T4: 500 n g m l, Sigma), and 3,3,5- 
triiodo-L-thyronine (T3: 500 n g m l, Sigma). Drugs were added after 20 h in culture and 
explants were cultured for at least a further 24 h (or as indicated) before loading the 
neurons with calcein AM  dye (1 p g  ml, M olecular Probes) and proceeding with fixation.
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2.2.5 T ransient transfection  o f  cell lines
M any param eters influence transfection efficiency, including cell culture conditions, vector 
characteristics and quality, and the transfection technology used. Cells should have a low 
passage number (<50 passage num bers) and be sub-cultured around 24 h before 
transfection. This ensures normal cell m etabolism  and increases the likelihood o f nucleic 
acid uptake. On transient transfection, m any copies o f  the DNA are present in the cell 
following transfection, but the introduced DNA does not integrate into the chromosom es. 
Transient transfection often results in high levels o f  expression o f  the introduced gene, but 
only for a few days following transfection. Cationic liposom es typically contain a m ixture 
o f  cationic and neutral lipids organised into lipid bilayer structures. Transfection-com plex 
form ation is based on the interaction o f the positively charged liposom e with the negatively 
charged phosphate groups o f the nucleic acid. The uptake o f the liposom e -  DNA 
com plexes may be m ediated by endocytosis. Com pared to other methods, liposom es often 
offer higher transfection efficiency and better reproducibility. Serum often lowers the 
transfection efficiency, and it is therefore usually omitted. Cells were plated one day before 
transfection at 500,000 cells/well in a 6-well plate and they were -8 0 %  confluent at the 
time o f transfection. Transfection mix was prepared by adding DNA to DMEM  with no 
serum followed by Fugene-6 (Roche) (Fugene-DNA  ratio = 3:1). The mix was incubated 
for 15 min at room tem perature and then added dropw ise to the cells.
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2 3  Cell assays
2.3.1 A nalysis o f  sensory and cortical neuron grow th cone area
Random fields o f  calcein- or G AP43-labelled axons at the perim eter o f the axonal halo that 
grew out from the explant cell bodies were scored using a X40 objective and Olympus 
BX51 m icroscope equipped with epifluorescence optics. The perim eter o f  labelled growth 
cones was traced with a light pen and the area was calculated using Im age-Pro Plus 
software. Images o f  cortical neurons w ere acquired from 10 random fields with a X20 
objective. For each drug treatment at least 100 growth cones were measured. The 
experim ent was repeated as described in the figure legends.
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2.3.2 PO enzym e activity assay
Brains were removed from mice or rats, weighed and hom ogenised in 5X volum e o f  cold 
PBS. Cells from 10 cm dishes were washed with cold PBS and subsequently sonicated in 
500 pi o f  cold PBS. Homogenates were centrifuged at 16,000g for 5 min at 4°C and 
supernatants analysed for PO activity. Duplicate reactions w ere prepared for each sample 
consisting o f 20 pi supernatant (neat or diluted), 160 pi PBS and 20 pi o f substrate N- 
benzyloxycarbonyl-glycyl-7-am ino-4-m ethylcoum arin (Z-Gly-Pro-AM C, 30 pM  final, 
Bachem) according to a modification o f  the m ethod by (Venalainen et al., 2002) (Fig. 2.1). 
Z-Gly-Pro-AM C was dissolved in 60% (v/v) m ethanol, as this solvent has been reported to 
m inim ally affect PO activity.
. o .  . 3 .
tT O' o
Z-Gly-Pro-AM C
Fig. 2.1 Chemical structure o f Z-Gly-Pro-AMC.
The arrow indicates the peptide bond cleaved by PO.
The reaction was perform ed at room tem perature for the time indicated and term inated by 
addition o f 400 pi o f  1.5 M acetic acid. A blank for each reaction was also included, 
consisting o f no addition o f enzyme or substrate, or a zero incubation time, which was 
subtracted from the results. 200 pi from each reaction were transferred into 2 wells o f  a 96- 
well plate with white base and sides (total four replicates). M easurement o f  the fluorescent 
AM C liberated by PO cleavage o f  the prolyl bond was quantified spectrofluorom etrically 
using a FlexStation plate reader, with excitation and em ission wavelengths set at 355 nm 
and 460 nm, respectively. Values wrere norm alised to protein concentrations for cell lysates 
or protein weight for tissues.
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2.4 Biochemical techniques
2.4.1 D eterm ination o f protein concentration
Protein concentration was determined using a standard BCA™ protein assay kit (Pierce). 
Bovine serum albumin was used as standard, prepared according to the m anufacturer’s 
instructions. Sample protein levels w ere quantified by colorimetric detection using a 
SpectraM ax 340PC plate reader after 30 m in incubation at 37°C. Several dilutions o f  the 
unknown samples were prepared in order to obtain values w ithin the standard curve range.
2.4.2 W estern blotting
Cells were washed with cold PBS and lysed in sample buffer consisting o f  2% (w/v) 
sodium dodecyl sulphate (SDS), 10% (v/v) glycerol, 25 mM TRIS pH 6.8, 1% (w/v) 
bromophenol blue, 1% (v v) p-mercaptoethanol. For p-catenin extraction, a detergent-free, 
hypotonic buffer was used (Cross et al., 2001). Equal am ounts o f  protein lysates wrere 
resolved by SDS polyacrylam ide gel electrophoresis (SDS-PAGE) using 4-20%  Tris- 
Glycine gels (N ovex) and TGS buffer (25 mM Tris pH 8.6, 192 mM Glycine, 0.1% (w/v) 
SDS, Bio-Rad). W et im munoblotting was perform ed using TG buffer (25 mM Tris pH 8.3, 
192 mM Glycine and 20%  (v/v) methanol, Bio-Rad) and 20V overnight in order to transfer 
the proteins to the nitrocellulose m embrane (Amersham). Precision Plus Dual Colour 
marker was from Bio-Rad. Transfer quality was assessed by Ponceau S (Sigma) staining. 
A fter 1 h blocking with 10% (w/v) non-fat dry milk in TBST (Tris buffered saline 
containing: 150 mM  NaCl, 50 mM Tris-HCl pH 7.5/0.1%  (v/v) Tween 20) the blots were 
probed with the prim ary antibody in 5% (w/v) non-fat dry milk TBST overnight.
Prim ary antibodies used were: rabbit polyclonal anti-m itogen-activated protein kinase 
(ERK1/2) (Upstate, used at 1:10,000), m onoclonal anti-tau de-phosphorylated on Ser 
189/207 (clone Tau-1, Chemicon, used at 1:1,000), m onoclonal anti-tau phosphorylated on 
Ser 202 (clone AT8, Autogen Bioclear, used at 1:1,000), monoclonal anti-P-catenin 
(Chem icon, used at 1:1.000), m onoclonal anti-phospho-glycogen synthase (generated and
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validated at G laxoSm ithKline, used at 1:500), rabbit polyclonal anti-PO #1216 (Cam bridge 
Research Biochemicals, used at 1:1,000), rabbit polyclonal anti-GAP43 (Abeam, used at 
1:3,000), rabbit polyclonal anti-P-GAP43 (Zym ed, used at 1:3,000). The blots were then 
washed with TBST for 45 min, changing the buffer every 15 min, incubated with goat anti­
rabbit IgG or goat anti-m ouse IgG H RP-conjugated secondary antibodies (Santa Cruz, used 
at 1:10,000) in 5% (w/v) non-fat dry m ilk TBST and developed using the SuperSignal 
W est Pico Chem ilum inescent Substrate (Pierce). Protein levels w ere norm alised to ERK1/2 
and expressed as fold-induction relative to control. Q uantitation was perform ed using 
GeneTools software from Syngene. Single sam ple t test was used for statistical analysis.
2.4.3 Im m unoprecip itation and co-im m unoprecip itation
Cells were lysed in a mild lysis buffer consisting o f  50 mM Tris-HCl pH 7.5, 150m M  
NaCl, 0.5% (v v) Triton X-100, 1 mM  EDTA. Protease and phosphatase inhibitors (Sigma 
protease inhibitor cocktail, used at 1:200, Sigma phosphatase inhibitor cocktail II, used at 
1:100) were added just before use. In order to allow formation o f the antibody-antigen 
complex, 500 pi o f  cell lysates were used for each im m unoprecipitation reaction and 
aliquoted into pre-chilled tubes. The specific antibody directed against target protein or 
epitope-tag was added to the lysate (1-5 pg o f  antibody per sample). Samples were 
incubated at 4°C on a rotating wheel overnight. 25 pi bed volum e o f  Protein G Sepharose 
(Sigma) was used per sample, washed 3 times in TBS, followed by 3 washes with lysis 
buffer. Beads were finally resuspended in lysis buffer to give a 50% solution. 25 pi bed 
volum e protein G Sepharose was added per sample and incubated on the rotating wheel at 
4°C for 1-3 h. The com plex was briefly spun and the supernatant was carefully rem oved 
and discarded. Three washes with suitable wash buffer were performed, twice with protein 
lysis buffer followed by one wash w ith lx  TBS. A fter the last wash, all traces o f  liquid 
w'ere carefully rem oved with a fine pipette tip. In order to elute proteins from Protein G 
Sepharose, 35 pi o f  2x protein sample buffer (4%  (w/v) SDS, 20% (v/v) glycerol, 50 mM 
TRIS pH 6.8, 2% (w/v) brom ophenol blue, 2% (v/v) P-m ercaptoethanol) were added to the 
Protein G Sepharose pellet and boiled for 5 min at 100°C, spun briefly, and the supernatant 
run on a SDS-gel.
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2.4.4 PO antibody generation
The typical peptide length for good antibody production is in the range o f  15-20 residues. 
Peptide sequences o f  this length should contain at least one epitope, should be easy to 
synthesise, be relatively soluble in aqueous solutions and should adopt a limited num ber o f 
conformations.
PO peptide sequences were selected based on the crystal structure and the following 
criteria:
1. Hydrophilic pattern: it is im portant to determ ine which parts o f the protein are exposed 
and thus available for reaction:
2. Content o f  charged residues: the selected peptides should be neutral. It is also best to 
avoid m ultiple am ino acid repeats:
3. Peptide solubility: it is preferable to avoid hydrophobic residues, such as tryptophan, 
valine, leucine, isoleucine and phenylalanine, as well as glutamine, which can form 
hydrogen bonds betw een peptide chains:
4. Post-translational modifications: some sites within a protein may be m odified e.g. by 
glycosylation. These sites must be avoided.
A Blast search was perform ed to eliminate any sequences with significant hom ology with 
other proteins. Considering the high PO sequence hom ology among species, antibodies 
w ere expected to recognise PO protein from rat, m ouse and human, am ongst other species 
(Fig. 2.2). The follow ing peptides (or whole protein) were used:
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LSFQYPDVYRDET (N-terminal sequence) (rabbits #1216, #1217) 
Y PQ Q DG KSDG TETSTNLH  (internal sequence) (rabbits #9635, #9636) 
IVGRSRKQSNPLLIH (close to C-term inal) (rabbits #1422, #1423)
Full-length recom binant PO (made at G laxoSm ithKline, C-terminal His-tagged) 
(rabbits #1890, ff!891)
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# 1 2 1 6 , # 1 2 1 7
20 4 0 £0
rHGHKICDPi
8 0 100 120 1 4 0 1 8 0
LDPDSEQH’JirVlAQKKlTVPFLIQCPIRCLYKIRHTILyDYPKYSCHFKKCKrmmTGLQKQPVLYVQDSLIGIAPVPLDPl
LEDPDSEQTKAFVEAQHKITVPFLEQCPIPGlYKBWtTElYl'YPKYSCHFlXGEFYFYFYIJTGlQNQPVLYVQt’SLEGEAPVFll'PK
LSri'GTVALFGYAFSEl’GEYFAYGLSASGSI’WVTIKFHPr.TGAKELPti 
LSt'I>GTVALPGYAFSn-GIYFAYGLSASGSI>BVTIKFHKVr-GAKILPD
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  LSDrGTVAlPGYAFSEI'GBYFAYGLSASCSI,WVTIKPHKVI>GAKELPI>
LEI>FI'SBQTKAFmQATITVFFLEQCPIPGLYKEPltTELYrwmCHFKKGm7YFYHTGLQHQPVlYV0PSLEGBAPVFLEPHHLSPI'GTVALPGYAFSBI'GEYFAYGLSASCSDWTIKFHKVt‘GAKELPr'm
HLSFQYPDVYPDIT vQdYHGHKiCDPYaVLlDPDSEQTKAFVIAQNKITVPFLEQCPIRGLYKHRHTILYDYPKYSCHFKKGKRYFYFYHTCLQNQRVLYVQDSLEGEARVFLDPN LSDDGTVALRGYAFSEDGIYFAYGLSASGSDWT1KFMKVDGAK1LP0
#96 3 5 , # 9 6 3 6
VLKRVKF CHAWTHDGKGHFYNsYPQQDGKSDGTITSTITLHQKL YHVLGTDQSIDiLCAlFPDEPKWGGAILSDDGRYVLLSI KGCDPVMRLWYCDLQQesnGI GILKWVKLIDHFEGEYDYvTNEGTVFTFKTHR SPM Y R lIH ID FtD P BSKVKVLVPE
*  4 8 0  *  S
D SE E |  : 498
2525$ \ : 498I : 498
I : 498
HIKDVLBWvACVRSBFLVLCYLhdVKNi LQLHDLtIGALLKteFPLdVGSvVGYSG KKD IIF Y Q F IS F L SP G  IYHCDLTkEILIPrVFRIVTVKGIDAsDYQT QiFYPSKDGTKIPKFIVHKKGIKLDGSHPAFLYCYCGFNISITPKYSVSRLIFVRHRGGv 
0 0  * 5 2 0  * 5 4 0  *  5 6 0  *  5 8 0  *  6 0 0  * 6 2 0  *  6 4 0  *  6 6 0
LAVAWIP.GGGEYGETWHKGGILAK:QNCFr<r>FQCAAEYLIKEG-rT»:PLTIHGGSNGGLLVA|CANQPPDLFGCVIAQVGVHr'HLKFH13jTIGHAWIir1YGC£I<KOHFEVLjJPTSPLHirl?KLPEAI'I'IQYPSHLLLIAI'Hr<t'Pn,P l1H£lKFIATLOYIVGPS 
LAVANIP.GGGEYGEIW HKGGILANi:QNCFIl»FQCAAEYLn:EGYT»:PLTIKGGSNGGLLVAlcANQPPiaFGCVIAQVGVTC'HLKF»flTIGHAW ITr.YGCSlA:QHFEVLlTSPLHIW:LPEAI'r'IQYPSMLLLTAI«'r'PWPl,HSLP:FIATLQYIVGPS 
LAVANIP,GGGEYGETmKGGILAlJKQHCFPr*FQCAAEYLIP:EGYT#KPLTIKGGSNGGLLyA|CANQPPI'LFGCVIAQVG^ir'HLKFB|TIGHAWIir'YGCSr»fcQHFEWL|^'SPLHIIVi:LPEAri'IOYPSHLLLTAI'K'I'PWPLH£LP:FIATLQYIVGPS 
LAVAHIP.GGGEYCITllHKGGIlAinCQHCFPPFQCAABYLmGnKPlIIHGGSllGGLLVAlcAIJQPlDLFGCVIAQVGVHDMLKFHIlTlGHAWTIOYGCSDKQHFEWLKYSPLHBVKLPIAI't'IQYPSllLLLTAl'HI'tP.VVPLHSLPIFIATLQYIVCPS
LAVANIR&GGEYGETWHKGGILAKKQHCPDDFQCAABYlIKECYTspKRLTIItGGSIGGLLVAaCANQRPDLFGCVIAQVGVllDHLKFHK TIGHA¥TTDYGCSDsKQHFEWL KYSPLHNVKLPEADDIQYPSMLLLTADHDDPWPLHSLKFIATLQYIVGRSR 
6 8 0  ♦  7 0 0  *
664
664
664
664
KQ sN P L LIHVD TKAGHCaGKPTAKVIEEVSDHFAFIARC LH i f l
# 1 4 2 2
# 1 4 2 3
. 2.2 Alignment o f PO protein sequence from rat, mouse, human and pig.
Conserved residues are indicated in dark blue, white residues represent amino acids that are not conserved amongst species, light blue are residues that are partially 
conserved. Peptides that have been selected for antibody generation are highlighted with a red bar together with the rabbit identification number (#).
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Peptides were sulpho-linked (via cysteine) to keyhole limpet hem acyanin (KLH). Rabbits 
were immunised with the peptides or recom binant protein, serum collected and antibodies 
purified by Cam bridge Research Biochemicals (CRB) (#1216, #1217, #1890, #1891) or 
Research Genetics (#1422, #1423, #9635, #9636). Antisera were tested by ELISA by the 
suppliers.
In peptide com petition studies, the prim ary antibody was incubated overnight at 4°C with 
the respective peptide (re-suspended in distilled water). Peptides were used in excess o f  ten 
fold (in pg) over the antibody. Peptide or antibody alone solutions were also incubated at 
4CC using the same experimental conditions.
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2.4.5 Im m unocytochem istry
Primary neurons and cell lines: Cells were fixed with 4% (v/v) paraform aldehyde (PFA) 
for 15 min, washed three times with PBS and permeabilised with 0.3% (v/v) Triton X-100 
for 5 min. Cells were then blocked with 5% (v/v) normal goat serum (Chem icon) in PBS 
for 1 h, followed by incubation with prim ary antibody for 1-3 h at room tem perature or 
overnight at 4°C in PBS with 5% (v/v) normal goat serum. A secondary A lexa-conjugated 
goat anti-rabbit or m ouse IgG antibody (M olecular Probes, used at 1:400) was added after 
3 washes with PBS for 1 h. Coverslips w ere m ounted with ProLong Gold antifade reagent, 
with or without the nuclear marker DAPI (M olecular Probes).
Sensory neurons: Explants were loaded with the fluorescent dye calcein for 30 min at 37°C 
and then fixed with 4%  (v/v) PFA and 0.2% (v/v) glutaraldehyde (Sigma) in PBS for 
30 min. Coverslips were labelled with prim ary and secondary antibodies as above and 
mounted.
2.4.6 Im m unohistochem istry
Rats or mice (w ild-type and PO null-mutant) were perfused with 4% PFA (v/v) 
(Laboratory Animal Support group, G laxoSmithKline). Brains were removed, im m ersed in 
the same fixative for -2 4  h and then transferred into 30% (w/v) sucrose solution for 1-2 
days. Brains w ere cut as 30-40 pm sections free-floating in PBS. Sections were 
subsequently incubated for -3 0  min in 20% (v/v) m ethanol, 1.5% (v/v) hydrogen peroxide 
in PBS followed by a 10 min wash in PBS. Sections were incubated for 30-45 min in 
blocking solution m ade o f PBS with 3% (v/v) normal goat serum, 2 g/1 bovine serum 
albumin, 0.1% (v/v) Triton X-100 followed by incubation with the primary anti-PO #1216 
antibody in blocking solution for 24 h at 4°C with gentle shaking. Three 10 min washes 
with 0.3% (v/v) Triton X-100 in PBS were perform ed and sections incubated for 1 h at 
room tem perature, with gentle shaking, with biotinylated goat anti-rabbit or anti-m ouse 
antibody (Vector, used at 1:200) in blocking solution. Three 10 min washes with 0.3% 
(v/v) Triton X-100 in PBS were perform ed and sections were then incubated for 1 h at 
room tem perature with gentle shaking in A vidin/Biotin reagent (Vector, following 
m anufacturer’s instructions) followed by three 10 min washes with 0.3% (v/v) Triton X-
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100 in PBS. Sections were transferred into TBS and incubated with diam inobenzidine 
tetrahydrochloride (DAB) substrate (V ector) following the m anufacturer's instructions until 
suitable staining developed. The reaction was stopped by transferring sections into distilled 
water. Sections were m ounted onto slides and allowed to air dry thoroughly before 
m ounting them with coverlips using DPX (Sigma).
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2.5 Molecular protocols
2.5.1 RNA extraction
Freshly dissected cortices from wild-type and PO null-m utant mice were lysed with 500 pi 
o f  RLT buffer (Qiagen) containing 1% (v/v) p-m ercaptoethanol. Similarly, prim ary 
neurons were washed with PBS and lysed with 500 pi o f RLT buffer containing 1% (v/v) 
P-mercaptoethanol. Samples were hom ogenised using the M ixer Mill MM 300 (Retsch) 2 
x 2 min at 30 Hz. RNA extraction was perform ed using Q iagen RNeasy Mini Kit following 
the m anufacturer’s instructions, including the DNase digestion step. RNA from rat cortex 
and kidney (postnatal day 21) was obtained by the same procedure. RNA quality was 
determ ined by m easuring absorbance at 260 nm and 280 nm. To ensure significance, A260 
should be higher than 0.15. An absorbance o f 1 unit at 260 nm corresponds to 40 pg o f 
RNA per ml at neutral pH. All samples were considered o f good quality and purity if  the 
260 280 ratio was >1.8. The concentration o f RNA can be calculated using the following 
equation: [RNA] in pg/pl = (A260 x 40 x D )T000, where 1 optical density unit is 
equivalent to 40 p g  ml single stranded RNA and D is the dilution factor. O ccasionally, the 
RNA quality was checked on a 1% (w/v) agarose gel.
2.5.2 R everse transcrip tion  reaction
In order to reverse transcribe (RT) RNA to cDNA, two masterm ixes were prepared (+ RT 
and -  RT), triplicates for the >RT reaction and one reaction for the -RT. 8 pi o f  m astermix 
were added in each well (2 pi o f lOx buffer RT, 2 pi o f  dNTP mix (5 mM each), 2 pi o f 
O ligo-(dT) 12-18 prim er (Invitrogen) (0.5 pg/pl, diluted 1:10 with dH20), 1 pi o f  RNase 
out inhibitor (Invitrogen) (40 units/pl, diluted 1:4 with lx  RT buffer), 1 pi o f  Omniscript 
Reverse Transcriptase (Qiagen) (or water in the negative reaction). RNA (50 ng-2 pg) and 
w ater were added to bring the reaction volum e to 20 pi. Samples were incubated for 
60 m in at 37°C in a PCR machine (MJ Research). 60 pi o f  dH20 were added to each well 
(total volum e 80 pi) and aliquoted at 4 pl/well w ith an H ydra m achine (M atrix) into 96- 
well optic plates.
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2.5.3 T aqm an R T -PC R
RT-PCR analysis was performed using an Applied Biosystems ABI 7700 PE m achine (or 
ABI 7900 in m ore recent studies) following the m anufacturer’s instructions. The 
m astermix used was Excite 2x probe m asterm ix (GeneSys), primers were synthesised by 
Invitrogen and probes by Operon B iotechnology or ABI. Rat or mouse genomic DNA (BD 
Biosciences) was used to generate the standard curve. Analysis was performed following 
M edhurst et al. and Harrison et al. (H arrison et a l., 2000; M edhurst et al., 2000). The 
following prim er and probe sequences were used (Table 2.1):
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Gene/Species/Accession n°
Cyclophilin/ Rat and Human/ 
M19533
|}-actin/ Rat/ NM 031144
|5-actin/ M ouse/ NM 031144
PO / Rat and M ouse/ NM 031324 
PO / Hum an/ NM 002726
SMIT1/ Rat/ NM 053715
HMIT/ Rat/NM  133611
SMIT2/ Rat/ Prediction 
XM 574554.1 
MIP syn thase / Rat/ 
N M 001013880  
GAP43/ Rat/ M88356
Forward primer
5'-T GT GCCAGGGT GGT GACTT
5'-T CT GT GT GGATT GGT GGCT 
3’
5'-T CT GT GT GGATT GGT GGCT 
3’
5'-AGGCT CACGAT CAAT GGAG
5'-T CCAT GACCT GACTACT GG 
3'
5'-AT GAAGACGT CCCAT GGCC
5'-T CGAAT CGCT CTT CGACCAf 
5'-T CCT GT GGCT CT GT GGGAT
5'-AAGAT GGAGCGCCCTTT CC
5'-
T CCT CCAAGGCCGAAGAT G 
-3'
Table 2.1 Taqman primers and probe sequences.
Primers and probes have been designed at the 3 '-prime end of the sequence.
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Reverse primer
5'-T CAAATTT CT CT CCGT AGAT GGACT
5'-CT GCTT GCT GAT CCACAT CTG-3'
5'-CT GCTT GCT GAT CCACAT CT G-3'
5'-GT GGAACTT CAACAT GT CCAT CAC- 
5'-GACCGCT GT ACCCT ACAAT GCT-3'
5'-CCCT CT GCACGAT GACTT GG-3'
5'-CCTT CACGCGGAT GT ACT CG-3'
5'-T GCACACAAT GCAGTT GACG-3'
5'-AGCT CT GGT GTT GGT GCCT G-3'
5'-T CAGT GAC AGCAGCAGGCAC-
3'
Taqman probe
5'-CCACCAGT GCCATT AT GGCGT GT-3
5'-CCT GGCCT CACT GT CCACCTT CC-3
5'-CCT GGCCT CACT GT CCACCTT CC-3
5'-T CCAAT GGCGGCCT CTTAGT GGC-c 
5'-CTT AAGACCTT CCCGCT CGAT GT C(
5'-ATT CATT CTT GGGCAGACCCCAGC< 
3'
5'-CGGACT CGGACGAGGGCAGGT AC/ 
5’-
CCCCAAGCAAAGT GGAGCCT GT CAT /  
5'-CCACT GCCTT GCAAGAAAGAGT CC 
3'
5'-CCAAGGAGGAGCCT AAACAAGCC0
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2.5.4 T ransform ation o f  bacteria
One to 5 ng o f DNA were added to TOP 10 com petent cells (Invitrogen) and incubated on 
ice for 30 min. Cells were subjected to heat shock at 42°C for 30 s and then placed 
im m ediately on ice. 250 pi o f pre-w arm ed SOC medium  (Invitrogen) were added and 
incubated at 37°C for 1 h with m oderate shaking. 20 to 200 pi o f  transform ation mix were 
spread on Luria-Bertani (LB) agar plates (made by dissolving 10 g Bacto Tryptone, 5 g 
yeast extract, 10 g NaCl, 15 g Bacto Agar in 1 1 water, pH 7.5 and including the 
appropriate antibiotic, e.g. 50 -  100 pg  ml am picillin), and incubated at 37°C overnight.
2.5.5 DNA purification
Qiagen plasmid purification kits are based on a m odified alkaline lysis procedure followed 
by binding o f  plasm id DNA to anion-exchange resins under appropriate low-salt and pH 
conditions. Plasmid DNA is eluted in a high-salt buffer and then concentrated and desalted 
by isopropanol precipitation. A single colony was picked from a freshly streaked plate and 
inoculated into 5 ml LB medium (made by dissolving 10 g Bacto Tryptone, 5 g yeast 
extract, 10 g NaCl in 1 1 water, pH 7.5 and including the appropriate antibiotic, i.e 50 - 100 
pg  ml ampicillin), for ~~8 h at 37°C with vigorous shaking. This starter culture was diluted 
1 500 into selective LB medium and grown at 37°C for 12-16 h with vigorous shaking at 
37°C. The bacterial cells were harvested by centrifugation for 20 min at 4°C and the 
Qiagen protocol was followed. DNA was re-suspended in TE buffer or water, the 
concentration m easured spectrophotom etrically and purity checked by 260/280 ratio (DNA 
was considered o f  good quality if  260 280 ratio was between 1.7-2.0).
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2.5.6 PO sub-clon ing
Rat PO was amplified from pcDNA3.1 D/V5-His-TOPO  (Fig. 2.3) (generated at 
G laxoSm ithKline, stop codon not rem oved) by PCR and subcloned into pcDNA4/V5-His 
(Invitrogen) (Fig. 2.4) using the following primers:
Rat P O F w  3 ’ -C C G G T ACC AT GCT GT C'CTT CC AGT ACC-3 ’
Rat PO Rev 5 ’-C C C TC G A G C TG G A TC C A C TC G A TG T TC -3’
W here GGTA C’C is a Kpnl site and C T C G A G  is a Xhol site. CC were added at the 5 ’- 
prim ed end to im prove the PCR amplification. The PO stop codon was removed in order to 
obtain a His-V5 tagged clone.
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p c D N A “3.1 D/ 
V5-His-TOPO® 
5514  bp
Comment* for pcDNA"3.1D/V5-His-TOPO* 
5514 nucleotides
CMV promoter bases 232-819
T7 promoter/priming site: bases 863-882
TOPO* recognition site 1: bases 930-934
Overhang sequence (complementary strand): bases 935-938
TOPO* recognition site 2: bases 939-943
V5 epitope: bases 1011-1052
Polyhistidine (6xHis) tag: bases 1062-1079
BGH reverse priming site: bases 1102-1119
BGH polyadenytation signal: bases 1108-1332
SV40 early promoter and origin: bases 1833-2142
Neomycin resistance gene: bases 2217-3011
SV40 early poiyadenylaton signal: bases 3189-3319
pUC origin: bases 3700-4373 (complementary strand)
Ampicillin (bto) resistance gene: bases 4518-5378 (complementary strand) 
bia promoter bases 5379-5477 (complementary strand)
Fig. 2.3 pcDNA3.1D/V5-His-TOPO plasmid map from Invitrogen.
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I
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V5 epitope I 6xH is
pcDNA “4/V5-His 
A, B, c ;
rn 5 kb A5 kb / y  • Th«r» a  i  u n q u t  SKE I  KM. DU no
X b »  I or I M H  n  v a n o n  C
** T h an  «  a  unique Sac •  te a
between t ie  A p t I arte ana *ve Stu  I 
a te  m vara*on B o r  ty
Comm ents for pcONA '"4/VS-His A 
5092 nucleotides
CMV prom oter: b a s e s  209-063
T7 p t o m o t e t f p n m m g  s e e  b a s e s  863-882
Multiple ctorang sue: b a se s  895-1008
V5 epi lope b a s e s  1009-1050
Polytiistidine tag  b a s e s  1060-1077
BGH reverse  pnm tng site: b a s e s  1100-1117
BGH poiyadenytatioo signal: b a s e s  1009-1313
f1 origin: b a s e s  1366-1789
SV40 prom oter an d  origin: b a s e s  1854-2178
EM7 prom oter b a s e s  2186-2241
Z e o a n '  res is tan ce  gen e : b a s e s  2261-2635
SV40 potyadenytation signal: b a s e s  2764-2894
pUC on gin b a s e s  3278-3951
A m pictfn res is tan ce  g e n e  b a s e s  4095-4956 (com plem entary)
Fig. 2.4 pcDNA4/V5-His plasmid map from Invitrogen.
100 ng o f  DNA template and the Expand High Fidelity PCR System (Roche) were used to 
amplify PO. The following PCR conditions were applied: (i) 2 min at 94°C, (ii) 15 s at 
94°C, 30 s at 55°C, 90 s at 72°C, (iii) step ii repeated lOx, (iv) 15 s at 94°C, 30 s at 55°C, 
90 s at 72°C, (v) step iv repeated lOx, (vi) 5 min at 72°C. 10 pi o f  PCR product were run 
on a 0.8% (w/v) agarose gel (1 kb DNA marker, Invitrogen). Agarose (ultra pure, 
electrophoresis grade) was dissolved in boiling lx  Tris-acetate-EDTA (TAE) buffer (50x: 
40 mM Tris-acetate, 1 mM  EDTA pH 8.0) with the addition o f ethidium bromide (0.5 
pg/ml). The gel was cast on a gel bed with a suitable comb using a horizontal gel apparatus 
and placed in an electrophoresis tank containing lx  TAE buffer to a level just above the gel 
surface. The DNA sample containing DNA loading buffer (lOx: 50% (v/v) glycerol, 0.25% 
(w/v) bromophenol blue in TAE) was loaded into the sample wells and run at 2-10 V/cm. 
Gels were placed in a UV transilluminator (X= 302 nm) and DNA visualised. A  2.1 kb 
product was observed (Fig. 2.5).
M echanisms o f  action o f  mood-stabilizing drugs Chapter 2 Page 81
3 —
2.1 _
kb
k  p o
Fig. 2.5 Rat PO cloning.
PO was amplified by PCR from pcDNA3.1D/V5-His-TOPO. A ~  2.1 kb band was observed. 10 pi 
o f 1 kb DNA marker and reaction product were loaded.
The product was purified using the PCR purification kit following the m anufacturer’s 
instructions (Qiagen) and eluted in 30 pi water. Enzyme digestion was performed for 2 h at 
37°C (30 pi DNA + 3 pi Kpnl (10 u/pl) + 1.5 pi Xhol (20 u/pl) (both NEB), using buffer 1 
(100% Kpnl activity and 75% Xhol activity). 3 pg o f the vector pcDNA4/V5-His were 
also cut using the same conditions, treated with alkaline phosphatase (Roche) for 10 min at 
37°C, followed by  15 m in at 65°C to inactivate it. A preparative 0.8% (w/v) agarose gel 
was made, all the digestion products loaded and bands were excised with a clean scalpel. 
The Quiaex II purification kit was used following the m anufacturer’s instructions (Qiagen) 
and DNA eluted in 40 pi water. Products were run on a 0.8% (w/v) agarose gel (10 pi) and 
concentration determ ined based on the band intensity observed: for PO: ~  150 ng/pl, for 
the vector: ~10 ng/pl. Ligation was performed using T4 ligase (NEB) overnight at 4°C 
using different am ounts o f  DNAs (200 ng total/8 pi reaction). M aximum efficiency TOP 10 
cells were transformed with 5 pi DNA as described in section 2.5.4. 2 to 3 colonies were 
counted in vector only transformed bacteria (negative control) and 24 in plates with the 
ligation product. All 24 colonies were picked, grown overnight at 37°C and DNA extracted 
using the M iniprep kit following the m anufacturer’s instructions (Qiagen). DNA sequence 
was confirmed by  the Sequencing group at GlaxoSmithKline, using primers that I have 
designed every ~  500 base pairs.
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2.5.7 G eneration o f  catalytically-dead PO
Rat PO in pcDN A3.1D/V5-His-TO PO  (untagged) was used as template. TCC was m utated 
to G CC (Ser 554 to Ala) using Q uickchange II Site-Directed iMutagenesis kit following the 
m anufacturer’s instructions (Stratagene). The positive control from the kit was also 
included. Four reactions were set up using 10-20-50-100 ng DNA. A 5 min extension time 
and 12 cycles were used. The following prim ers were designed, both containing the 
m utation highlighted in bold red:
Fw 5’-GGCTCACGATCAATGGAGGCGCCAATGGCGGCCTCTTAGTGGC-3’
Rev 5 ’-GCCACTAAGAGGCCGCCATTGGCGCCTCCATTGATCGTGAGCC-3’
A fter transform ation, -1 0 0  blue colonies were observed in the positive control plate and 22 
colonies were counted in the plates containing the catalytically-dead PO. These colonies 
were picked, grown overnight at 37°C and DNA extracted using the M iniprep kit from 
Qiagen. Five colonies were judged to be o f bad DNA quality (260/280 ratio < 1.6) while 
the remaining 17 colonies had a 260/280 ratio > 1.8. The latter were sequenced with the 
same primers used in the PCR reaction in order to check for the mutation (Sequencing 
group, G laxoSm ithKline). DNA from 11 colonies contained the desired mutation. Two 
were chosen (clones #1 and #17) and fully sequenced using 5 prim er sets that were 
designed every -3 0 0  bp o f the PO gene. No other mutations were observed in both clones.
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2.5.8 PO -null m utant m ouse generation
PO null-mutant mice were generated by Deltagen by targeting a LacZ-Neo cassette to exon 
2 and part o f  exon 3 o f  the PO m ouse gene (Accession N°: BCO12869). The deleted 
sequence is shown in bold red (Fig. 2.6). Genom ic DNA isolated from ES lines was 
digested with restriction enzymes chosen to cut outside o f the construct arms and the DNA 
was analysed by Southern hybridization (perform ed by Deltagen). ES cells derived from 
the 129'OlaHsd mouse substrain were used to generate chimaeric mice. FI m ice were 
generated by breeding with C57BL/6 females. F2 homozygous mutant mice were produced 
by intercrossing FI heterozygous males and females (Laboratory Animal support team, 
GlaxoSm ithK line). Experiments were perform ed on m ice fully backcrossed to C57B1/6 (N 
= 5 or greater). M ice were made homozygous in order to sim plify analysis o f  embryos and 
early post-natal mice. M ouse genotyping was perform ed at GlaxoSmithKline.
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F.xons: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
ATGCTGTCCTTCCAGTACCCCGACGTGTACCGCGACGAGACCTCCGTGCAGGAGTATCATGGACATAAAATTTGTGACCCGTATTCTTGGC 
TT GAAGACCCAGACAGCGAGCAGACTAAGGCTT CGT GGAGGCACAAAACAAGATT ACT GT GCCATTT CTT GAGCAAT GT CCAAT CAGAGG 
TTT AT ACAAGGAGAGAAT GACT GAGCT GT ACGACTACCCCAAGTACAGCTGCCACTTCAAGAAAGGAAAGCGGTACTTTTATTTTTACAAT 
ACAGGTTT GCAGAACCAACGCGTGTTATATGTGCAAGACTCCTTAGAGGGGGAGGCCAGAGTGTTCCTGGACCCCAACACACT GTCGGATG 
AT GGTACAGT GGCACTCCGAGGTTAT GCCTT CAGT GAAGAT GGCGAAT ACTTT GCCT AT GGT CT GAGCGCCAGCGGCT CCGACT GGGT GAC 
GAT CAAGTT CAT GAAGGTCGAT GGT GCCAAAGAGCTCCCGGAT GT GCT GGAGAGAGT CAAGTTCACCTGCATGGCCTGGACGCATGACGGG 
AAGGGAAT GTT CT AT AACT CAT ACCCGCAGCAGGACGGGAAGAGCGAT GGCACAGAGACAT CCACCAAT CT CCACCAAAAGCT CT GCT ACC 
ACGT CTT GGGGACGGAT CAGT CAGAAGATATTTTGTGTGCTGAGTTCCCCGATGAGCCTAAATGGATGGGAGGAGCTGAGCTATCCGACGA 
T GGCCGGT ACGT CTT GTTAT CCAT CT GGGAGGGAT GT GATCCAGT AAACCGACT GT GGT ACT GT GACCTCCAGCAAGAACCCAAT GGT AT C 
ACCGGAATCCTGAAGT GGGT AAAACT GAT AGACAACTTT GAAGGAGAAT ACGACT ACGT AACCAACGAGGGCACAGT GTT CACATT CAAGA 
CGAACCGC AATT CT CCCAATT ATCGGCT GAT CAATATCGACTTCACGGACCCTGACGAGTCCAAGTGGAAAGTGCTCGTACCGGAGCACGA 
GAAGGAT GT CTT AGAAT GGGT GGCTT GT GT CAGGT CCAACTT CCT GGT CTT GT GCT ACCTCCAT GACGT GAAGAACATT CT ACAGCTT CAC 
GACCT GACGACT GGT GCT CT CCT CAAGACCTTCCCCCT GGAT GT GGGCAGCGT GGT GGGCTACAGT GGGCGCAAGAAGGACT CT GAGAT CT 
T CT ACCAGTT CACAT CCTTCCT AT CT CCAGGT GT CATTT ACCACT GCGAT CTT ACCAAAGAGGAACT GGAGCCCAT GGTTTTCCGAGAGGT 
GACGGTGAAGGGAATCGATGCTGCTGATTACCAGACAATCCAGATTTTCTACCCTAGCAAGGATGGCACCAAGATTCCCATGTTTATTGTG 
CAT AAAAAAGGCAT AAAGCT GGAT GGCT CACACCCT GCTTT CTT AT AT GGCT ACGGGGGCTT CAACAT CT CCATT ACACCCAACT ACAGCG 
T GTCCAGGCT CATTTTT GT GAGACAT AT GGGCGGCGT CCTCGCGGT GGCT AACAT CAGAGGCGGCGGT GAATACGGAGAGACGTGGCACAA 
AGGT GGT AT CTT GGCCAACAAACAGAACTGTTTT GAT GACTTCCAGT GT GCT GCT GAGT ACCT CAT CAAGGAAGGTT ACACAT CT CCCAAG 
AGGCTCACGATCAACGGAGGCTCCAACGGCGGCCTCTTAGTAGCTGCTTGCGCAAATCAGCGTCCAGACCTCTTCGGCTGTGTTATTGCCC 
AGGTT GGAGT GAT GGACAT GTT GAAGTT CCACAAATTTACT AT CGGCCAT GCAT GGACCACT GATT ACGGGT GCT CCGACACT AAACAACA 
CTTTGAATGGCTTCTCAAATACTCGCCACTACACAATGTGAAGCTTCCGGAGGCAGACGACATCCAGTACCCGTCCATGCTTCTCCTCACG 
GCTGACCACGACGACCGCGTGGTCCCGCTGCACTCACTGAAGTTCATTGCCACCCTTCAGTACATCGTGGGCCGCAGCCGGAAGCAGAGCA 
ACCCCCT GCT CATCCACGT GGACACCAAGGCCGGCCACGGGGCCGGGAAACCCACCGCCAAAGTGATAGAAGAAGTCTCGGATATGTTTGC 
GTT CAT AGCACGGT GCCT GAACATCGAGT GGAT CCAGT AA
Fig. 2.6 PO mouse sequence.
PO consists o f  15 exons (black boxes). The PO P-propeller domain is encoded by exons 3-10 (black 
line), whereas the catalytic domain is encoded by exons 1-3 and 10-15 (blue line) (Kimura et al . ,  
1999). Highlighted in bold red is exon 2 and part o f exon 3 o f the PO gene, which was replaced in 
the PO-null mutant mice with a LacZ-Neo cassette.
2.6 Statistical analysis
Statistical analysis was performed using Statistica v6. Results were considered significant 
at /?<().05 (*). Briefly, separate one-way ANOVAs were performed on the data from the 
grow th cone studies. Comparison o f treatment groups was made using Fisher's LSD test. 
Single sample t test was used to analyse results from W estern blotting.
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CHAPTER 3
Analysis of the effects of mood stabilizers 
on GSK3 vs Pins pathways
The results presented in this chapter have been published (Di Daniel et a l 2006). M uch o f 
the content is taken from the published work, which was written together with Professor 
A nne Mudge.
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3.1 Introduction
The three most-frequently prescribed mood stabilizers -  lithium, VPA and CBZ -  have a 
com m on effect on the dynamic behaviour o f  rat sensory neurons: all three drugs inhibit the 
collapse and increase the spread area o f  grow th cones (W illiams et al., 2002). M oreover, 
these effects are reversed by inositol, suggesting that all three mood-stabilizing drugs 
inhibit recycling o f Pins. The com m onality o f  the drug effects on Pins signalling suggests 
that this pathway m ay be the therapeutic target for the mood stabilizers and furthermore, 
that defects in the regulation o f Pins signalling m ay underlie BD (Kim et a l., 2005b).
Lithium  directly inhibits two key enzymes involved in Pins recycling: IM Pase and IPPase. 
Berridge et al. (Berridge et al., 1989) and later Batty and Downes (Batty & Downes, 1995) 
suggested that these inhibitory effects on the P ins cycle m ay partly explain the therapeutic 
action o f  lithium. In contrast, lithium ’s inhibition o f  GSK3 has led to the suggestion that 
this kinase m ay be the therapeutically-relevant target for lithium in mood stabilization 
rather than Pins signalling (Klein & M elton, 1996; O 'Brien et a l , 2004; Phiel & Klein, 
2001). There are several reports that VPA also inhibits GSK3 either directly or indirectly 
(Chen et al., 1999a; Hall et al., 2002; W erstuck et a l., 2004), although these observations 
are disputed by other studies (De Samo et a l., 2002; Jin et al. , 2005; Phiel & Klein, 2001; 
W illiams et al., 2002).
Inhibition o f GSK3 with potent but non-selective inhibitors induces changes in growth 
cone morphology. Owen and Gordon-W eeks reported that the GSK3 inhibitor SB-216763 
and l O mM lithium increased the growth cone spread area o f  chicken sensory neurons 
(Owen & Gordon-W eeks, 2003). Therefore, confusion exists as to whether the effects o f 
lithium  and VPA are mediated by GSK3 or inositol. W hile studying the effects o f  W nt 
signalling on neural development, Salinas and colleagues found that both lithium and VPA 
increased the spread area o f growth cones o f  rat cerebellar m ossy and granule neurons and 
these drug effects were not inhibited by inositol (Hall et al., 2000; Hall et al., 2002; Lucas 
& Salinas, 1997). Guidance molecules, such as Sema3A, provide cues that are involved in 
directing axons to or away from particular targets and induce a dramatic ‘collapse’ o f 
growth cones and axon retraction. This Sem a3A-induced ‘collapse and retraction’
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behaviour is dependent on activation o f  a highly localised pool o f inactive GSK3 at the 
leading edge o f the growth cone, which was elegantly dem onstrated by Eickholt et al. 
using the GSK3 inhibitors SB-216763 and SB-415286, as well as 20 mM lithium (Eickholt 
et a l., 2002). In discussing whether the relevant therapeutic target o f lithium in the 
treatm ent o f BD is either inhibition o f  GSK3 or inhibition o f Pins signalling, O 'Brien et al. 
m ake no distinction between sem aphorin-induced 'collapse and retraction’ and the cycles 
o f  dynam ic 'collapse and spread’ described in W illiam s et al. (O 'Brien et a l., 2004; 
W illiam s et al., 2002). In addition, Klein and colleagues comment that there m ay be 
additional functions o f inositol other than the known effect on Pins recycling, because 
addition o f  inositol can reverse the developm ental defects induced by dominant negative 
G SK 3p in Xenopus (Hedgepeth et al., 1997).
The study o f W illiam s et al. is the only exam ple dem onstrating a common effect o f  all 
three mood stabilizers -  lithium, VPA, and CBZ -  on a intracellular signalling pathway in 
neurons (W illiam s et a l., 2002). Given the im portance o f  determ ining the therapeutically 
relevant targets o f  these drugs, we sought to clarify the effects o f mood stabilizers on 
growth cone dynam ics and to further characterise this assay.
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3.2 Results
3.2.1 Characterisation o f rat sensory neuron growth cones
Growth cones from rat DRG explants were characterised in terms o f tubulin expression, 
using an antibody specific to the post-translational acetylated form, which is a marker o f 
stable microtubules (Bianchi et al., 2005; Dent & Kalil, 2001) Stable microtubules do not 
usually extend into the growth cone in control cultures (Fig. 3.1 A). Treatment with 10 mM 
LiCl, however, alters microtubule dynamics by inducing coiled structures, which penetrate 
the growth cone in a small percentage o f  neurons (Fig. 3 .IB). Because this effect was 
observed with 10 mM LiCl only and not with a more therapeutically-relevant LiCl 
concentration or with VPA or CBZ - it is likely that this effect may not derive from 
modulation o f  the pathway commonly regulated by the drugs.
A B
Fig. 3.1 Expression o f  acetylated tubulin in rat sensory neurons.
Neurons were treated with LiCl for 24 h and labelled with anti-acetylated tubulin (Sigma, 1:3,000)
(red) and anti-GAP43 (Abeam, 1:5,000) (green) antibodies. A control cultures B LiCl 10 mM-
treated neurons. The arrow shows abnormal microtubules penetrating the growth cone area.
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3.2.2 Effect o f PTN and GPT on sensory neuron growth cones
In order to test whether the growth cone assay is a useful model for mood-stabilizing drug 
action, growth cones were labelled and scored as collapsed or spread as illustrated in Fig. 
3.2A. Using this assay we confirmed previous findings by Williams et al. that lithium 
inhibits the frequency o f  collapse and that this effect is reversed by the addition o f  1 mM 
inositol to the culture medium (Fig. 3.2B) (W illiams et al., 2002). To determine the 
specificity o f this morphological assay, we then tested GPT (50 pM) and PTN (50 pM), 
two anticonvulsants with no mood-stabilizing properties (Yatham et al., 2002). There was 
no effect o f  either drug on collapse (Fig. 3.2C). These results show that two 
anticonvulsants that are not effective as anti-manic drugs do not induce inositol-reversible 
effects on sensory neuron growth cones and, therefore, do not mimic the effects o f the 
mood stabilizers lithium, VPA, or CBZ.
B
Collapsed
Spread area 
<100 pm*
Spread area 
>100 par**
25
L O  LiCl * inocoot ino
75
25
GPT PTNc o o t
Fig. 3.2 Drug effects on sensory neuron growth cones.
A Micrographs showing a collapsed growth cone (top) and spread growth cones (middle and low 
panels). Sensory explants were labelled with calcein and fluorescent images acquired with a X40 
objective using an Olympus BX51 microscope.
B The histogram shows the effect o f LiCl (3 mM) with/without inositol (1 mM) on the number o f  
growth cones collapsed expressed as a percentage o f total. Data are presented as mean ± sem. 
Significant change from control is indicated (one-way ANOVA and Fisher's LSD test, *** 
p<0.001 in LiCl-treated explants). Results shown are from two independent experiments each in 
duplicate (n = 4). C The histogram shows the percentage o f growth cones collapsed in cultures 
treated with GPT 50 pM or PTN 50 pM. Results are from one representative experiment (n = 3 
explants). This experiment was repeated three times with similar results.
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3.2.3 Effect o f SB -216763 on sensory neuron grow th cones
To determine whether G SK3-m ediated effects on growth cones are sensitive to inositol 
levels as suggested by Klein and colleagues from studies in Xcnopus (Hedgepeth et al., 
1997; O 'Brien et al., 2004), sensory neuron explants were treated with the GSK3 inhibitor 
SB-216763 (10 pM ), with or without addition o f  extracellular inositol (1 mM). SB-216763
treatm ent did not change the percentage o f  collapsed growth cones (Fig. 3.3A), but it did
•*>
increase the percentage o f large growth cones with area >100 pm" (control: 6 ± 3%, SB- 
216763-treated: 20 ± 5%; mean ± sem). There was no difference when inositol was added 
with the inhibitor (SB-216763 plus inositol-treated: 17 ± 5%) (Fig. 3.3A). There was an 
increase in the mean spread area o f growth cones; for those with areas <100 pm" or >100
pm 2, the increases in drug-treated explants were -4 0 %  and -7 5 % , respectively (Fig. 3.3B).
->
The mean spread area o f all growth cones in control was 53 ± 4 pm" and this area doubled 
in the presence o f  SB-216763. Importantly, the addition o f  1 mM  inositol together with the 
GSK3 inhibitor did not change significantly the mean growth cone area (96 ± 18 vs. 89 ± 
17 pm 2) as shown in Fig. 3.3B. SB-415286 was also tested with similar results (data not 
shown). These results show that the effects o f  mood stabilizers reported by W illiams et al. 
and o f lithium, in the present study, are not mimicked by GSK3 inhibitors, thus excluding 
GSK3 as the com m on target for the mechanism o f  action o f  these drugs on sensory neuron 
growth cones (W illiam s et al., 2002).
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B
control
Collapse Mean area (pm7 ± sem)
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57± 3 41 ± 2  131 ± 8 53 ± 4
SB-216763 50 ± 11 58 ± 6 229 ±41 96 ±18
SB-216763 50± 2 5 2 ± 3  182±17 89±17
♦ inositol
Fig. 3.3 Effect o f  SB-216763 on sensory neuron growth cones.
A SB-216763 (10 pM) increases sensory neuron growth cone area and inositol does not reverse 
the effect. Histograms show the percentage o f sensory neuron growth cones that were collapsed or 
had spread areas between 10-100 pm2 or >100 pm2 in control or SB-216763-treated cultures 
with/without inositol (1 mM), as indicated. *p<0.05 in SB-216763-treated cultures in the 
population o f growth cones with area >100 pm2 when compared with control (ANOVA and 
Fisher's LSD test). Results were pooled from three independent experiments (n = 3 explants each). 
The total number o f growth cones scored in each bar was ~300.
B SB-216763 increases the growth cone spread area values when compared with control. The table 
shows the percentage o f collapse and growth cone area values for control or SB-216763-treated 
cultures with/without inositol (mean ± sem). Data are from the same experiment shown in Fig. 
3.3A.
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3.2.4 Effect o f m ood stabilizers on cortical neuron grow th cone area
W e next analysed the effect o f mood stabilizers on rat prim ary neurons derived from the 
cerebral cortex, a brain region that has been implicated in the pathophysiology o f mood 
disorders. Lithium (2 mM), VPA (1 mM ) and CBZ (25 pM ) each increased the percentage 
o f  growth cones with an area >140 pm 2 (control: 4%, LiCl: 43%, VPA: 26% and CBZ: 
67% ), with a concomitant reduction in the percentage o f  growth cones with areas between 
20-140 nm 2 (control: 90%, LiCl: 56%, VPA: 71%, CBZ: 41%) (Fig. 3.4). Addition o f 
inositol (1 mM) reversed this increase in growth cone area induced by the drugs in a 
sim ilar way to that observed in sensory neurons (Fig. 3.4). These results show that the 
com m on inositol-reversible effects o f  mood stabilizers on growth cone area that we 
observed in sensory neurons can be replicated in neurons that are more relevant for mood 
disorders.
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Fig. 3.4 Effect o f mood stabilizers on growth cone area in cortical neurons.
Histograms show the percentage o f spread growth cones after treatment with drugs with/without 
the addition o f inositol, as indicated. LiCl, VPA and CBZ at the concentrations indicated each 
induced a shift to larger areas and addition o f inositol completely or partially (CBZ) reversed the 
drug effects. Data are from one experiment (n = 3 coverslips, pooled data) and the total number o f  
growth cones scored in each bar was -100-150. The experiment was repeated with similar results. 
Note that cortical neurons do not have a cycle o f complete collapse and so the first bar shows 
small growth cones with area <20 pm2.
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3.2.5 Effect o f SB-216763 on cortical neuron growth cones
We then analysed the effect o f  SB-216763 on cortical neurons. This GSK3 inhibitor 
induced the formation o f large growth cones with an area >140 jam2 (control: 3%, SB- 
216763-treated neurons: 19%), and the addition o f  inositol did not reverse this effect (SB- 
216763 plus inositol-treated cultures: 21%) (Fig. 3.5A and B). These results confirm our 
findings with sensory neurons showing that the increase in growth cone area induced by 
the GSK3 inhibitor SB-216763 is not reversed by inositol.
Control SB-216763 (10 nM)tD
S>
SB-216763 + inositol (1 mM)
m
<20 20-140 >140 <20 20-140 >140 <20 20-140 >140
B
spread area (nm2) spread area (pm2) spread area (pm2)
control SB-216763 SB-216763 plus inositol
Fig. 3.5 Effect o f SB-216763 on cortical neuron growth cones.
A SB-216763 (10 jiM) increases cortical neuron growth cone spread area and inositol does not 
reverse the effect. Histograms show the percentage o f different size cortical neuron growth cones 
treated with SB-216763 with/without inositol. Data are from one experiment (n = 3 coverslips 
pooled data). The total number of growth cones scored in each bar was -100-150. The experiment 
was repeated with similar results.
B Representative images o f cortical neurons untreated or treated with SB-216763 (10 pM) with or 
without inositol (1 mM) labelled with an anti-GAP43 (red) and anti-acetylated tubulin (green) 
antibodies. Images were acquired with a X60 oil lens.
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3.2.6 Effect o f m ood stabilizers on G SK 3 dow nstream  targets
To clarify further the involvement o f GSK3 as the com mon mechanism o f  action o f  mood 
stabilizers, the drug effects on intracellular proteins activated/inhibited by GSK3- 
dependent phosphorylation were analysed. Cortical neurons were treated at 5 days in 
culture with two different concentrations o f  mood stabilizers for 6 h (1 and 10 mM  LiCl, 1 
and 2 mM VPA, 50 and 100 pM CBZ; in each case, the lower concentration is close to the 
therapeutic range for blood levels o f the drugs). The therapeutic concentrations for the 
m ood stabilizers analysed in this study are: LiCl 0.6-1.5 mM, V PA 0.3-0.6 mM , CBZ 20- 
50 pM  (Goodwin & Young, 2003). W e used W estern blotting to study phosphorylated 
glycogen synthase (GS), tau, and p-catenin expression. GS is a w ell-characterised GSK3 
substrate and it is inactivated by GSK3-mediated phosphorylation. Phospho-GS protein 
levels were reduced to nearly undetectable levels after treatm ent with high concentrations 
o f LiCl (10 mM ) or SB-216763 (10 pM) (Fig. 3.6A, B). In contrast, LiCl at the therapeutic 
concentration o f  1 mM , as well as VPA ( 1 , 2  mM ), and CBZ (50, 100 pM ) did not 
significantly affect phospho-GS levels. Likewise, only 10 mM lithium and 10 pM  SB- 
216763 decreased phosphorylation o f the neuronal-specific m icrotubule-associated protein 
tau (assessed using the monoclonal antibody (mcAb) AT8 that recognises the 
tau. phosphoserine202 epitope), whilst both lithium and SB-216763 increased 
dephosphorylated tau levels (assessed using mcAb Tau-1). These results are consistent 
with lithium (but not VPA or CBZ) inhibiting endogenous GSK.3 activity; m oreover, the 
effect o f LiCl was only seen with the high concentration o f  l OmM and not with the 
therapeutically-relevant 1 mM. When we analysed p-catenin levels, we found that LiCl (10 
mM ), SB-216763 (10 pM ) and VPA (2 mM) each increased levels o f  cytoplasmic p- 
catenin. The HDAC inhibitor TSA also induced a 3-fold increase in p-catenin levels (data 
not shown), suggesting that the effects o f  VPA on p-catenin levels are likely due to HDAC 
inhibition. Our results strongly suggest that only lithium (and not VPA or CBZ) inhibits 
GSK3 either directly or indirectly. Similar conclusions were drawn in a recent study where 
only lithium decreased tau phosphorylation (mcAb AT270 was also used) (Ryves et a l., 
2005). In the latter study, however, neither lithium nor VPA changed p-catenin levels, 
whereas we saw an increase in p-catenin levels in response to LiCl, VPA and TSA, 
confirm ing a previous report (Phiel et a l , 2001). The lack o f  effect o f  VPA on p-catenin in 
Ryves et al. m ay be due to differences in extraction procedure as they used a detergent-
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based extraction buffer that is reported to solubilise membranes as well, therefore m asking 
the drug effect on the cytosolic pool o f  P-catenin (Ryves et a l., 2005). Our data, together 
with the growth cone results presented above, strongly support the idea that the common 
effects o f mood stabilizers on both sensory and cortical neuron growth cones are mediated 
by inhibition o f Pins signalling rather than by inhibition o f GSK3 signalling.
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Fig. 3.6 Effect o f  mood stabilizers on GSK3 downstream targets.
A Lithium inhibits GSK3 activity in cortical neurons. Western blotting analysis o f  cortical neurons 
treated with drugs for 6 h. A representative blot is shown.
B Quantitative changes of GSK3 downstream target expression after treatment with mood 
stabilizers or with the GSK3 inhibitor SB-216763. Data were quantified from at least three 
independent experiments and normalised to ERK/MAPK for sample loading. Increase in protein 
expression when compared with control is indicated with T and decrease with -I. Mean ± sem are 
shown. Single sample t test was used in the analysis and the p value is given when the effect was 
statistically significant (*p<0.05).
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3.2.7 SM IT, M IP-synthase and H M IT expression in cortical neurons
W e then investigated several genes encoding proteins involved in regulating inositol 
availability in the CNS, namely M IP-synthase and the known wvo-inositol transporters. 
RT-PCR analysis was performed on mRNA  isolated from lysates o f cortical neurons 
cultured for either 5, 7 or 9 days (die). Rat (post-natal day 21) kidney and brain mRNA 
w ere used as positive controls for SM IT and M IP-synthase, respectively. W e did not detect 
M IP-synthase, SMIT1 and SMIT2 m RN A  expression in cortical neurons (Fig. 3.7A). In 
contrast, neurons expressed HMIT mRN A at all culture days analysed (Fig. 3.7A). W e also 
confirm ed the presence o f HM IT protein in cultured cortical neurons by 
im m unocytochem istry (Fig. 3.7B). HMIT was expressed in all neurons, both in cell bodies 
and in neuronal processes, as shown by co-localisation with the neuronal marker p-III- 
tubulin. Incubation o f  the antibody with the peptide abolished the labelling (Fig. 3.7C).
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MIP-synthase SMIT1 SMIT2 HMIT
+ mRNA measured 
in cortical neuron 
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HMIT lll-tubulin
HMIT peptide HMIT + peptide
Fig. 3.7 Expression o f  HMIT, SMIT1, SMIT2 and MIP-synthase in primary neurons.
A Cortical neuron mRNA analysis. Taqman RT-PCR analysis o f primary cortical neurons at 5, 7 
and 9 days in culture shows expression o f HMIT mRNA at all culture times examined. Cyclophilin 
was used as housekeeper control gene.
B Cortical neurons express HMIT protein. Fluorescent micrographs show HMIT immunolabelling 
in cell soma and neurites (green). HMIT colocalises with the neuronal marker P-III-tubulin (red). 
Cell nuclei are labelled with DAPI. Images were acquired with an epifluorescence microscope 
using a X I00 oil objective.
C HMIT peptide competition performed on die 5 cortical neurons. HMIT antibody was used at 
10 pg/ml and peptide used at 100 pg/ml. Images were acquired with a X40 oil objective using the 
same exposure time.
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3.3 Discussion
In this chapter some controversial issues about the growth cone assay were addressed and 
the role o f the Pins signalling pathway in the com mon action o f LiCl, VPA, and CBZ on 
neurons has been further investigated. GPT and PTN, anticonvulsant drugs not com m only 
used to treat BD (Yatham et al., 2002), did not m im ic the effects o f the mood stabilizers on 
sensory neuron growth cones. Thus, the action o f  the anticonvulsants on growth cones 
parallels their clinical efficacy in the treatm ent o f  BD rather than their efficacy in the 
treatm ent o f  epilepsy. The growth cone assay m ay be a useful screen for BD drugs. LiCl, 
VPA and CBZ each increased the spread area o f  growth cones o f rat cerebral cortical 
neurons and these effects are inositol-dependent. These are important results as they 
suggest that signalling pathways present in sensory explants m ay be com mon to the CNS 
and, therefore, effects observed with the drugs in sensory explants may be also 
extrapolated to CNS neurons. Whilst it is im portant that the drugs work in a sim ilar fashion 
on neurons from a brain region known to be involved in mood control, sensory neurons 
offer several advantages over cortical neurons for assay. In fact, growth cones from DRG 
explants show directionality, are well-separated and can be easily scored as collapsed or 
spread, whereas dissociated cortical neurons form an intricate network where it is more 
difficult to identify the nerve endings. M oreover, DRG growth cones present cycles o f 
complete ‘collapse’ as they continue to grow, which can be easily scored as a percent o f 
total growth cones. This results in reduced bias in area measurements.
In both sensory and cortical neurons, the GSK3 inhibitor SB-216763 induced a population
 ^ •*) 
of very large grow th cones (>100 pm~), some o f  which had m icrotubules abnormally
penetrating into the growth cone. Addition o f inositol did not change the num ber o f  large
growth cones, nor did inositol reverse the increase in average growth cone area o f  20-100
pm" induced by the inhibitor. The latter population generally did not contain stable
m icrotubules abnorm ally penetrating into the growth cone. These results contrast with
Hedgepeth et al., who reported that inositol reversed the effect o f GSK3 ablation in
developing Xenopus (Hedgepeth et al., 1997). Since inositol-reversibility was used to
argue that the com m on effect o f the mood stabilizers on growth cones was m ediated by
inhibition o f  Pins signalling (W illiams et a l., 2002), the fact that inositol did not reverse
the effects o f GSK3 inhibition on growth cones adds further support to the previous
conclusions by W illiams et al.
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In the sensory neuron study by W illiams et al. the authors commented that there was a 
small population (2%) o f  very large growth cones with penetrating microtubules in the 
presence o f 10 mM, but not 3 mM, lithium, but these did not contribute significantly to the 
growth cone data presented (W illiams et al., 2002). In contrast, Owen & Gordon-W eeks 
describe many m ore abnormal growth cones in 10 mM LiCl-treated chicken em bryonic 
day 8-neurons (Owen & Gordon-W eeks, 2003). These chicken embryonic neurons would 
still be at the stage where axons are using guidance cues such as semaphorin to navigate to 
their targets, whereas the postnatal rat neurons used would have reached their peripheral 
targets prior to explanting, so axon growth would be o f  a regenerative nature where axons 
use laminin in Schwann cell basem ent mem branes to navigate. Because Sema3A action 
uses an active pool o f GSK3 in the growth cone, a difference in the levels o f GSK3 present 
in em bryonic vs postnatal neurons could explain the extent to which lithium produces 
G SK3-dependent effects on growth cone spreading.
Chicken sensory neurons have larger growth cone areas under control conditions than do
■y
postnatal rat neurons (~ 150 vs 100 pm “). The cerebellar neurons (both mossy and granule) 
used by Salinas and colleagues to study W nt (Hall et a l., 2000; Hall et al., 2002; Lucas &
-y
Salinas, 1997) w ere also large (-200 pm~) compared with both the rat sensory and cortical 
neurons used here. Sensory neurons provide a convenient morphological readout o f  
intracellular signalling events, while growth cone function is probably better studied using 
neurons with large growth cones that do not collapse spontaneously and where the effects 
o f GSK3 inhibition m ay be greater.
Interestingly, biochem ical analysis o f some GSK.3 downstream targets has shown that 
10 mM LiCl inhibits GSK3 at higher levels compared with the GSK3 inhibitor SB-216763. 
These findings do not correlate with growth cone morphological observations, as SB- 
216763 only induced a pronounced increase in the percentage o f very large growth cones. 
Possible reasons for this discrepancy are different effects o f lithium and SB-216763 on 
different targets, w hich may be localised into different intracellular com partments or 
expressed at different levels in the cell body and neurites. It would be interesting to 
perform  a lithium concentration-response in prim ary neurons in order to determ ine the 
concentration at which expression levels o f GSK3 targets start to change. It has been 
reported that a low concentration o f  lithium, w hich can partially inhibit GSK3, favours the
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extension o f neurites from developing neurons, whereas a high concentration o f  the drug 
impaired neurite growth (M unoz-M ontano et a l., 1999). Similar effects were observed with 
the GSK3 inhibitor 6-bromoindirubin-3-acetoxim e in DRG and hippocampal neurons. 
Interestingly, the differential regulation o f  prim ed versus all GSK3 substrates is associated 
with a specific morphological outcom e (see CRM P2 versus MAP IB) (Kim et a l., 2006). In 
our study, we have used the antibody clones AT8 and TAU1, which recognise unprim ed 
sites o f  tau (Cho & Johnson, 2003) and an anti-GS and anti-P-catenin antibodies, which 
recognise primed substrates. It is, therefore, not unexpected that the effect o f  GSK3 
inhibitors on these substrates may be different.
Lithium inhibition o f GSK3 directly led Klein and colleagues to suggest that GSK3 m ay be 
the therapeutically-relevant target for lithium in mood stabilization rather than Pins 
signalling (Klein and Melton, 1996; O 'Brien et al., 2004; Phiel and Klein, 2001). 
M oreover, there is much controversy regarding the question o f  whether VPA inhibits 
GSK3, either directly or indirectly. We have shown here that LiCl at non therapeutic 
concentrations, but not VPA affects phosphorylation o f known GSK3 targets in cortical 
neurons in agreem ent with others (De Samo et a l., 2002; Jin et al., 2005; Phiel et a l., 2001; 
W illiams et al., 2002). In contrast to W illiams et al. and Ryves et al., both VPA and 
lithium increased the levels o f P-catenin (Ryves et a l., 2005; W illiams et a l., 2002); the 
VPA effect was m im icked by TSA suggesting that VPA increased P-catenin levels by 
inhibiting HDAC in cortical neurons, as predicted by earlier work (Phiel et al., 2001). VPA 
inhibition o f HDAC is probably responsible for the teratogenic effects o f  VPA (Gurvich et 
al., 2005).
M IP-synthase and the inositol transporters SMIT1 and SMIT2 have been suggested as 
therapeutically-relevant targets for the mood stabilizers. Given that cortical neurons in 
culture do not express these proteins, they are not expected to play a part in the inositol- 
dependent effects o f  the drugs on cortical neurons. The location o f M IP-synthase in brain 
endothelial cells and the high levels o f  SMIT1 in the choroid plexus make it likely, 
however, that both are involved in regulating the level o f inositol in the brain, which is ~ 
10-fold higher than in blood (Fisher et a l., 2002). Cortical neurons express HMIT, but not 
SMIT1 or SMIT2. HMIT is expressed predom inantly in the brain, suggesting that it has a 
unique role in regulating brain inositol metabolism  (Uldry et al., 2001). The cellular
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location o f HMIT is regulated by neuronal activity, which m ay link the supply o f  inositol 
to activity o f the Pins cycle (Uldry et a l., 2004). HMIT is present in subsets o f  neurons in 
the cerebral cortex, an area im plicated in mood control (Uldry et a l., 2001; Uldry et al., 
2004). Our results show' that HMIT is expressed in cultured cortical neurons, whereas 
SMITs and M IP-synthase are not, suggesting that HMIT plays a crucial role in regulating 
the supply o f inositol for Pins synthesis. It is, however, not clear whether HM IT is 
expressed at the plasma m embrane in neurons either in resting or in activated state.
In summary, the present results confirm and extend previous conclusions that the common 
effects o f  the three mood stabilizers on neurons are mediated by inhibition o f Pins 
signalling and that these inositol-reversible effects do not involve GSK3 inhibition. 
M oreover, the growth cone assay should prove useful for identifying drugs that m imic the 
com m on effect o f lithium, VPA, and CBZ on inositol-reversible signalling in neurons that 
is independent o f  drug effects on GSK3, SMIT or M IP-synthase. Our results also raise 
intriguing questions about how cortical neurons regulate their levels o f  intracellular 
inositol, w'hich is crucial for Pins synthesis and thus Pins signalling pathway function.
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CHAPTER 4 
PO interaction with GAP43
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4.1 Introduction
PO protein comprises a seven-bladed p-propeller domain and a peptidase domain with an 
a /p  hydrolase fold (Fulop et al., 1998). The catalytic dom ain is split, with the first 72 
amino acids in the N-terminus o f  the protein and the rem aining approxim ately 300 residues 
at the C-terminus, as shown below highlighted in red (Fig. 4.1). The three amino acids 
ffom the catalytic triad are highlighted and underlined in green (Ser554, Asp641 and 
H is680 in the PO human enzyme).
V1LSLQYPDVY RDETAVQDYH GHKICDPYAW LEDPDSEQTK A FVEA Q N K IT  V P F LE Q C P IR
GLYKERMTEL YDYPKYSCHF KKGKRYFYFY NTGLQNQRVL YVQDSLEGEA R V F L D P N IL S
DDGTVALRGY AFSEDGEYFA YGLSASGSDW VTIKFM KVDG  AKELPDVLER VKFSCMAWTH
DGKGMFYNSY PQQDGKSDGT ETSTNLHQKL YYHVLGTDQS ED ILC A EFPD  EPKWMGGAEL
SDDGRYVLLS IREGCDPVNR LWYCDLQQES S G IA G IL K W V  K L ID N FE G E Y DYVTNEGTVF
TFKTNRQSPN Y R V IN ID F R D  PEESKWKVLV PEHEKDVLEW IA C V R S N F L V  LCYLH DVK NI
LQLHDLTTGA LLKTFPLDVG SIVGYSGQKK D T E IF Y Q F T S  F L S P G IIY H C  DLTKEELEPR
V F R E V T V K G I DASDYQTVQI FYPSKDGTKI P M F IV H K K G I KLDGSHPAFL Y G Y G G F N IS I
T P N Y S V S R L I FVRHMGGILA VANIRGGGEY GETWHKGGIL ANKQNCFDDF Q CAA EYLIK E
G Y T S P K R L T I NGGSNGGLLV AACANQRPDL FGCVIAQVGV MDMLKFHKYT IGHAWTTDYG
CSDSKQHFEW LVKYSPLHNV KLPEADDIQY PSMLLLTADH DDRVVPLHSL K F IA T L Q Y IV
GRSRKQSNPL L IHVDTKAGH GAGKPTAKVI EEVSDM FA FI ARCLNVDWIP
Fig. 4.1 A m ino acid sequence o f  hum an PO enzyme.
The catalytic dom ain is indicated in red and the P-propeller in blue. PO source: NP 002717.
The PO crystal structure has revealed a cylindrical shape o f  60 A height and 50 A diameter 
(Fig. 4.2). The peptidase domain consists o f a central eight-stranded p sheet with all 
strands except the second one aligned in parallel. The p sheet is twisted and it is flanked by 
two helices on one side and six helices on the other (Goossens et al., 1995). The propeller 
is based on a seven-fold repeat o f four antiparallel P sheets. The sheets are tw isted and 
radially arranged around a central tunnel. There are only hydrophobic interactions between 
the first and the last blade, instead o f a Cys-Cys bond m ore com m only found in p-propeller 
structures. One o f  the catalytic residues, Ser 554, is found at the tip o f a very sharp turn, 
referred to as nucleophile elbow. It was hypothesised that the narrow entrance o f  the 
propeller (4 A) might be enlarged by spatial separation o f the unclosed blades 1 and 7. 
Interestingly, Szeltner et al. showed that the propeller domain increases the catalytic 
capability o f the peptidase domain and, in particular, Cys 255 (in the 4th blade o f  the
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propeller domain) seems to contribute to catalysis (Szeltner et al., 2000). It has been 
proposed that the p-propeller provides a tunnel that allows only small peptides to access 
the active site, and introduction o f a disulphide bond between blades 1 and 7 o f the P- 
propeller results in loss o f enzymatic activity (Fulop et al., 1998). More recent studies have 
shown, however, that the propeller domain is rigid and does not permit the substrate to 
approach the active site through this domain (Juhasz et al., 2005; Fuxreiter et a l , 2005). 
Instead, a smaller tunnel at the inter-domain region comprising the highly flexible N- 
terminal segment o f the peptidase domain facing the hydrophilic loop from the propeller 
(AA 192-205) was identified as the only likely pathway for the substrate to access the 
catalytic site.
A B C
Fig. 4.2 Porcine PO crystal structure.
A Stereorepresentation o f PO enzyme with the propeller domain in green/blue and the catalytic 
domain in red and orange on the top.
B Perpendicular representation of the propeller domain only with the first and seventh blades non- 
covalently bound.
C Cut-through view of the enzyme as in A, where binding o f the inhibitor Z-Gly-Pro-prolinal to 
the catalytic site can be observed at the top right indicated with a red arrow.
Source: (Fulop et al., 1998).
The PO enzyme is structurally intriguing since each domain appears to modulate the 
function o f the other. Moreover, PO is functionally interesting as it is has been reported to 
play a role in cognition via its effect on neuropeptide cleavage. However, neuropeptides 
are secreted molecules and PO does not appear to be secreted, at least in mammals, 
therefore suggesting that PO may exert other unknown intracellular functions within the 
cell, and in particular, in neurons. PO has recently been linked to the mechanism o f action
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o f m ood-stabilizing drugs via possible m odulation o f  the Pins signalling pathway 
(W illiams et al., 2002). Importantly, amongst mood stabilizers, VPA inhibits recom binant 
PO directly (Cheng et a l., 2005).
The aim o f this study was to shed light on the PO intracellular functions by analysing PO 
protein interactors. PO antibodies were not com m ercially available at the beginning o f this 
thesis. Antibodies were therefore generated and extensively characterised using 
biochem ical techniques. M oreover, a PO null-m utant mouse was acquired from Deltagen 
and characterised. A yeast-two-hybrid analysis (Y2H) (performed at G laxoSmithKline) 
revealed several potential protein interactors, including GAP43, which is o f  interest due to 
its involvem ent in growth cone plasticity. This hit was chosen for further investigation and 
interaction was confirmed in over-expressing m am m alian cells and, subsequently, in 
tissue. In addition, catalytically-dead PO (S554A) was generated by site-directed 
mutagenesis, as described in the Method section 2.5.7; the interaction o f  PO with GAP43 
was analysed, and, interestingly both the native and the catalytically-dead PO interacted 
with GAP43.
M echanisms o f  action o f  mood-stabilizing drugs Chapter 4 Page 108
4,2 Results
4.2.1 C haracter isa tion  o f  a PO  n u ll-m u ta n t m ou se
In order to characterise the PO null-m utant m ouse generated by Deltagen, brains were 
rem oved and analysed for PO mRNA  expression. No PO mRN A was detected by Taqm an 
RT-PCR in PO null-mutant cortices (as well as in other brain areas -  data not shown), 
w hereas PO was highly expressed in w ild-type samples, with intermediate levels in the 
heterozygotes (-60%  compared with wild-type) (Fig 4.3A). Further confirm ation o f  the PO 
null-m utant mouse was obtained by analysing LacZ expression in brain lysates. Only PO 
null-m utant brain extracts showed p-galactosidase expression (band > 100 kDa), 
confirm ing insertion o f the LacZ cassette in the PO null-m utant mouse (Fig. 4.3B).
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Fig. 4.3 PO mRNA and LacZ expression in the PO null-mutant mouse.
A PO mRNA analysis was performed by TaqMan RT-PCR. No PO mRNA was detected in the 
cortices from PO null-mutant mice (KO), while intermediate levels were measured in 
heterozygotes (HET) when compared with wild-type mice (WT) (n = 5 mice, mean ± sem). Data 
are expressed as a percentage o f P-actin.
B PO KO and WT brain extracts were analysed by Western blotting using a polyclonal anti-P- 
galactosidase antibody (Abeam, 1:5,000, overnight). A band >100 kDa, representing the 
expression o f LacZ, can be observed in the PO KO extract only. The lower molecular weight band 
represents a cross-reactive protein.
In order to determine PO activity in the PO null-mutant mouse, an enzymatic assay for PO 
was established (see Materials and Methods section 2.3.2) and optimised in terms o f 
concentration o f  brain homogenate, substrate, and incubation time (Fig. 4.4).
195839
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Fig. 4.4 Optimisation o f the PO enzyme activity assay.
The PO enzyme activity assay was optimised for mouse brain homogenate by testing different 
concentrations o f  (A) brain lysate, (B) substrate and (C) reaction incubation time. Wild-type (WT) 
and PO heterozygote mice (HET) were analysed.
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After establishing the optimal conditions (>0.4 mg brain tissue, -3 0  pM  substrate, 20- 
30 min reaction time), the PO activity was analysed in the PO null-mutant mice. No PO 
activity was detected in the PO null-mutant mice brain (limit o f  the assay: <0.003%), 
whereas high levels were measured in wild-type and heterozygote brains (-60%  activity in 
heterozygotes compared with wild-type) (Fig 4.5). These results show that the PO null- 
mutant mouse is devoid o f PO activity, at least in the brain soluble fraction.
75000-,00
to
50000
25000
KO HET WT
Fig. 4.5 PO enzymatic activity assay in the PO null-mutant mouse brain.
No PO activity was detected in the PO null-mutant brain (KO). when compared with wild-type 
(WT) and heterozygote (HET) mice (n -  5 mice, mean ± sem). Data are expressed as activity mg of 
tissue.
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4.2.2 PO expression studies
In order to study the functions and neuronal localisation o f  PO, it is critical to have 
selective antibodies. As there were no com m ercially available antibodies at the start o f 
these studies, we chose peptide sequences specific to PO and antibodies were generated by 
Cam bridge Research Biochemicals and Research Genetics, as described in the M ethod 
section 2.4.4. Before proceeding with the validation, I exam ined a number o f cell lines for 
their endogenous mRNA PO expression by Taqm an RT-PCR (Fig. 4.6A). PO expression 
was also analysed in rat prim ary neurons (cortical, hippocampal and striatal) cultured for 5, 
7, 9, 12, 15, and 20 days (die) (Fig. 4.6B). PO expression was detected in all cell lines and 
in prim ary neurons, independent o f time in culture.
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Fig. 4.6 Rat PO mRNA expression.
A PO mRNA expression in rat cell lines. RNA was analysed from glioma C6, fibroblast Rat-1, 
liver RLC-27, glial B12, skeletal muscle myoblast L6C10, adrenal pheochromocytoma PC 12 
(undifferentiated and differentiated with NGF), mouse neuroblastoma x rat glioma hybrid N18, 
mouse neuroblastoma x rat glioma hybrid NG118-15, pituitary tumour GH4, and basophilic 
leukaemia granulocytes RBL. All these cell lines were cultured at GlaxoSmithKline. PO 
expression was normalised to cyclophilin.
B PO mRNA expression in primary neurons. Cells were lysed at the times indicated. RNA was 
extracted and PO mRNA levels measured by Taqman RT-PCR.
Mean ± sem are from three + RT reactions (both A and B).
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A number o f human cell lines were also examined, all o f  which expressed PO (Fig. 4.7).
PO expression normalised to cyclophilin
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Fig. 4.7 PO mRNA expression in human cell lines.
Embryonic kidney HEK293T, HEK293 (1 and 2 in brackets refer to two different sources). HEK- 
MSRII. human neuroblastoma SK-N-MC, brain neuroglioma H4. peripheral blood-T-cell 
leukaemia Jurkat, neuroblastoma SH-SY5Y (1 and 2 in brackets refer to two different sources), 
hepatocyte carcinoma HepG2. osteosarcoma U 20S, astrocytoma CCF-STTG1. brain astrocytoma 
132INI, brain teratocarcinoma NT2 (1 and 2 in brackets refer to two different sources), IMR32 
(undifferentiated (-) and differentiated with NGF and cAMP ( *)). All these cell types were 
cultured at GlaxoSmithKline within the Psychiatry Biology department. Mean -  sem are from 
three -  RT reactions.
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In order to further analyse PO expression in the brain, different brain regions 
(hippocampus, cortex, hypothalamus, cerebellum, hindbrain and midbrain) were dissected 
from rats at different ages and analysed for PO mRNA expression. Values were normalised 
to the housekeeper gene cyclophilin (Fig. 4.8). PO was found to be expressed in all brain 
regions examined and the expression generally decreased with age from postnatal day 1 to 
90 in all brain areas analysed. Subsequently, expression o f  the PO interactor GAP43 was 
analysed in the same samples. A very similar expression profile was observed for GAP43, 
which seemed to decrease with the age o f  the rats (Fig. 4.8B) in accordance with literature 
data (Neve et a l 1987). Brain dissection and plate generation were performed at 
GlaxoSm ithKline within the Psychiatry Biology Department.
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Fig. 4.8 PO and GAP43 mRNA expression during rat brain development.
A PO Taqman RT-PCR expression.
B GAP43 Taqman RT-PCR expression.
The following regions were dissected from postnatal day (P) rats (1-3-5-7-10-12-14-21-90): cortex, 
midbrain, hippocampus, hypothalamus, cerebellum and hindbrain. Brain regions from several 
animals were pooled in order to extract RNA. Data are mean  ^ sem o f three -  RT reactions (from 
the same sample) and are expressed as arbitrary units normalised to cyclophilin.
The very similar expression profile observed for PO and GAP43 during rat brain 
development suggests that these proteins may interact and exert similar functions in the 
brain. In this respect, GAP43 has been linked with neurite outgrowth and axonal 
remodelling, processes that occur in embryonic and early life and to a lesser extent in the
adult brain.
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4.2.3 G eneration o f V 5-H is-tagged PO cD NA
A useful method to validate antibodies is to use over-expressing cells. Rat PO was cloned 
at GlaxoSmithKline into pcDNA3.1D/V5-His-TOPO, without removing the stop codon. In 
order to obtain a V5-His-tagged enzyme, PO was sub-cloned into the expression vector 
pcDNA4/V5-His, in frame with the V5-His tags, as described in the M aterials and 
M ethods section 2.5.6.
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4.2 .4  PO antibody ch aracterisation  in H E K  cells over-expressing  PO
HEK cells (293T or MSRII depending on availability) were chosen for transfection studies. 
Cells were transfected with pcDNA4/V5-His-ratPO and then analysed two days later by 
Western blotting, immunoprecipitation and immunocytochemistry. A total o f  eight 
antibodies were initially tested in over-expression studies. Subsequently, we proceeded 
w ith the validation o f  antibody #1216 only, as this appeared to be the most specific 
antibody. I am, therefore, showing data for antibody #1216 only, as this has been 
extensively used in subsequent studies. A  band o f  ~75 kDa was observed by W estern 
blotting in untransfected HEK cells and the signal strongly increased in over-expressing 
cells (Fig. 4.9). An additional band o f  ~35 kDa was also observed in both samples.
kDa 
75 -
35 -
T ransfection 
+ PO
Fig. 4.9 Western blotting o f PO over-expressing HEK cell lysates as well as o f untransfected HEK. 
Anti-PO antibody #1216 (1:1,000, overnight) was used.
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PO was immunoprecipitated from HEK-MSRII cell lysates using anti-PO or anti-V5 
antibodies and W estern blotting performed with the reciprocal antibody (Fig. 4.10). 
Antibody #1216 detected PO using immunoprecipitation, as well as Western blotting, and 
a band o f ~ 75 kDa was observed (Fig. 4.10 A and B).
A
PO transfection 
+ +
kDa
<- PO75
50
25
V5 #1216 V5 IP
WB #1216
B
PO transfection 
+ +
kDa
75 - <+ PO
V5 #1216 V5 IP
WBV5
Fig. 4.10 Immunoprecipitation in PO over-expressing HEK-MSRII cells.
Immunoprecipitation was performed using the anti-PO #1216 or anti-V5 antibodies, as indicated, 
and Western blotting subsequently performed (A) with the anti-PO #1216 antibody (1:1,000 
overnight) or (B) with an anti-V5 antibody (1:5,000 overnight), respectively. PO transfection is 
indicated by + and no transfection by -. The 25 and 50 kDa bands represent the light and heavy 
antibody chains, respectively, normally observed in immunoprecipitation experiments.
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Immunocytochemistry was also performed on PO-transfected HEK cells. Fixed cells were 
incubated with the anti-PO polyclonal antibody #1216 together with an anti-V5 
monoclonal antibody in order to confirm detection o f PO. Several dilutions o f the PO 
antibody were used (from 1:100 to 1:1,000). Fig. 4.11 shows that transfected cells, labelled 
with the anti-V5 antibody, are also labelled with the anti-PO antibody #1216, therefore 
showing that the anti-PO antibody is specific for this protein at the level o f  protein 
expression and antibody dilution analysed.
Fig. 4.11 Immunolabelling o f PO transfected HEK-MRSII cells.
Cells labelled with the anti-PO antibody #1216 (1:100) (green) are also labelled with the anti-V5 
antibody (1:5,000) (red). Nuclei are visualised with DAPI (blue). A merged microphotograph is 
shown on the bottom right panel. Images were acquired with a X 40 objective.
In summary, o f the anti-PO antibodies tested, antibody #1216 was shown to recognise PO 
in over-expressing cells by Western blotting, immunoprecipitation and 
immunocytochemistry. Therefore, only this antibody was characterised further in neural 
tissue.
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4.2.5 PO antibody characterisation in tissue
The antibody #1216 was tested in brain tissue by W estern blotting. Cerebella and cortices 
from wild-type and PO null-mutant mice were analysed for PO expression. Antibody 
#1216 detected PO protein at ~  75 kDa, as well as lower MW bands at -6 5 , -3 5  and -2 5  
kDa. The latter were evident also in the PO null-mutant samples, whereas the 75 kDa band 
was not as it represented PO. W hen the peptide chosen for the immunisation was pre­
incubated with the antibody, none o f  the bands were visible (Fig. 4.12).
# 1 2 1 6  # 1 2 1 6  + p ep tid e
KO W T  KO W T
Ctx Cereb Ctx Cereb Ctx C ereb Ctx Cereb
kD a
75 < -  PO
6 5  - — * ------ “  ‘  -  —
3 5  -
2 5  ~ ■ ■■ - - ‘1"~
Fig. 4.12 W estern blo tting  on PO null-mutant and wild-type brain lysates.
W estern blotting  w as perform ed with antibody #1216 (1:1,000, overnight) on PO null-m utant 
(KO) or w ild-type (W T) cortex (Ctx) and cerebellum  (Cereb) lysates. The PO band is ~  75 kDa. 
The panel on the right is a parallel blot where antibody #1216 was pre-incubated w ith the peptide 
and subsequently  applied to the blot.
These results show that antibody #1216 recognises PO in the mouse brain and can be used 
by W estern blotting. Other cross-reactive bands o f smaller molecular weight were also 
observed both in PO null-mutant and wild-type samples suggesting that they are specific to 
the epitope used in the immunisation, but not specific to PO.
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In order to understand better the PO intracellular localisation, it is critical to have an 
antibody that detects the protein in neurons and/or in brain slices. Antibody #1216 was 
therefore tested by immunocytochemistry on primary cortical neurons dissociated from 
E l5 wild-type or PO null-mutant mice (Fig. 4.13). Neuronal cell bodies and processes 
were labelled with the antibody. There was, however, a strong signal in wild-type as well 
as in the PO null-mutant neurons. These findings were not unexpected, as several cross­
reactive bands were previously observed by Western blotting.
Fig. 4.13 Immunocytochemistry o f wild-type and PO null-mutant cortical neurons.
PO labelling o f  processes and cell bodies showed similar intensities in WT and PO KO cultures.
Images were acquired with a X 40 objective.
Similar results were also obtained when antibody #1216 was tested by 
immunohistochemistry on brain slices from wild-type and PO null-mutant (data not 
shown). In brain slices the PO immunoreactivity was widespread amongst brain areas and 
similar between the wild-type and PO null-mutant mouse. No decrease in labelling 
intensity was observed in the null-mutant brain, therefore indicating that the labelling is not 
specific for PO protein. For these reasons a detailed analysis o f PO protein expression in 
the brain and at the subcellular level has not been performed in the course o f my studies. 
Only very recently, protein expression data have been presented by Schulz et al. (Schulz et 
a l ,  2005). During the course o f my thesis, I have analysed a total o f eight antibodies (3 
peptides and the whole protein were injected into two rabbits each) and only two 
antibodies (#1216 and the whole protein -  data not shown for the latter) specifically 
recognised PO protein. The reasons for this low success rate are at present unclear but are 
unexpected for a cytosolic protein such as PO.
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In summary, these results indicate that antibody #1216 cannot be used for 
immunocytochemistry or im m unohistochem istry to detect endogenous PO. The antibody 
#1216 can, however, be used for W estern blotting and im m unoprecipitation because with 
the latter techniques the 75 kDa PO protein band can be clearly identified, as crucially this 
band is missing from the PO null-mutant samples. Overall, antibody #1216 can be used for 
the purpose o f our study, which focuses on the confirm ation o f the interaction, identified in 
an Y2H study, between PO and GAP43.
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4.2.6 PO and G AP43 interaction
Y2H involves expression o f  a sequence o f interest fused to the DNA binding domain o f the 
transcription factor GAL4 (the bait = PO), and a library o f target proteins fused to the 
GAL4 transcription activation domain (the prey). Association o f the bait with the prey 
protein reconstitutes a functional transcription factor and this is detected by the expression 
o f  a reporter gene controlled by a prom oter bearing the cognate DNA binding domain site, 
as schematically illustrated in Fig. 4.14. The most com mon detection system exploits the 
use o f  X-GAL (5-bromo-4-chloro-3-indolyl-P-D-galactopyranoside), which is hydrolysed 
by p-galactosidase, forming an intense blue precipitate.
In order to identify PO protein interactors, Y2H was performed (Helen Sanderson and Julia 
W hite at GlaxoSmithKline) using two baits: the rat full-length PO and the P-propeller 
domain only (73-437 AA) and human adult and foetal brain and rat brain libraries. A total 
o f  135 interactors were revealed when the PO full-length bait was used (27 in human foetal 
brain, 39 in human adult brain, 69 in rat brain libraries), whereas 177 interactors were 
identified in the P-propeller screen (72 in human adult brain and 105 in human foetal brain 
libraries). O f these interactors, 16 confirmed in a 1:1 interaction assay in yeasts. 
Interestingly, when the propeller domain was used as a bait, stronger and a greater number 
o f interactors were observed when compared with the full-length enzyme screening. This 
suggests that the catalytic domain may destabilise the protein. In fact, it was recently 
reported that the propeller domain could exist as a separate protein and it is stable in 
solution, in contrast to the catalytic domain, which has not been isolated as a separate 
protein (Juhasz et a l. , 2005). O f the hits, we have selected GAP43 as the most interesting 
one in terms o f biological functions and relevance to our study. In this respect, GAP43 is a 
cytosolic neuronal protein involved in growth cone morphology, axonal growth and 
synaptic plasticity and its putative interaction with PO appeared to be quite intriguing. The 
interaction between full-length PO and GAP43 was reported using a human adult brain 
library. Other interesting hits identified were a-synuclein, succinate dehydrogenase and 
cadherin 10 precursor, amongst others.
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Fig. 4.14 Y2H schematic. Source: GlaxoSmithKline Y2H website.
The schematic shows the two plasmids used (GAL4 DNA-binding domain bait and the GAM  
activation domain prey). When co-expressed, they induce the formation o f a functional 
transcription factor, which induces expression o f the reporter P-galactosidase gene. Blue colonies 
are identified.
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4 .2 .6 .1  P O -G A P 4 3  in te ra c tio n  in  o v e r -e x p r e s s in g  ce lls: c o - im m u n o p r e c ip ita tio n
In order to confirm the interaction in mammalian cells, co-immunoprecipitation was
performed in HEK-MSRII cells transfected with/without PO and/or GAP43 plasmids, as 
indicated in Fig. 4.15. pcDNA3.1D/V5-His-TOPO-PO (stop codon not removed) was 
transfected alone or in combination with pcDNA3.1D/V5-His-TOPO-GAP43 (in frame 
with V5-His tags) (both constructs were generated at GlaxoSmithKline). Appropriate 
negative controls were used, as indicated in the figure legend. Cells were lysed two days 
after transfection and analysed by co-immunoprecipitation, as described in Materials and 
M ethods in section 2.4.3.
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Fig. 4.15 PO and GAP43 co-immunoprecipitation in HEK-MSRII over-expressing cells.
A Immunoprecipitation (IP) was performed with the anti-V5 antibody (3 pi) (detects GAP43) and 
WB with the anti-PO antibody #1216 (1:1,000). PO is ~ 75 kDa. Lane 8 shows IP performed using 
an unrelated anti-mouse antibody in PO- and GAP43-transfected cells. Lane 5 shows that PO and 
GAP43 interact. No band at 75 kDa is observed in lanes 6 and 7 (negative controls). Cell lysates 
were also loaded on the gel. The 25 kDa band represents the antibody light chains.
B IP was performed with the anti-PO antibody #1216 (5 pi) and WB with the anti-V5 (1:5,000). 
GAP43 is ~-43 kDa band. Lane 8 shows IP performed using an unrelated anti-rabbit antibody in 
PO- and GAP43-transfected cells. Lane 5 shows that PO and GAP43 interact. The band observed 
in lane 6 shows interaction between endogenous PO and transfected GAP43. No band is observed 
in lane 7 (negative control). The experiment was repeated at least three times. Representative blots 
are shown.
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4 .2 .6 .2  P O -G A P 4 3  in te r a c tio n  in  tis su e :  c o - im m u n o p r e c ip ita tio n
In order to confirm that the above interaction occurs in neuronal tissue, wild-type and PO 
null-mutant brains (male, ~1 month old) were dissected and snap-frozen. Brain lysates 
were obtained following the same procedure used for cell lysates and co- 
immunoprecipitation performed using the anti-PO #1216 or the anti-GAP43 antibodies. 
Negative controls used were the PO null-mutant mouse lysates and immunoprecipitation 
with an unrelated anti-rabbit antibody (Fig. 4.16). Lane 8 shows that PO and GAP43 
interact in endogenous tissue, whereas no interaction was observed in the PO null-mutant 
m ouse (highlighted with a red box, lane 5), as expected due to the lack o f  PO.
WB G A P43  
WT KO KO WT
<  G A P43
lysates IP #1216 (PO) 
IP GAP43
Fig. 4.16 PO and GAP43 co-immunoprecipitation in mouse brain.
IP was performed with the anti-PO antibody #1216 (5 pi) or GAP43 (3 pi) and Western blotting 
with an anti-GAP43 antibody (1:5,000). GAP43 is the 43 kDa band. Lanes 3 and 6 show IP with 
an unrelated anti-rabbit antibody in the PO null-mutant (KO) or wild-type (WT) brain, 
respectively. Brain lysates were also loaded on the gel (lanes 1 and 2). The band at ~25 kDa 
represents the antibody light chains.
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4 .2 .6 3  C a ta ly tic a lly -d e a d  P O -G A P 4 3  in te r a c tio n  in  o v e r -e x p r e s s in g  ce lls :
c o - im m u n o p r e c ip ita tio n
The literature suggests that the two domains (catalytic and P-propeller) o f  the PO protein 
m odulate each other’s functions and PO activity can be altered by the propeller domain 
(Szeltner et al., 2000). We, therefore, asked if  the PO enzymatic activity affects the PO 
interaction with its binding partner GAP43. A catalytically-dead PO was generated by site- 
directed mutagenesis, as described in the M aterials and M ethods section 2.5.7. Cells w ere 
transfected in parallel with either native PO or with the catalytically-dead PO plasm ids 
(both in pcDNA3.1D/V5-His-TOPO, untagged as stop codon not removed) and lysed two 
days after transfection. Cell lysate from 1x10 cm dish was split into two tubes. In one tube, 
the lysate was sonicated and analysed for PO enzymatic activity, whereas the other sample 
was used to analyse PO protein expression. Lysates from cells transfected with the 
catalytically-dead PO (clone #1 or clone #17) did not show any increase in PO enzymatic 
activity when com pared with untransfected cells, in contrast to the robust increase in 
activity in cells over-expressing the PO native enzyme (Fig. 4.17A). W hen PO protein 
levels were analysed by W estern blotting, a strong increase in PO expression was observed 
in cells transfected with either the native or the catalytically-dead PO, therefore showing 
that PO protein levels are not affected by the mutation (Fig. 4 .17B).
Mechanisms o f  action o f  mood-stabilizing drugs Chapter 4 Page 130
A
PO activity/pg of protein
75000-
3  50000-
25000-
control m ut#1 m ut# 1 7  PO native
B WB #1216 + ERK/MAPK
. _  - +mut#1 +mut#17 +PO nativekDa
75 — ►  PO
— M  B B  +  ERK/MAPK42
Fig. 4.17 Validation o f  catalytically-dead PO.
A CHOJK.1 cells were transfected using Fugene with pcDNA3.1D/V5-His-TOPO-PO native or 
catalytically-dead (S554A) plasmids and lysed two days later. PO activity was measured and 
expressed per pg o f  protein. The experiment was repeated with similar results (n = 2 experiments, 
n = 2 reactions/experiment).
B Lysates from PO transfected cells were analysed by Western blotting with the anti-PO antibody 
#1216 (1:1,000) and ERK/MAPK (loading control) (1:10,000). Lane 1: untransfected CHO_Kl; 
lane 2: cells transfected with catalytically-dead PO clone #1; lane 3: cells transfected with 
catalytically-dead PO clone #17; lane 4: cells transfected with native PO plasmid.
99
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In order to determine if  the PO enzymatic activity affects the interaction between PO and 
GAP43, the catalytically-dead PO (S554A) was transfected into HEK-MSRII cells and co- 
immunoprecipitation performed, as previously described (Fig. 4.18).
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Fig. 4.18 Catalytically-dead PO and GAP43 co-immunoprecipitate in HEK-MSRII over-expressing cells.
A IP was performed with the anti-V5 antibody (3 pi) (recognises GAP43) and Western blotting 
with the anti-PO antibody #1216 (1:1,000). PO is the ~ 75 kDa band. Lane 8 shows IP performed 
using an unrelated anti-mouse antibody in PO and GAP43 transfected cells. Lane 5 shows that PO 
and GAP43 interact. Lane 7 shows interaction between endogenous PO and transfected GAP43. 
Cell lysates were also loaded on the gel (lanes 1, 2, 3, 4). The 25 kDa band represents the antibody 
light chain.
B IP was performed with the anti-PO antibody #1216 (5 pi) and Western blotting with the anti-V5 
(1:5,000). GAP43 is ~ 43 kDa band. Lane 8 shows IP using an unrelated anti-rabbit antibody in 
PO and GAP43 transfected cells. Lane 5 shows that PO and GAP43 interact. The band observed in 
lane 6 shows interaction between endogenous PO and transfected GAP43. No band is observed in 
lane 7 (negative control).
These results show that catalytically-dead PO also interacts with GAP43, therefore 
indicating that lack o f  enzymatic activity is not sufficient to disrupt the interaction with 
GAP43 and that the enzyme is probably folded correctly.
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Furthermore, in order to determine if  the small V5-His tags, which may affect PO 
enzymatic activity, have a detrimental effect on PO interaction with GAP43, co- 
immunoprecipitation was performed in cells transfected with PO and GAP43 plasmids, 
both in frame with the V5-His tags. Results shown below indicate that the V5-His tags do 
not affect the PO-GAP43 interaction (Fig. 4.19).
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Fig. 4.19 PO (V5) - GAP43 (V5) interaction.
IP was performed with the anti-PO antibody #1216 (5 pi) and Western blotting with an anti-V5 
antibody (1:5,000). In this experiment PO and GAP43, both V5-His tagged, were transfected in 
HEK-MSRII cells. GAP43 is -43  kDa. Lane 8 shows IP using an unrelated anti-rabbit antibody in 
PO- and GAP43-transfected cells. Lane 5 shows that PO and GAP43 interact, but in this case two 
bands are observed. The faint band in lane 6 shows interaction between endogenous PO and 
transfected GAP43. Cell lysates were loaded on the same gel (lanes 1, 2, 3,4).
In summary, we have shown that the interaction observed in Y2H between PO and GAP43 
also occurs in mammalian cells. Firstly, the interaction was confirmed using an over­
expression strategy and, subsequently, in mouse brain tissue. The validation in brain tissue 
is important as it confirms the interaction at native levels o f cellular expression. 
Appropriate controls were used in the experiments as described in detail, which include 
immunoprecipitation using unrelated primary antibodies and the use o f the PO null-mutant 
mouse. Interestingly, we have shown that mutation o f  one o f  the catalytic residues, which 
abolishes the PO enzymatic activity, does not affect the interaction with the binding partner 
GAP43. Moreover, when the PO-V5-His tagged plasmid was used in the experiments, it 
gave similar results to the untagged contruct, therefore suggesting that addition o f  these
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small tags do not affect the conformation o f the enzyme in such a way as to disrupt its 
interactions with other proteins, specifically GAP43.
Furthermore, the PO-GAP43 interaction was also analysed in terms o f  intracellular 
localisation, but the results were inconclusive as both proteins are highly abundant in the 
cytosol and therefore their co-localisation at the subcellular level cannot be assessed even 
with the use o f the confocal microscopy. HEK-MSRII cells transfected with 
pcDNA3.1D/V5-His-TOPO-GAP43 assumed a neuronal-like m orphology with long 
processes and growth cone-like structures, in accordance with literature data (V erhaagen et 
al., 1994).
Mechanisms o f  action o f  m ood-stabilizing drugs Chapter 4 Page 134
4.3 Discussion
The study described here is one o f  the few that explores the biological functions o f PO, 
with particular focus on its intracellular binding partners. In order to analyse the results 
from Y2H, we generated/validated several tools e.g. plasm ids expressing PO, Taqm an 
primers and probes and antibodies. These tools also allowed us to increase understanding 
o f  PO expression in the rat brain and in cell lines.
Using Taqman RT-PCR, we showed that PO mRNA is widely distributed am ongst a 
variety o f human and rat cell lines. All cell types analysed by Schulz et al. also expressed 
PO, suggesting that PO exerts critical cellular functions (Schulz et al., 2005). Other studies 
have looked at PO activity during brain development. Agirregoitia et al. reported that PO 
activity in cortex, striatum, cerebellum and hypothalamus decrease during rat developm ent 
(Agirregoitia et al., 2003). The temporal profile was area specific and differences between 
the soluble and particulate forms were observed. This study on PO mRNA expression in 
the rat brain seems to parallel those findings on PO activity, as we observed a decrease in 
PO expression with age in several brain areas (cortex, cerebellum, hippocam pus, 
hypothalamus, hindbrain and midbrain). Interestingly, a similar expression profile has been 
observed for GAP43 during post-natal development. The decrease in GAP43 expression 
with age is in accordance with its role in synaptic plasticity and neurite outgrowth, 
processes that occur predominantly in embryonic and early post-natal life. Considering that 
PO interacts with GAP43 and that its mRNA expression decreases after birth, these data 
suggest putative critical roles o f PO in the same processes affected by GAP43. In contrast, 
other studies have reported an increase in PO expression in aged mice, in particular in the 
hippocampus, which correlated with a decline in cognitive performance (Rossner et a l ,  
2005).
At present there is very little information on PO protein expression, and reliable antibodies 
are not commercially available. The PO antibodies generated, and in particular #1216, 
were extensively characterised by im munocytochemistry, W estern blotting, 
im munoprecipitation and competition with peptide antigen. Antibody validation was 
further carried out by showing that the PO band o f  -7 5  kDa was not detected in PO null- 
mutant brain lysates. However, several cross-reactive bands (65, 35, 25 kDa) were
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observed both in wild-type and in PO null-mutant brain lysates. The identity o f  these 
bands, which are unrelated to PO, is at present unknown given that the PO null-m utant 
mouse did not show any PO enzymatic activity. The peptides chosen for im m unisation 
were not expected to recognise any other proteins, as predicted from a Blast search. We 
showed that antibody #1216 is suitable for use by W estern blotting and 
immunoprecipitation and it has proven a valuable tool to validate the interaction between 
PO and GAP43.
The interaction between PO and GAP43 is o f particular interest as it suggests that PO may 
m odulate intracellular events, such as growth cone m orphology, secretion and trafficking, 
all regulated by GAP43, and possibly affected in BD and by mood stabilizers. A Y2H 
screening was also recently reported by Schulz et al. in a study where interaction with a -  
tubulin was shown, which suggested PO modulation o f  cytoskeletal dynamics (Schulz et 
al., 2005). In the Y2H study performed at G laxoSmithKline, however, tubulin was not 
identified as a binding partner, perhaps due to the different libraries used (HeLa cells vs 
brain in our study). In the study by Schulz et a l., the interaction in mammalian cells was 
shown only by im munofluorescence co-localisation o f the two proteins and not by co- 
immunoprecipitation, which is the standard and most robust technique to confirm an 
interaction. M oreover, it is not clear how specific their anti-PO antibodies are. It is 
interesting to note that they have been designed to the N-terminal region o f  the protein 
(amino acids 10-15 o f  the human PO), similar to our antibody #1216 (amino acids 2-14). 
Another weak point in the Schulz et al. study is the fact that PO and a-tubulin  are very 
abundant cytosolic proteins, and a conclusion o f  their co-localisation cannot be definitely 
made. In contrast, our data supporting the interaction between PO and GAP43 are robust, 
as the interaction was confirmed by co-immunoprecipitation in mammalian cells. W e first 
analysed interaction in over-expressing cells and subsequently in brain tissue. Co- 
immunoprecipitation experiments are very labour intensive and often yield false positives 
or negatives, particularly using over-expressed proteins. A more reliable confirmation o f 
interaction can be obtained by studying endogenous proteins and in these studies the PO 
null-mutant mouse was a valuable negative control due to the absence o f the PO protein.
PO consists o f  a catalytic and a p-propeller domain, which seem to modulate each other’s 
functions. It has been shown that besides selecting substrates by size, the P-propeller
Mechanisms o f  action o f  mood-stabilizing drugs Chapter 4 Page 136
domain remarkably contributes to catalysis o f  the peptidase domain via its Cys 255 
(Szeltner et al., 2000). We analysed whether loss o f enzymatic activity affects the PO 
interaction with GAP43. Interestingly, loss o f  enzymatic activity obtained by mutating 
Ser554 to Ala did not disrupt PO-GAP43 interaction, therefore showing that m utation o f  
one amino acid, although critical for activity, was not sufficient to disrupt the folding o f  
the protein. Moreover, addition o f  two tags (V5-His) to the PO enzyme, w hich m ay alter 
the structure o f the protein, did not prevent interaction with GAP43 either, therefore 
indicating that also in this case the interaction is stable.
GAP43 is a growth-associated phosphoprotein enriched in growth cones and in presynaptic 
term inals and its interaction with PO is very interesting in this context. The expression o f 
the protein is restricted to neurons and is highest in the first week after birth, whereas in the 
adult brain, GAP43 is enriched in areas with high synaptic plasticity (O estreicher & 
Gispen, 1986). Transgenic mice over-expressing GAP43 show spontaneous form ation o f 
new synapses and enhanced sprouting after injury (Aigner et a l., 1995). In contrast, 
GAP43 null-m utation disrupts axonal pathfinding and it is generally lethal shortly after 
birth (M aier et a l., 1999). Furthermore, chicken embryonic sensory neurons in culture fail 
to extend axons w hen treated with antisense oligonucleotides complementary to portions o f 
GAP43 mRNA (A igner & Caroni, 1993). Regulation o f GAP43 gene expression occurs 
both at the transcriptional and post-transcriptional level by unknown mechanisms. Several 
post-translational m odifications have been described: ADP-ribosylation and palm itoylation 
in the membrane binding domain, phosphorylation o f Ser41 by PKC and casein kinase II, 
and dephosphorylation by several phosphatases. GAP43 is bound to the plasm a membrane 
via palmitoylation o f  two cysteine residues and can undergo cytosol-to-mem brane 
translocation upon activation (Skene & Virag, 1989). Interactions o f GAP43 have been 
described with calm odulin, PIP kinase, F-actin, and phospholipids (He et al., 1997). In 
particular, in growth cones, GAP43 is associated with the cytoskeletal proteins actin, a -  
actinin, and talin (M eiri & Gordon-W eeks, 1990; M oss et a l., 1990). Phosphorylation state 
and amount o f calmodulin bound to GAP43 appear to regulate the rate o f neurotransm itter 
release. Calmodulin binds to GAP43 but GAP43 phosphorylation on Ser41 prevents this 
interaction (Meiri & Gordon-W eeks, 1990). There is, therefore, the possibility that PO m ay 
form part o f a protein complex and regulates several cellular processes. Interestingly, 
GAP43, and in particular the phosphorylated form, has been shown to m odulate the Pins
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pathway by inhibiting PIP kinase in the rat brain and in the nerve growth cone (Van 
Dongen et a l 1985; Van H ooff et a l., 1988). A model has been proposed through which 
GAP43 mediates local sequestration o f PIP2 into lipid rafts and releases the inhibitory 
activity that Pins exerts on actin-regulating proteins, such as profilin, cofilin and gelsolin 
(Laux et al., 2000). As a result, actin dynamics are increased, resulting in decreased 
cytoskeleton stability and growth cone elongation. The latter effects are reversed by 
GAP43 phosphorylation (Caroni, 2001; Laux et al., 2000). The interaction between PO and 
GAP43, therefore, may be the key link between PO and the action o f  mood stabilizers on 
the Pins pathway. Thus, the interaction between PO and GAJP43 is o f particular interest in 
term s o f growth cone and synaptic function.
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CHAPTER 5
Characterisation of sensory neuron growth
cones from PO null-mutant mice
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5.1 Introduction
The first report o f a common effect o f  the mood stabilizers - lithium, VPA and CBZ -  
showed that each drug inhibited collapse and increased growth cone spread area in rat 
sensory neurons (W illiams et a l., 2002). These effects were reversed by addition o f  either 
extracellular wvo-inositol or by PO inhibitors, therefore suggesting that PO m odulates the 
action o f mood stabilizers possibly via the Pins signalling pathway (W illiams et a l., 2002). 
Interestingly, PO had previously been linked with the Pins pathway; an inverse correlation 
between PO and IP3 levels was found in an astroglioma cell line using PO inhibitors and 
antisense technology. In fact, treatment with PO inhibitors induced an increase in 
intracellular IP3 levels (Schulz et a l., 2002). Increased IP3 levels were also observed in a 
Dictyostelium discoideum  PO mutant, which also showed resistance to the effects o f 
lithium and VPA on the mould morphology (W illiams et al., 1999). More recently, PO was 
reported to be inhibited directly by VPA (but not by lithium or CBZ), suggesting this 
enzyme to be a key modulator in mood regulation (Cheng et a l , 2005). The authors 
proposed that euthymic mood may be dependent on stable Pins signalling and that a mood 
stabilizer, like VPA, may limit mood swings to mania by decreasing Pins signalling and 
limit those to depression by enhancing Pins signalling, via PO inhibition. Further data 
point to regulation o f  the Pins pathway by PO: treatment o f primary neurons with the PO 
inhibitor S -17092 reversed the effect o f lithium on CDP-DAG accumulation, m im icking 
addition o f mvo-inositol (Thomas J. & Mudge A.W ., personal communication).
A clinical study has shown lower PO activity in the plasma o f  depressed individuals and 
higher levels in m anic subjects when compared with control; however, only limited 
numbers o f individuals were analysed (Maes et al., 1995). Intriguingly, depressed subjects 
treated with the antidepressant drug fluoxetine showed increased PO activity in plasma, 
while treatment o f  m anic individuals with VPA decreased PO plasm a activity. Neuroleptic 
treatments had no effect on PO levels (Maes et al., 1995). Importantly, a second enzyme, 
called ZIP, is present in the blood, as described in the Introduction section 1.4.5, which can 
be a confounding factor for these observations. M oreover, these studies lack analysis o f  the 
drug effects on PO expression levels in control subjects.
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In order to analyse the involvement o f PO in the mechanism o f action o f mood stabilizers, 
we have analysed the cellular m orphology o f sensory neurons derived from a PO null- 
m utant mouse. We also compared the growth cone morphology o f the PO null-mutant 
neurons with that o f wild-type neurons treated with a selective PO inhibitor. Unexpectedly, 
PO null-mutant growth cones exhibited a phenotype that was different from wild-type 
neurons and resembled that observed in wild-type neurons treated with a mood stabilizer. 
M oreover, addition o f a mood stabilizer did not alter the percentage o f collapse any further. 
Phenotype rescue experiments were performed by transducing sensory neurons with an 
adenovirus expressing native or catalytically-dead PO. W e also exam ined whether levels o f 
GAP43 and its phosphorylated form were altered in the PO null-mutant mouse. GAP43, 
identified as a PO interactor in an Y2H screening, is involved in growth cone structure and 
alterations in levels o f this protein may result in changes in growth cone area.
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5.2 Results
5.2.1 Effect o f the PO inhibitor S-17092 on PO activity
A potent and selective PO inhibitor, S-17092, developed by Servier as a potential 
therapeutic for memory impairment (M orain et al., 2002), was synthesised at 
GlaxoSmithKline. S-17092 inhibited PO activity in rat brain homogenate, with an I C 5 0  in 
the sub nM range (Fig. 5.1), in agreement with published data (Barelli et al., 1999).
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Fig. 5.1 PO inhibition by S-17092 and chemical structure.
Rat brain homogenate was processed as described in Materials and Methods and incubated with 
different concentrations o f S-17092 for 30 min. Data are expressed as a percentage o f total activity.
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5.2.2 G row th cone analysis o f m ouse w ild-type neurons treated w ith m ood  
stabilizers: effect o f S-17092
Sensory neuron ganglia were dissected from post-natal day 1 wild-type mice and treated 
with the PO inhibitor S-17092 over the concentration range o f  1 nM - 10 pM. No changes 
in the percentage o f growth cone collapse were observed at any concentration (Fig. 5.2A).
Explants were subsequently treated with VPA (1 mM ), CBZ (50 pM ) or LiCl (1 mM ), with 
and without the PO inhibitor. M ouse wild-type sensory neurons responded to each o f  the 
m ood stabilizers with a decrease in the percentage o f collapse (Fig 5.2B) (from -6 0 %  in 
control to -30%  in drug-treated explants (VPA: 34%; CBZ: 38%; LiCl: 35%), in 
agreement with previous findings in rat DRGs (chapter 4 o f  this thesis and (W illiams et al., 
2002)). Moreover, when the PO inhibitor was added together with a mood stabilizer, the 
percentage o f  collapsed growth cones returned to control values (control: 66%, VPA + 
POi: 65%, CBZ + POi: 60%, LiCl + POi: 55%) (Fig. 5.2B).
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Fig. 5.2 Effect o f mood stabilizers and of the PO inhibitor S-17092 on mouse wild-type growth cones.
A Concentration response effect of S-17092 on sensory neuron growth cone collapse. Growth cones 
were treated with 1 nM - 10 fiM S-17092 and scored as collapsed or spread.
B Percentage o f growth cone collapse in wild-type sensory neurons treated with the mood stabilizers 
LiCl (1 mM), VPA (1 mM) or CBZ (50 pM) with/without the PO inhibitor S-17092 (1 jiM) (n = 6 
independent experiments with at least two explants per experiment). Mean ± sem are indicated. P 
value <0.01 is indicated with ** (One-way ANOVA).
These results confirm previous findings with the three mood stabilizers in rat sensory 
neurons (Williams et al., 2002) and extend the observations to mouse sensory neurons. 
Moreover, we showed that the potent and selective PO inhibitor, S-17092, produces similar 
effects to those described by Williams et al., where two other potent compounds were used 
to inhibit PO (BOC-Glu (NHO-Bz)-Pyr and Z-Pro-Pro-aldehyde-dimethyl acetal).
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5.2.3 Growth cone analysis o f mouse w ild-type neurons treated w ith PTN or GPT
In order to determine if  the effects o f LiCl, VPA and CBZ are specific for mood stabilizers 
or whether they are shared by other anticonvulsants, PTN (25, 50 pM) or GPT (25, 50 
pM ), two anticonvulsants without mood-stabilizing properties, were added to mouse wild- 
type explants and growth cones scored as collapsed or spread, as previously performed in 
rat explants (see Fig. 3.2C). Neither o f these drugs modified the percentage o f  collapse, as 
previously observed in rat DRGs (Fig. 5.3).
75 i
control PTN25 PTN50 GPT25 GPT50
Fig. 5.3 Effects o f PTN and GPT on mouse wild-type growth cones.
Explants were treated with drugs (25 or 50 pM) 24 h after plating and cultured for a further 20 h. 
Growth cones were scored as collapsed or spread and plotted as a percentage o f the total number o f  
growth cones examined (n = 3 explants, representative experiment, >100 growth cones scored). 
Mean ± sem are indicated. Similar results were obtained in a second experiment.
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5.2.4 Growth cone analysis o f mouse PO null-m utant neurons treated with mood 
stabilizers
Sensory neuron explants were immunolabelled for GAP43 in order to visualise the growth 
cone morphology, while an anti-acetylated tubulin antibody was used to visualise stable 
microtubules. Fig. 5.4 shows examples o f  a sensory ganglion explant (left, low 
magnification), and spread and collapsed growth cones (right panel, indicated with 
arrows).
Fig. 5.4 Morphology o f sensory neuron explants from the PO null-mutant mouse.
Explants were labelled with an anti-acetylated tubulin (red) (Sigma, monoclonal, 1:10,000) together 
with an anti-GAP43 antibody (green) (Abeam, polyclonal, 1:2,000). Goat anti-rabbit IgG Alexa488 
and goat anti-mouse IgG Alexa594 secondary antibodies were used. Single arrow (right panel) 
shows a collapsed growth cone, and double arrows indicate a spread growth cone.
Growth cones o f  sensory neurons from PO null-mutant mouse displayed an unexpected 
morphology. Untreated explants showed a decreased percentage o f collapsed growth cones 
(-30%  of the total) when compared with wild-type explants; these values were similar to 
those obtained when wild-type neurons were treated with mood stabilizers (Fig. 5.5A). 
Addition o f a mood stabilizer did not reduce further the percentage o f collapse (Fig. 5.5A). 
Analysis o f growth cone spread area revealed an increase in the percentage o f growth 
cones with area >100 pnT and a decrease in the percentage o f ‘small’ growth cones with 
area <20 pm (Fig. 5.5B), with the mean area increasing from 33.55 ± 1.90 pm“ in wild- 
type cultures to 56.94 ± 2.14 pm 2 in PO null-mutant neurons.
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Fig. 5.5 Analysis o f  growth cones from the PO null-mutant mouse.
A Percentage o f growth cone collapse in PO null-mutant sensory neurons (KO) with/without 
addition o f a mood stabilizer (VPA: 1 and 2 mM; CBZ: 50 and 100 pM; LiCl: 2 and 10 mM). 
Control (WT) and LiCl-treated wild-type explants (WT + drug) are shown for comparison (n = 6 
independent experiments with at least two explants per experiment, T-test, *P<0.05).
B Growth cone area distribution o f WT and KO DRGs. Explants were labelled with an anti-GAP43 
primary antibody followed by a goat anti-rabbit Alexa488 secondary antibody.
Mean ± sem are indicated (both A and B).
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5.2 .5  A nalysis o f  in osito l e ffects and levels in PO  n u ll-m u ta n t n eu ron s
As addition o f extracellular mvo-inositol has been shown to reverse the decrease in the 
percentage o f collapse induced by mood stabilizers in rat sensory neurons (W illiam s et al 
2002), explants from the PO null-mutant mouse were treated with ravo-inositol and growth 
cone collapse scored. Fig. 5.6 shows that addition o f inositol did not modify the percentage 
o f  collapse in the PO null-mutant explants.
4 5  -
KO + inositol
Fig. 5.6 PO null-mutant sensory explants treated with mo-inositol.
Explants were treated with 1 mM inositol, fixed after 24 h and growth cones were scored as 
collapsed or spread (n = 2 experiments, n > 100 growth cones/condition). Mean sem are indicated.
These data show that the reduction in the percentage o f growth cone collapse observed in 
the PO null-mutant neurons when compared with wild-types is not altered by treatment 
with inositol. It can be hypothesised that inositol requires PO in order to exert any cellular 
effects.
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In order to determine whether inositol levels are altered in the PO null-m utant mouse, 
measurements were performed in DRG extracts dissected from wild-type or PO null- 
mutant mice. No differences in inositol levels were observed between the PO null-mutant 
and wild-type extracts (Fig. 5.7).
Fig. 5.7 Measurements o f inositol levels in PO null-mutant DRGs.
Six DRGs were lysed in 100 (al o f water and sonicated. Samples were analysed by Ajit Shah within 
the Neurochemistry Department at GlaxoSmithKline using liquid chromatography followed by 
tandem mass spectrometry (LC-MS MS). Values are expressed as nmoles o f inositol; pg o f protein. 
Results are expressed as mean == sem from six samples.
Overall, these data show that inositol levels are not altered in the PO null-m utant mouse 
neurons. Similar data were obtained when cortical and brain extracts were analysed. 
However, it is possible that other components o f  the pathway, such as PIP2 or other inositol 
phosphates, are altered in the PO null-mutant mouse and it would be interesting to measure 
their levels/turnover.
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5.2.6 G A P43 expression  levels in the PO n u ll-m u tan t m ouse
In order to determine if  the increase in growth cone spread area observed in the PO null- 
mutant neurons is associated with changes in expression levels o f  the PO interactor, 
GAP43, protein levels were analysed in brain and in sensory neuron extracts (data not 
shown for the latter) (Fig. 5.8A). Moreover, in order to determine i f  changes in the 
phosphorylation state o f GAP43 protein occurred in the PO null-mutant mouse, parallel 
blots were probed with an anti-phospho(Ser41)-GAP43 antibody (Fig. 5.8B). The PO 
antibody was used to confirm PO null-mutant and wild-type samples. No differences in 
either GAP43 or in phospho-GAP43 were detected between the PO null-mutant and wild- 
type samples (Fig. 5.8C).
A
kDa KO W T
PO75 —
65 ^
43 —  — ---------------------------------------— -----------—  < -  G A P 4 3
B
 — — — P 0
65 —
^  +  P -G A P 4 3  (S e r 4 1 )
4 3  —  —  —  —  —
G A P 43 P -G A P 4 3
c
13
I'JDW_<
T
WT K O W T
Fig. 5.8 GAP43 protein expression in PO null-mutant brain.
A GAP43 expression was analysed in the hippocampus from six WT and six PO KO mice. 20 pg o f  
proteins were loaded per well. The blot was probed with an anti-GAP43 antibody (1:5,000) together 
with the anti-PO antibody #1216 (1:1,000). B P-GAP43 expression was analysed in the 
hippocampus from six WT and six PO KO mice. C GAP43 and P-GAP43 quantitation. Mean ± sem 
(n = 6). Quantitation was performed using Genetools from Syngene. T-test was performed to 
determine significance.
Mechanisms o f  action o f  mood-stabilizing drugs Chapter 5 Page 150
A similar analysis was performed using sensory neuron explant lysates and no differences 
in GAP43 expression were observed between wild-type and PO null-m utant samples. 
These data suggest that the increase in growth cone area observed in the PO null-mutant 
mice is not due to alterations in GAP43 protein. Furthermore, these changes are also not 
due to differences in phosphorylation levels o f GAP43. It is possible that other post- 
translational modifications o f GAP43 not analysed in this study e.g. palm itoylation, may 
be responsible for the changes in growth cone morphology. A nother possibility is that 
analysis o f steady-state levels does not allow detection o f  changes in dynam ic interactions 
at the growth cone.
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5.2.7 Viral transduction studies in sensory neurons: PO native enzym e
In order to determine if  the null-mutant phenotype can be rescued by re-introduction o f 
PO, an adenovirus expressing PO (untagged), as well as GFP (hum anised form) 
(bicistronic construct) was made by Colin Glover at Bristol University 
(Ad.CMV.POiREshrGFPII.WPRE). Several viral concentrations were tested on sensory 
explants (up to 10 pi o f undiluted stock). Only weak GFP fluorescence was observed up to 
5 days post-transduction and this was m ainly confined to the explant cell bodies. The 
fluorescence was not strong enough to allow visualisation o f neurites and m easurem ents o f 
growth cone area. An antibody approach could not be used due to the lack o f  specificity o f  
the PO antibody #1216 by im munocytochemistry in tissue and to the lack o f  a suitable 
com mercially available anti-GFP (humanised) antibody.
Therefore, another approach was adopted. An adenovirus was made by Colin G lover that 
expressed PO protein in frame with the V5 tag (Ad.CM V.POV5.W PRE), as specific anti- 
V5 antibodies exist that can be used for immunocytochemistry. As enzyme function may 
be altered as a consequence o f the introduction o f a tag, PO activity was measured in 
explants transduced with the PO native or V5-tagged viruses, as well as w ild-type and PO 
null-mutant explants. Data showed that the V5 tag clearly decreased PO activity when 
compared with the PO untagged-transduced neurons (Fig. 5.9).
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Fig. 5.9 PO activity in PO-transduced DRGs.
PO KO neurons were transduced with an adenovirus containing PO untagged or V5-tagged and 
analysed for PO activity 5 days after transduction. WT explants were used as a positive control. Ten 
DRGs were pooled per condition and 20 pi o f homogenate were analysed in the PO activity assay as 
described in Materials and Methods (n = 4 replicates per condition, mean sem).
These results showed that the V5 tag decreases PO catalytic activity to levels that are 
similar to those observed in wild-type primary neurons. Viral transduction o f  PO null- 
mutant neurons with the PO untagged virus restores PO activity, and the levels were much 
higher than those m easured in wild-type extracts, therefore suggesting that PO over­
expression occurs. As we showed that the V5 tag alters PO enzymatic activity we decided 
to go back to the PO untagged virus and adopt a different strategy in order to perform 
growth cone area measurements.
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A combination approach was therefore adopted, consisting o f addition o f  the PO untagged 
adenovirus together with a CMV-EGFP adenovirus (Ad.CMV.EGFP.WPRE, generated by 
Colin Glover), previously shown to transduce explants efficiently, with the assumption that 
the two viruses should both transduce the same cells (James Uney and Colin Glover, 
personal communication). Transduction efficiency was determined by labelling the 
explants with an anti-GAP43 antibody, which labels all neurites, and scoring the GAP43- 
labelled as well as the GFP-fluorescent growth cones. The transduction rate was calculated 
between -50-60%. Importantly, it became evident that the fluorescence, although quite 
strong, was not homogeneous along the neurite length and it was occasionally absent in the 
growth cone, therefore preventing reliable growth cone measurements (Fig. 5.10).
GAP43 GFP fluorescence
Fig. 5.10 Examples o f adenoviral transduction o f DRG explants.
Explants were labelled with an anti-GAP43 antibody (Abeam, 1:2,000) followed by the secondary 
antibody goat anti-rabbit Alexa594. GFP fluorescent images were also acquired in the same field.
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In order to determine if  the PO adenovirus was able to transduce sensory neurons and 
restore PO protein expression, lysates from PO-transduced, wild-type or PO null-mutant 
sensory neurons were analysed by Western blotting (Fig 5.11). PO is endogenously 
expressed in wild-type sensory neurons, whereas it is not expressed in PO null-mutant 
neurons. Transduction o f PO null-mutant neurons with the PO adenovirus restored PO 
protein expression, whereas addition o f the virus to wild-type cultures induced PO protein 
over-expression.
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Fig. 5.11 PO protein expression in PO-transduced DRG.
Six DRGs from WT or PO KO mice transduced or not with the PO adenovirus (1 pi) were lysed 5 
days after transduction in ~30 pi o f lysis buffer. Western blotting was performed using the anti-PO 
antibody #1216 (1:1,000) (band o f -75  kDa). An anti-ERK/MAPK antibody (1:10,000) (bands o f  
44,42 kDa) was used as a loading control.
Mechanisms o f  action o f  mood-stabilizing drugs Chapter 5 Page 155
Growth cone scoring was subsequently performed. G AP43-labelled cultures were analysed 
and a statistical approach was adopted in order to take into consideration that only 50% o f 
the neurons were actually transduced. The statistical power calculation identified the 
number o f replicates required in order to obtain statistically significant results (18-20 
replicates needed). Therefore, four independent experiments were perform ed with a total o f  
>20 replicates. Reintroduction o f the PO native protein into the PO null-m utant sensory 
explants reversed the percentage o f  collapsed neurons to values that were sim ilar to those 
observed in untreated wild-type neurons (KO: 35%; KO + EGFP: 36%; KO + EGFP +PO: 
46%; WT: 51%) (Fig. 5.12).
KO KO + KO + WT
EGFP EGFP +
PO
Fig. 5.12 Growth cone analysis o f PO null-mutant sensory neuron transduced with PO native adenovirus.
Explants were left untreated or they were transduced w'ith an EGFP adenovirus or w'ith the EGFP 
adenovirus together with the PO native untagged adenovirus (1 pi o f virus/well). Explants w'ere 
fixed 4 days post-infection, labelled with anti-GAP43 antibody and scored as collapsed or spread 
(n = 4 independent preparations, n>20 explants/condition). Mean ± sem are indicated, p***<0.001; 
Two-way ANOVA was performed.
These results show that PO is a key component in the nerve terminal where it affects 
processes involved in growth cone morphology.
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5.2.8 Viral transduction studies in sensory neurons: catalytically-dead PO
Subsequently, in order to dissect the involvement o f  PO enzymatic activity in growth cone 
morphology, neurons were transduced with an adenovirus expressing catalytically-dead 
(Ser554Ala) PO (Ad.CMV.cat-deadPOiREshrGFPII.WPRE) (made by Colin Glover). 
Protein lysates were analysed to determine if  the virus was able to induce PO protein 
expression in PO null-mutant sensory explants. W estern blotting data showed that PO 
protein can be detected in PO null-mutant PO catalytically-dead-transduced sensory 
neurons (Fig. 5.13).
KO
<  ERK/MAPK
Fig. 5.13 PO protein expression in catalytically-dead PO-transduced DRG.
Six DRGs from PO KO mice transduced or not with the catalytically-dead PO adenovirus were 
lysed 5 days after transduction in ~30 pi o f lysis buffer. Western blotting was performed using the 
anti-PO antibody #1216 (1:1,000) (band o f -75  kDa). An anti-ERK/MAPK antibody (1:10,000) 
(bands o f 44, 42 kDa) was used as loading control.
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PO enzymatic activity was also measured in DRG explants transduced with the 
catalytically-dead PO adenovirus, as well as native PO. Results in Fig. 5.14 show that the 
catalytically-dead PO is devoid o f  PO enzymatic activity, as expected.
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Fig. 5.14 PO activity in DRGs transduced with catalytically-dead PO.
PO KO DRGs were transduced with the adenovirus for native or catalytically-dead PO and 
analysed for PO activity 5 days after transduction. Ten DRGs were pooled per condition and 20 p i 
o f homogenate were analysed for PO activity, as described in Materials and Methods. Mean ± sem 
are shown (n = 4 replicates per condition).
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Following on from these experiments, which showed that the adenovirus expressing 
catalytically-dead PO is able to restore PO protein w ithout inducing any increase in PO 
enzymatic activity, the catalytically-dead PO adenovirus was applied to sensory neurons 
dissected from the PO null-mutant mouse in com bination with the EGFP expressing 
adenovirus and growth cones were scored as collapsed or spread. Explants transduced with 
the catalytically-dead PO showed an increase in the percentage o f  collapsed growth cones 
when compared with EGFP-transduced neurons or with PO null-mutant neurons (KO: 
34%; KO + EGFP: 36%; KO + EGFP + PO dead: 57%) (Fig. 5.15).
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Fig. 5.15 Growth cone analysis o f PO null-mutant sensory neuron transduced with a catalytically-dead PO 
adenovirus.
Explants were left untreated or they were transduced with an EGFP adenovirus or with the EGFP 
adenovirus together with the catalytically-dead PO adenovirus (1 pi o f virus/well). Explants were 
fixed 4 days post-infection, labelled with an anti-GAP43 antibody and scored as collapsed or 
spread (n -  4 independent, n>20 explants/condition). Mean ± sem are indicated. Two-way 
ANOVA was performed, *p<0.05.
These results show that the PO null-mutant phenotype can be altered not only by re- 
introduction o f the PO native enzyme, but also when the PO enzyme without the catalytic 
activity is expressed. This indicates that the PO enzymatic activity is not necessary for the 
effect o f PO on growth cone morphology. These data are in agreement with the findings 
that treatment o f w ild-type explants with the PO inhibitor S -17092 does not alter growth 
cone morphology when added on its own (Fig. 5.2A).
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A summary table o f the viruses used and the issues encountered with each o f  them is 
presented below (Table 5.1):
Viruses used Summary
Ad.CMV.PO|REshrGFPII.WPRE 
(cv 73, 1.5 x 1010 pfu/ml)
- Restores PO protein and activity
- Weak hrGFP fluorescence
- No suitable Ab anti-PO or anti-hrGFP for ICC
- Can be used only if statistical approach applied
Ad.CMV.cat-
deadPO|REshrGFPII.WPRE 
(cv 76, 2.23 x 109 pfu/ml)
- Restores PO protein but not activity
- Weak hrGFP fluorescence
- No suitable Ab anti-PO or anti-hrGFP for ICC
- Can be used only of statistical approach applied
Ad.CMV.P0V5.WPRE 
(cv 79, 1.0 x 1010 pfu/ml)
- Growth cones can be visualised using an anti-V5 
antibody
- Restores PO protein but PO activity is 
compromised
- Cannot be used
Ad.CMV.EGFP.WPRE 
(cv 31, 2.25 x 109 pfu/ml)
- Good EGFP fluorescence, but sometimes 
fragmented
Table 5.1 Summary o f viruses used in the study.
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5.3 Discussion
PO has been implicated in the mechanism o f  action o f mood stabilizers but the nature o f 
the interaction remains largely unknown.
In this study we show that, unexpectedly, the growth cone m orphology o f sensory neurons 
dissected from PO null-mutant mice is altered; in particular, the percentage o f  collapsed 
growth cones is decreased to -3 0 %  compared with wild-type neurons (-60% ) and the 
percentage o f enlarged growth cones is increased. These results suggest that PO plays a 
central role in growth cone dynamics.
W hen PO null-mutant neurons were treated with a mood stabilizer, no alterations in the 
percentage o f growth cone collapse were observed, suggesting that PO m odulates a 
pathway that is also affected by mood stabilizers, probably upstream o f their action. In 
contrast, addition o f  a mood stabilizer to wild-type neurons increased the growth cone 
spread area and decreased the percentage o f collapse. Furthermore, when the PO inhibitor 
was added in com bination with the drugs it reversed/prevented the mood stabilizer effect 
(Table 5.2). The PO inhibitor alone, however, did not have any effect in wild-type neurons. 
It is possible, therefore, that mood stabilizers perturb PO interactions with putative target 
molecules and that PO inhibitors may have a further effect in combination with a mood 
stabilizer.
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A WT growth cones
Treatment
Untreated 
+PO inhibitor 
+mood stabilizer 
+P0 inhibitor plus 
mood stabilizer
Main phenot
Collapsed
Collapsed
Spread
Collapsed
B KO growth cones
Treatment
Untreated 
+mood stabilizer 
+PO native 
+PO catalytically 
dead
Main phenotype
Spread
Spread
Collapsed
Collapsed
Table 5.2 Summary of growth cone morphological changes in sensory neurons.
A WT neurons left untreated show a prevalence o f collapsed growth cones. Treatment with the PO 
inhibitor. S-17092, does not alter the percentage o f collapse. Treatment with a mood stabilizer 
increases the growth cone spread area, but co-application with the PO inhibitor restores the WT 
untreated phenotype.
B PO KO cultures left untreated show an increase in the percentage o f enlarged growth cones 
when compared with WT and treatment with a mood stabilizer does not alter the morphology any 
further. Re-introduction of PO (native or catalytically-dead) restores the WT phenotype.
W hen the PO native enzyme was re-introduced in the PO null-mutant DRG, using an 
adenoviral approach, we found an increase in the percentage o f collapse, which resem bled 
values observed in wild-type untreated cultures. These results confirm  that the 
morphological changes observed in the PO null-mutant mouse are due to the lack o f  PO 
protein and highlight the importance o f this enzyme in growth cone morphology. Viral 
delivery has proven to be challenging in terms o f growth cone visualisation due to the lack 
o f selective PO antibodies for immunocytochemistry. It is worth m entioning that the 
homologous recom bination in HEK293 cells was problematic and very inefficient for PO 
when compared with other proteins (1 week compared with 3 days with other proteins - 
personal communication from Colin Glover), therefore indicating some unusual properties 
o f this enzyme that would be interesting to clarify.
W hen PO null-mutant DRGs were transduced with a catalytically-dead PO adenovirus, the 
percentage o f collapsed growth cones increased in a statistically significant manner, when 
compared either to the PO null-mutant. These data lead us to conclude that the PO 
enzymatic activity on its own is not central to PO biological functions related to growth 
cone morphology. This is supported by the lack o f  effect o f a PO inhibitor on the growth 
cone morphology o f  wild-type neurons. The catalytically-dead enzyme was also able to 
interact with GAP43, indicating that mutation o f one amino acid does not alter the PO 
folding in such a way as to compromise its interactions and downstream functions and that 
catalytic activity is not critical for PO function.
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Addition o f m^o-inositol did not modify the percentage o f  growth cone collapse in PO 
null-mutant neurons and inositol levels were not changed in sensory explants or brain o f 
PO null-mutant mice when compared with wild-types. These latter findings were not 
unexpected as it seems highly unlikely to deplete the m illim olar inositol concentration 
measured in neurons. Overall, it seems likely that inositol requires PO in order to exert any 
cellular effects. cAMP was recently shown to decrease the percentage o f  collapse and 
increase the spread area o f sensory explants (Cheng et al., 2005). The same study reported 
that PO inhibitors reversed the effects o f cAMP, suggesting a functional link between these 
two molecules. It is possible that PO actions may involve modulation o f  the PKA/cAM P 
and/or the Pins signalling. To support the involvement o f the PKA/cAM P pathway, a 
proteomic study performed at GlaxoSmithKline has identified several com ponents o f  the 
PKA pathway whose expression may be altered in the PO null-mutant m ouse brain. 
Further studies are, however, required to confirm these findings and determ ine their 
functional relevance. The changes in growth cone m orphology observed suggest that 
alterations in actin and in the microtubule cytoskeleton m ay occur in the PO null-m utant 
mouse and, indeed, several cytoskeletal proteins were identified in the proteom ic study as 
differentially expressed in the PO null-mutant (e.g. MAP2, 14-3-3 zeta etc.). Interestingly, 
a-tubulin was also reported as a PO interactor in another Y2H screen (Schulz et a l., 2005).
Overall, the observations in the PO null-mutant mouse are interesting as they shed light on 
PO intracellular functions that have not been previously reported. The observed increase in 
growth cone area could be due to alterations in expression levels o f the growth cone 
protein GAP43, which we have reported to interact directly with PO. GAP43 
phosphorylation levels are low in neurites o f growth cones that have collapsed (Dent & 
Meiri, 1998) suggesting that phosphorylation o f GAP43 by PKC could direct the 
functional behaviour o f  the growth cone. Moreover, it is known that phosphorylation o f 
GAP43 weakens the binding o f GAP43 to phosphoinositides and as a result, GAP43 
interaction with lipid rafts is perturbed, therefore affecting axonal growth and guidance 
(Dent & Meiri, 1998). This was not, however, the case in our system as no changes in 
GAP43 or in P-GAP43 levels were detected at least at steady state, indicating that other 
GAP43 post-transtranslational modifications m ay be affected. It is possible that PO forms 
an intracellular complex with GAP43 and other proteins, which m ay be altered in the PO 
null-mutant mouse. We propose that GAP43 is a key molecule for further analysis in its
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interactions with PO and link with the Pins pathway. GAP43 has been reported to inhibit 
PIP kinase, a key enzyme in the synthesis o f  PIP2, and the interaction with PO suggests a 
possible link with the Pins signalling pathway. Our hypothesis is that PO interaction with 
GAP43 is key to regulate cellular processes, such as growth cone area enlargement; it is 
possible that mood stabilizers, as well as PO inhibitors may affect the interaction directly 
(Fig. 5.16).
Membrane
Ptdlns Ptdlns4P Ptdlns4,5P AlDAG :
p k c  :k in a s e
Mood stabilizers 
PO inhibitor actin
IC alm odulir
agonist_ . 1
M e m b r a n e
J Ptdlns-*- Ptdlns4P ^-Ptdlns4,5P2 R ; ^  DAG _
PIP /  ■■ V......,kinase PLC P K C
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C a lm o d u l i
Fig. 5.16 Schematic o f hypothesis for PO action in the growth cone.
A In resting conditions PO and GAP43 associate in a protein complex, which includes actin 
and calmodulin. Low level o f PIPkinase inhibition is achieved. The unphosphorylated form 
of GAP43 has been associated with collapsed growth cones. It is possible that mood 
stabilizers and PO inhibitors may affect the protein interaction between PO, GAP43 and 
other proteins in the complex, therefore resulting in alterations in growth cone morphology.
B After stimulation o f the Pins pathway (e.g. carbachol), GAP43 is phosphorylated on Ser41 
by PKC. This results in inhibition of PIPkinase, which negatively regulates PIP2 synthesis. 
P-GAP43 does not bind to calmodulin, therefore disrupting the protein complex. When the 
complex is disassembled, and the phosphorylated form o f GAP43 predominates, an increase 
in growth cone spread area is observed. The same phenotype is observed when PO is not 
present in the complex (in the PO null-mutant mouse) and die protein complex is, therefore, 
affected.
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CHAPTER 6 
Conclusions and future directions
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None o f the drugs currently used to treat BD, such as lithium, VPA and CBZ, were 
developed with that use in mind. They do not seem to act by binding to extracellular 
receptors, rather they may modulate intracellular signalling molecules. It is not clear at 
present which pathways are modulated in relation to the therapeutic action or to the side- 
effects o f the drugs.
One approach to better understand the therapeutic targets is to identify commonly- 
regulated molecules. It is, however, possible that each o f these drugs m odulates a com mon 
pathway, rather than a molecule, by acting at different levels in the pathway.
In this thesis the ERK/M APK and the Pins signalling pathways were exam ined and I have 
also focused on the signalling molecule GSK3, as discussed in the relevant chapters. The 
ERK/M APK pathway is implicated in neuronal survival and neurite outgrow th and it is 
activated by neurotrophins (Skaper & Walsh, 1998). Activation o f ERK/M APK has been 
shown for VPA and LiCl, but the mechanism o f activation is still not clear. In fact, VPA 
and LiCl induce phosphorylation o f ERK/M APK and exert downstream effects on some 
ERK/MAPK targets, such as Elkl (Di Daniel et al., 2005). Direct activation o f  R as/R af 
and MEK have not, however, been demonstrated for any mood stabilizers. M oreover, the 
effects on ERK/M APK activation seem to be cell-dependent in vitro.
In order to validate new targets and test new potential therapeutics for BD it is im portant to 
have good in vitro and/or in vivo models that predict efficacy in humans. Unfortunately, 
there are currently no useful animal models for BD and no useful drug screens for testing 
potential candidate drugs. There have been attempts to mimic different symptoms o f the 
illness, such as hyper-activity (observed in mania) or prepulse inhibition (PPI) deficits 
(also common to schizophrenia) or lack o f motivation (observed in depression). For BD 
and other psychiatric conditions it is very difficult to establish in vitro models as there are 
no obvious pathological/cellular abnormalities in BD brains that can be m imicked in a 
tissue culture environment.
The growth cone assay described here and previously (W illiams et al., 2002) is the first 
assay to show a common effect o f the three most widely-prescribed drugs for the treatm ent 
o f BD. W hile the system uses sensory neurons, which are not relevant for the pathology, it
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is important that by analysing the common effects o f  the drugs we m ay discover 
therapeutic targets. In this assay, inositol reverses the effects o f the drugs, suggesting the 
Pins pathway as the key therapeutic pathway. Importantly, I have shown that the effects o f  
the drugs are also observed in neurons from a more disease-relevant brain area - the 
cerebral cortex. These data give us confidence that by using the growth cone assay in 
sensory explants we may be able to extrapolate findings to the brain. M oreover, GPT and 
PTN, anticonvulsants that are not efficacious in the treatm ent o f  BD at least as 
monotherapy, did not produce inositol-reversible effects on growth cones, strengthening 
the hypothesis that alterations in the Pins pathway m ay specifically underlie BD. The 
growth cone assay, therefore, seems to be potentially useful for assessing new candidate 
drugs. Other anticonvulsant, antipsychotic or antidepressant drugs with efficacy in BD 
should be tested in this assay in order to validate this assay as predictive o f BD efficacy. 
GSK3 inhibitors increased sensory neuron growth cone area, in particular by increasing the 
percentage o f  very large growth cones; an effect that was not reversed by addition o f  
inositol. GSK3 inhibition does not seem to be a common effect o f lithium, V PA and CBZ, 
as only lithium affected GSK3 downstream targets e.g. GS and tau. However, only two 
drug concentrations were chosen -  1 and 10 mM  -  and in future studies a concentration- 
response analysis should be performed to determine at which concentration the effects on 
GSK3 targets can be observed.
Increasing evidence points to the Pins signalling as the key pathway that is affected in BD 
and which may be critical to modulate with drugs in order to restore the physiological 
status. In particular, it has been proposed that hyper-activation o f this pathway m ay be 
linked with mania and decreased activity (inhibition o f Pins recycling rather than 
decreased levels o f inositol) with depression and, therefore, normalisation o f  the activity o f 
this pathway may be key to mood stabilization (Cheng et al., 2005). We have analysed 
several components o f  the Pins pathway. One o f these, IMPase has been previously 
analysed as a drug target by Merck Sharp & Dohme. The IMPase inhibitors developed 
were potent competitive inhibitors and produced similar in vitro effects to those observed 
with lithium (accumulation o f inositol phosphates and CDP-DAG), although lithium  is an 
uncompetitive inhibitor (Atack et al., 1994). The compounds were not brain penetrant and 
for this reason they did not provide useful drug candidates (Atack et a l., 1993). Another 
critical component in the pathway is MIP-synthase. Both VPA and lithium increase the
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expression o f the M IP-synthase homologue INO-1 in yeast (Ju et al., 2004; Vaden et a l., 
2001) and Dictyostelium discoideum  (W illiams et al., 2002), although neurons appear to 
have evolved different mechanisms for regulating the availability o f  this im portant 
precursor for membrane Pins synthesis. This enzyme is unlikely to be a valid drug target as 
it is expressed in the vasculature (W ong et al., 1987) and it is unclear whether it 
contributes to the inositol-dependent effects o f mood stabilizers on neurons.
Recent focus has been given to the inositol transporters, in particular to SM IT and HMIT. 
Astrocytic SMIT activity was reported to be inhibited by lithium, VPA and CBZ after 
long-term treatment (8-14 days). Berry and colleagues reported that the fetal brains o f  mice 
with a SMIT1 gene deletion had normal levels o f  inositol phospholipids (Berry et al., 2004; 
Berry et al., 2003) and they raised the question o f how neurons obtain their inositol for 
Pins synthesis. Moreover, SMIT1 heterozygous mice did not show any obvious 
behavioural abnormalities (forced swim, amphetamine-induced hyperactivity, elevated 
plus maze, apomorphine-induced stereotypic climbing and lithium-pilocarpine seizure 
tests) (Shaldubina et a l., 2006a). SMIT1 and SMIT2 are highly expressed in the periphery, 
in particular in the kidney. Lithium is known to induce kidney toxicity and this m ay be 
related to inhibition o f  SMIT (Kitamura et al., 1998). Moreover, SMIT expression is 
upregulated by osm otic stress and it does not seem to contribute to the regulation o f the 
Pins pathway in neurons. In contrast, HMIT is a neuronal transporter, expressed 
predominantly in the brain and at very low levels in the periphery, therefore representing a 
potential therapeutic target for mood disorders. HMIT is expressed in endosomal 
compartments and is thought to translocate to the plasma membrane in an activity- 
dependent manner. However, little information on HMIT neuronal localisation in resting 
and/or activated cells is available at present and it is critical to determine whether this 
transporter is expressed at the plasma membrane, where it could transport inositol from the 
CSF. It is also not known at present whether HMIT is regulated directly by mood 
stabilizers. In this thesis I have shown that prim ary neurons do not express SMIT1 or 
SMIT2 mRNA, but they express both HMIT mRNA and protein. In future studies it will be 
worth investigating the role o f this transporter in mood stabilization and in the m echanism  
o f  action o f mood stabilizers.
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Another component o f  the Pins pathway that seems to be o f therapeutic interest is the 
enzyme PO. PO null-mutant mice have been extensively characterised behaviourally and 
neurochemically at GlaxoSmithKline. They did not show any gross abnorm alities in 
behaviour (e.g. locomotor activity, forced swim, P P I  tests) or in brain m onoam ine levels. It 
would be interesting to analyse further their behaviour in stressful conditions or by 
crossing the mutant into a different strain. Analysis o f mouse growth cone m orphology in 
wild-type sensory neurons showed PO inhibitors to reverse the effect o f  m ood stabilizers 
on the percentage o f collapse, m im icking addition o f rayo-inositol. PO inhibitors have been 
reported to increase I P 3 levels (two-fold) in cells, therefore suggesting that PO modulates 
the Pins pathway. However, the biological significance o f a two-fold change in I P 3 levels 
is unclear. Moreover, PO inhibitors reversed the effects o f lithium on CDP-DAG 
accumulation in neurons (Thomas J. & M udge A.W. personal communication). Growth 
cones from the PO null-mutant mice were analysed with the hypothesis that their 
morphology would have been resistant to the drug effects. Unexpectedly, PO null-m utant 
sensory neurons showed increased growth cone area and decreased percentage o f  collapse - 
two parameters that were measured independently. Moreover, treatment o f the PO null- 
mutant cultures with the mood stabilizers lithium or VPA or CBZ did not alter the 
morphology any further. These data suggest that PO is critical for growth cone m orphology 
and that mood stabilizers modulate a pathway that is common to PO.
Treatment o f PO null-m utant cultures with inositol did not alter the percentage o f  collapse, 
in contrast to the effect observed in wild-type cultures treated with mood stabilizers, where 
inositol reversed the drug effects. We have measured inositol levels in the PO null-m utant 
brain and sensory explants and no differences were observed when compared with wild- 
type. It is possible that inositol levels themselves do not change, but it would be worth 
analysing levels/turnover o f  other inositol phosphates. Interestingly, lithium induced 
accumulation o f CDP-DAG levels in the PO null-mutant neurons, as well as it did in wild- 
type neurons (Thomas J. & Mudge A.W. personal communication), suggesting that the 
Pins signalling is functional in the PO null-mutant mouse; however, lith ium ’s 
concentration response in the PO null-mutant neurons was altered, indicating that the 
pathway is somehow compromised. Further studies are required in order to explain these 
observations.
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Viral rescue studies were subsequently performed using an adenovirus expressing native 
PO. PO protein expression could be restored transducing PO null-mutant sensory explants 
with an adenovirus containing native PO or an adenovirus containing a catalytically-dead 
PO. PO activity was also restored with the PO native enzyme, but not with the 
catalytically-dead PO. Transduction with native or catalytically-dead PO virus induced a 
statistically significant increase in the percentage o f  growth cone collapse when com pared 
with PO null-mutant neurons. These results propose that PO has a central role in growth 
cone morphology and that the enzymatic activity on its own is not critical for growth cone 
morphology. Moreover, it is possible that the alterations in growth cone m orphology m ay 
be due to alterations in protein interaction with GAP43.
Questions that should be addressed in future experiments are:
o Can a mood stabilizer modulate the growth cone morphology in PO null-
mutant neurons transduced with catalytically-dead PO?- this would indicate that PO  
enzymatic activity is not key fo r  the drug action
o Do PO inhibitors modulate the growth cone morphology in PO null-m utant
neurons transduced with catalytically-dead PO and treated with a mood stabilizer? -  
this would indicate that PO inhibitors act at other sites apart from  the catalytic one 
o Do mood stabilizers and PO inhibitors modulate PO-GAP43 interaction 
directly? - this w ould indicate that drugs able to alter PO protein interactions should  
be designed
o W hat is the cellular phenotype o f neurons over-expressing PO? Is the
percentage o f  collapse increased? -  this w ould strenghten our finding that PO  is a 
key modulator o f  growth cone morphology
o Is neurotransm itter release (e.g. measured using the lipophilic dye FM 4-64)
affected in the PO null-mutant mouse? -  the Pins signalling pathw ay modulates 
neurotranmitter release, therefore it is possible that this is altered in the PO  null- 
mutant brain
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The growth cone alterations observed in the PO null-mutant neurons and the PO 
interaction with GAP43 provide novelty in that they highlight PO intracellular functions 
and thus move away from the proteolysis o f  neuropeptide theory that has dominated the 
PO field. While it is possible that PO cleaves peptides in the extracellular space, this would 
be restricted to the blood compartment only, where a PO-related enzyme ZIP exists. 
GAP43 may interact with inositol phospholipids and regulate actin dynamics. It seems 
likely, therefore, that PO modulates growth cone function via its interaction with GAP43.
To conclude, there is great need to develop better treatments for BD. New targets should 
be identified in the Pins pathway. PO is a candidate target and understanding o f  its site o f 
action in the pathway is critical. Inositol transporters, in particular HMIT, also represent a 
tractable and interesting drug target and future experiments should address this hypothesis.
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SUPPLEMENTAR Y 
Other pathways implicated in BD and in 
the mechanism of action of mood
stabilizers
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The biogenic amine neurotransm itter systems have long been im plicated in the 
pathophysiology o f BD, but there is still controversy as to whether dysregulation o f  these 
systems exerts a primary role in the illness. I will briefly review the key reports o f  mood 
stabilizers on the main neurotransmitters in the brain.
Lithium affects the release o f  glutamate, serotonin (5-HT), and the activity o f  GABA 
receptors among others (Price & Heninger, 1994). Lithium has been reported to increase 
extracellular glutamate in monkey and in mouse cerebral cortical slices (D ixon et a l., 1994; 
Dixon & Hokin, 1998), perhaps by inhibiting presynaptic glutamate reuptake (D ixon & 
Hokin, 1998). Intriguingly, VPA can also increase extracellular glutamate by a m echanism  
that stimulates glutamate release (Dixon & Hokin, 1997). Glutamate activates N M DA  
receptors which, through the activation o f PKC, leads to the accumulation o f  IP3 in post- 
synaptic cells (Dixon et al., 1994). Interestingly, it has been shown very recently that 
chronic treatment with LiCl and VPA also reduces synaptic expression o f  the AM PA  
(amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor subunit G luR l in the 
hippocampus, while treatment with the antidepressant imipramine enhances the synaptic 
expression o f G luR l. Interestingly, LTG, which has a predominant antidepressant effect in 
BD, significantly enhanced the surface expression o f  G luRl and GluR2 in a tim e - and 
concentration-dependent manner in cultured hippocampal neurons. This finding m im ics the 
effects o f the antidepressant drug imipramine and it is in contrast to VPA, which 
significantly reduces surface expression o f  G luR l and GluR2. Regulation o f  G luR l/2  
surface levels and function have therefore been suggested to be responsible for the 
different clinical profile o f  anticonvulsant drugs (antimanic or antidepressants) (Du et al. , 
2006).
Lithium increases inhibitory neurotransmitter GABA signalling during chronic treatment 
by increasing the levels o f GABAb receptors in the rat hippocampus (M otohashi, 1992). 
VPA also increases GABA neurotransmission by directly inhibiting enzymes that m odulate 
GABA levels. In particular, VPA inhibits GABA transaminase in vitro, an enzyme 
involved in degrading GABA to succinic semialdehyde, and it also inhibits succinate 
semialdhyde dehydrogenase. M oreover, VPA increases GABA synthesis by activating 
glutamic acid decarboxylase, an enzyme that converts glutamic acid to GABA
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(Johannessen, 2000). However, inhibition/activation o f  these enzymes in vivo has yet to be 
demonstrated.
Electrophysiological studies have shown that lithium increases the release o f  5-HT to the 
synapse, possibly by inhibiting 5 -H T lA autoreceptors (Haddjeri et a l., 2000 ), which are 
localised on the soma and dendrites o f  5-HT neurons and control their firing. Also 5-HT1b 
receptors are localised on presynaptic neuron term inals and control 5-HT release. 
Activation o f 5-HT1b autoreceptors decreases release o f  5-HT to the synaptic cleft. M assot 
et al. have shown that therapeutic concentrations o f  lithium, but not other m etallic cations, 
induced specific inhibition o f 5-HT 1b receptor binding in a m em brane preparation (M assot 
et a l., 1999). Lithium has been shown to induce antidepressant effects in the m ouse forced 
swim test and this effect has been suggested to be m ediated by 5-HT1b receptors (Redrobe 
& Bourin, 1999). However, other studies have related it to GSK3 inhibition. In fact, GSK3 
heterozygote mice showed antidepressant-like effects in the forced swim test that were 
mimicked by potent GSK3 inhibitors (Gould et al., 2004; O 'Brien et al., 2004).
Other pathways/signalling components not described in this thesis that deserve further 
study are briefly outlined below.
Lithium, VPA and CBZ have been shown to affect the arachidonic acid (AA) signalling 
pathway by m odulating key molecules. AA is an important second m essenger, which 
consists o f a polyunsaturated fatty acid, esterified at the sn-2 position o f phospholipids. 
Lithium, as well as VPA, have been shown to reduce specifically the turnover rate o f  AA 
(by 80% and 28-33%, respectively) in rat brain phospholipids (Chang et al., 2001). 
Reduced AA turnover is accompanied by down-regulation o f  gene expression and protein 
levels o f the AA-specific cytosolic phospholipase A2 (cPLA(2)). VPA, however, has no 
effect on cPLA(2) protein levels (Chang et al., 2001; Rapoport & Bosetti, 2002). 
M oreover, chronic lithium administration to rats significantly reduces brain protein levels 
and enzyme activity o f cyclooxygenase-2 (COX-2), w ithout affecting COX-2 m RN A  or 
COX-1. Lithium also reduces the brain concentration o f  prostaglandin E(2) (PGE(2)), a 
bioactive product o f AA formed via the COX reaction (Bosetti et al., 2002). VPA, instead, 
when chronically administered to rats significantly reduced brain protein levels o f  COX-1, 
as well as o f COX-2, without altering the mRNA levels o f these enzymes. COX activity
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was also decreased, as were the brain concentrations o f  11 -dehydrothrom boxane B2 and 
PGE2 (Bosetti et al., 2003). Chronic treatment with CBZ also induced a decrease in 
PLA(2) activity, protein and mRNA levels in rat brain. COX activity was decreased in 
CBZ-treated rats, but COX-1 or COX-2 protein levels did not change. Brain PGE(2) 
concentration was also reduced. The protein levels o f  other AA m etabolizing enzymes, 5- 
lipoxygenase and cytochrome P450 epoxygenase, were not significantly altered after CBZ 
treatment nor was the brain concentration o f  the 5-lipoxygenase product leukotriene B(4) 
(Ghelardoni et al., 2004). Overall, each mood stabilizer affects the AA pathway, but the 
molecules involved are not always the same. However, the general effect produced by the 
drugs is down-regulation o f the AA signalling. It is possible, therefore, that drugs that are 
effective in BD mania may act by downregulating the incorporation and turnover o f AA 
(20:4n-6), but not o f docosahexaenoic acid (DHA, 22:6n-3) in brain phospholipids 
(Bazinet et al., 2005). Further studies are required in order to validate and extend these 
findings.
Another area o f research that deserves attention is represented by the circadian clock. 
There are lines o f evidence that circadian rhythms m ay be altered in BD e.g. sleep 
disturbances and precipitation o f mania due to changes o f  time zones. C ircadian rhythm  
affects many aspects o f  behaviour and physiology, including sleep-wake cycle, blood 
pressure, body tem perature and metabolism. The central clock lies in the suprachiasm atic 
nucleus o f the hypothalamus, which is reset daily by light, but peripheral clocks exist (e.g. 
liver). Chronotherapy, which consists o f sleep deprivation and exposure to light, is 
currently used, in combination with drugs, to treat BD with very prom ising results 
(Pontiggia et al., 2006). Among clock proteins, several transcription factors have been 
identified, such as CLOCK and PER. Interestingly, a recent study reported that the nuclear 
receptor Rev-ErbA a is a direct target o f lithium, probably via GSK3 inhibition (Yin et al., 
2006). GSK3, in fact, phosphorylates and stabilises Rev-ErbA a. Lithium treatm ent, by 
inhibiting GSK3, therefore induces rapid proteosomal degradation o f  R ev-E rbA a and 
activation o f the clock gene B m all. It is interesting to note that lithium affected Rev- 
E rbA a at 10 mM, but also at the therapeutic concentration o f 1 mM. Genetic studies are 
also suggesting that some genes involved in circadian rhythm regulation m ay be m odulated 
in BD (Nievergelt et al., 2006; M ansour et al., 2006; M ansour et al., 2005), but these are
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preliminary findings that remain to be confirmed in larger populations. Studies on 
circadian rhythms may reveal new therapeutic targets.
W ord count: -37,000
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Please note that some o f the work with mood stabilizers and ERK/M APK had started 
before the registration for a PhD. However, additional experiments were performed after 
enrolling for the PhD. Due to the different focus o f  the study I have inserted the data as a 
supplementary publication.
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